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ABSTRACT 
 
The rapid increase in prevalence of chronic-degenerative diseases is probably the major global 
health problem nowadays. Several studies have emphasized the role that dietary patterns rich in 
specific foods or their bioactive compounds may play in the reduction of disease risk. In fact, 
nutritional intervention is considered one of the most significant, easily achieved and affordable 
primary prevention strategy. Recently, increasing interest has been focused on personalized 
dietary interventions accurately designed to meet specific nutritional needs of target groups of 
population. The personalized approach seems to be more effective to achieve a defined outcome, 
especially in targeted subgroups of population considered “at higher risk” to develop chronic 
diseases. Based on these premises, the aim of the present Ph.D. thesis was to evaluate the effect 
of specific foods and their bioactives in the modulation of risk factors for chronic-degenerative 
diseases in “at risk” groups of population, thorough both in vivo and ex vivo approaches.  
 
The first part (in vivo approach) was focused on the impact of two different dietary interventions 
in a population of Italian children and adolescents affected by primary hyperlipidemia and thus 
considered at “higher risk” to develop cardiovascular (CV) events later in life. Firstly, the study 
population was characterized for serum lipid profile and fatty acid (FA) composition of red blood 
cell (RBC) phospholipids, showing differences according to sex and diagnosis of hyperlipidemia. 
Moreover, in the hyperlipidemic pediatric patients we observed an overall low omega 3 index 
(eicosapentaenoic acid, EPA + docosahexaenoic acid, DHA: <4%), an emerging risk factor for 
cardiovascular diseases (CVD). Secondly, in the same population of hyperlipidemic pediatric 
patients, it was investigated the effect of regular intake of a specific food (hazelnuts, HZN) or 
food supplement (hempseed oil, HSO) rich in unsaturated fats and other bioactives, in the 
modulation of different CVD biomarkers related to hyperlipidemia. We documented that both 
dietary treatments were effective in the management of primary hyperlipidemia at pediatric age. 
In particular, we showed that 8-week of hazelnuts intake, consumed with skin (HZN+S) or 
without skin (peeled, HZN-S), significantly improve the serum lipid profile and had a favorable 
impact on FAs composition of RBC membranes. In addition, HZN treatments were able to reduce 
the levels of DNA damage, a marker of oxidative stress, even if the concentrations of plasma 
oxidized LDL (ox-LDL) did not change following the HZN intervention. The effect of HSO 
supplementation on lipid profile of hyperlipidemic children was evaluated through a pilot study. 
Even if preliminary, the results from this study showed an enhancement of the omega-3 index 
and the RBC phospholipid composition following the intake of HSO for 8 weeks.  
 
The second part of the Ph.D thesis was performed at the Department of Physiology and 
Biochemistry of Nutrition of Max Rubner-Institut (Karlsruhe, Germany) and devoted to ex vivo 
approaches. Considering that chronic diseases are often associated to a compromised immune 
response, the objective of this part of research was to investigate the potential immunomodulatory 
properties of different concentrations of long-chain polyunsaturated fatty acids (LC-PUFA) in 
conjunction with standard dose of vitamin D3 on ex vivo immune cells from healthy volunteers. 
The effect of these bioactives was evaluated on two mechanisms crucially involved in the innate 
immune response that specifically act against cancer cells as well as infectious agents: the natural 
killer (NK) cell activity and the phagocytosis. The findings showed that high dose of LC-PUFA, 
independently by the presence of the vitamin D, negatively affect the lytic activity of NK cell of 
target cancer cells, with a dose-dependent response. On the contrary, an enhancement of 
phagocytic activity of monocytes was observed only when LC-PUFA were combined with 
vitamin D, suggesting a potential synergic and immunomodulatory role of vitamin D.  
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In conclusion, through this Ph.D thesis it was possible to increase knowledge on the potential 
benefits of bioactives rich-diet in the modulation of different risk factors for chronic-degenerative 
diseases. This aspect is particulary important in at risk target groups of population for whom 
appropriate and personalized nutritional interventions are considered the primary prevention 
approach. Future studies on largest population groups aimed to clarify the specific mechanisms 
of action involved are needed to provide additional demonstration that confirm our results. 
 
Riassunto 
8 
 
RIASSUNTO 
 
Il rapido aumento dell’incidenza delle malattie cronico-degenerative è probabilmente uno dei 
maggiori problemi di sanità pubblica attuali. Sono numerosi gli studi che supportano il ruolo che 
determinati modelli alimentari ricchi in specifici alimenti o composti bioattivi hanno nella 
riduzione del rischio di sviluppare malattie. L’intervento di tipo nutrizionale è sempre più 
considerato una strategia di prevenzione primaria che risulta tra le più efficaci, convenienti e 
facilmente perseguibili. Recentemente, un interesse crescente si sta sempre più focalizzando su 
interventi dietetici personalizzati accuratamente studiati per soddisfare le specifiche esigenze 
nutrizionali di gruppi di popolazione target. Infatti, un approccio nutrizionale personalizzato 
sembra essere molto più efficace nell’ottenimento di uno specifico risultato, soprattutto in quei 
gruppi di popolazione target considerati più a rischio di sviluppare malattie croniche. 
Sulla base di queste premesse, lo scopo della presente tesi di dottorato è stato quello di valutare, 
attraverso approcci in vivo ed ex vivo, l'effetto del consumo di specifici alimenti e dei loro 
composti bioattivi nella modulazione di alcuni fattori di rischio per le malattie cronico-
degenerative, in gruppi di popolazione “a rischio”. 
 
La prima parte della tesi (approccio in vivo) ha avuto l’obiettivo di valutare l’impatto di due 
diversi interventi dietetici in una popolazione di bambini ed adolescenti italiani affetti da 
iperlipidemia primaria, e quindi considerati a maggior rischio di possibili eventi cardiovascolari 
futuri. In primo luogo, la popolazione pediatrica in studio è stata caratterizzata per il profilo 
lipidico sierico e per la composizione degli acidi grassi dei fosfolipidi delle membrane 
eritrocitarie, mostrando delle differenze in base al sesso e al tipo specifico di iperlipidemia. 
Inoltre, in questi soggetti è stata osservato un basso indice omega 3 (acido eicosapentaenoico, 
EPA + acido docosaesaenoico, DHA: <4%), un marker che è stato suggerito essere associato a 
un elevato rischio di sviluppare malattie cardiovascolari. In secondo luogo, nella stessa 
popolazione di pazienti pediatrici iperlipidemici è stato studiato l’effetto del consumo regolare di 
uno specifico alimento (nocciole, HZN) o un supplemento alimentare (olio di semi di canapa, 
HSO), entrambi ricchi in acidi grassi insaturi e altri bioattivi, nella modulazione di diversi 
biomarker di rischio cardiovascolare collegati all’iperlipidemia. Entrambi gli interventi dietetici 
sono risultati efficaci nella gestione dell’iperlipidemia pediatrica. In particolare, abbiamo 
dimostrato che l’assunzione per 8 settimane di nocciole, consumate con la cuticola (HZN+S) 
oppure pelate (HZN-S), migliorava significativamente il profilo lipidico sierico e aveva un 
impatto favorevole anche sulla composizione degli acidi grassi delle membrane eritrocitarie. 
Inoltre, i trattamenti dietetici con le nocciole sono stati in grado di ridurre i livelli di danno al 
DNA, un marker di stress ossidativo. Tuttavia, le concentazioni plasmatiche di LDL ossidate (ox-
LDL) non hanno subito alcun cambiamento in seguito all’intervento con le nocciole. L’effetto 
della supplementazione con olio di semi di canapa nella modulazione del profilo lipidico in 
bambini iperlipidemici è stato valutato attraverso uno studio pilota. Anche se preliminari, i 
risultati di questo studio hanno mostrato un miglioramento dell’indice omega 3 e della 
composizione degli acidi grassi delle membrane eritrocitarie in seguito all’assunzione dell’olio 
di semi di canapa per 8 settimane. 
 
La seconda parte della tesi di dottorato è stata svolta su modelli ex vivo presso il Dipartimento 
di Fisiologia e Biochimica della Nutrizione del Max Rubner-Institut (Karlsruhe, Germania). 
Considerando che le malattie cronico-degenerative sono spesso associate ad una risposta 
immunitaria compromessa, l’obiettivo di questa parte di ricerca è stato quello di studiare il 
potenziale effetto immunomodulatorio di diverse concentrazioni di acidi grassi polinsaturi a lunga 
catena (LC-PUFA), in combinazione con dosi standard di vitamina D3, in cellule immunitarie ex 
vivo prelevate da volontari sani. L’effetto di questi composti bioattivi è stato valutato su due 
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meccanismi implicati nella risposta immunitaria innata, che agiscono specificatamente contro le 
cellule tumorali e gli agenti patogeni: l’attivita delle cellule natural killer (NK) e la fagocitosi. I 
risultati ottenuti hanno mostrato che gli LC-PUFA ad elevate dosi, indipendentemente dalla 
presenza o meno della vitamina D, interferiscono negativamente sulla capacità delle cellule NK 
di lisare e contrastare le cellule tumorali target, mostrando una risposta dose-dipendente. Al 
contrario, è stato osservato un miglioramento dell’attività fagocitaria dei monociti quando gli LC-
PUFA erano coincubati con la vitamina D, suggerendo un potenziale effetto sinergico e 
immunomodulatorio della vitamina D. 
 
In conclusione, attraverso questa tesi di dottorato è stato possibile aumentare le conoscenze sul 
potenziale effetto di diete ricche in composti bioattivi nella modulazione di alcuni fattori di 
rischio per le malattie cronico-degenerative. Questo aspetto risulta particolarmente importante 
soprattutto nelle popolazioni target considerate più a rischio e per le quali un intervento 
nutrizionale appropriato e personalizzato viene considerato l’approccio di prevenzione primario. 
Studi futuri su gruppi di popolazione più ampi e volti a valutare i meccanismi d’azione specifici 
sono necessari al fine di fornire delle dimostrazioni aggiuntive che confermino i nostri risultati. 
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1 INTRODUCTION 
 
1.1 CHRONIC DEGENERATIVE DISEASES: THE DEMAND FOR PREVENTIVE 
STRATEGIES  
Chronic degenerative diseases are onset of noncontagious and long duration illness resulted 
from a variety of risk factors, mainly related to lifestyle and environmental conditions (World 
Health Organization 2005). In the last years, the global rising of all chronic diseases, including 
cardiovascular diseases (CVD), chronic respiratory diseases, autoimmune and inflammatory 
diseases, diabetes and cancers, make current strategies for their management unsustainable. 
According to the World Health Organization (WHO), in 2012 approximately 68% of all deaths 
worldwide were ascribed to chronic diseases, among which the 46.2% were principally caused 
by CVD (WHO 2014). In spite of its public health importance, the growing incidence and 
prevalence of chronic diseases generally result in significant losses to society, in terms of 
increase in human suffering and loss of living quality. In addition, the cumulative effects of 
diseases create a strong impact on the health-care system, becoming an important public issue 
with several indirect economic impacts (Yach et al. 2004). There is clear evidence that preventive 
interventions can reduce the burden of morbidity, disability and premature mortality. Moreover, 
effective actions need strong and long-term public strategies that have a significant public health 
impact and, at the same time, are affordable and feasible to implement.  
In this regard, nutritional intervention is considered one of the most important and easily 
achieved primary prevention strategy to reduce risk factors for chronic degenerative diseases. 
Despite dietary patterns vary across the world, according to traditionally based and locally 
available food, there are some shared characteristics underlying healthy dietary habits. In 
particular, scientific evidence support that disease burden could be considerably reduced among 
the overall population through preventive measures directed to improve dietary choices, 
including: the increase of fruits and vegetables consumption up to the recommended 5 servings 
a day, the selection of whole grains, the replacement of saturated and trans fatty acids with 
unsaturated fatty acids, the reduction of sugar and sweetened beverages consumption, and the 
limitation of salt intake (FAO/WHO 2003; Saeed et al. 2014; Sofi & Dinu 2016). Most of these 
interventions have been targeted to the populations using ‘one size fits all’ public health 
recommendations (e.g. “eat at least 5 portions of fruits and vegetables daily”). However, in most 
cases the effect size achieved in such interventions was usually relatively modest, especially in 
the longer term (Celis-Morales et al. 2015). Moreover, the global burden of premature death and 
chronic ill-health continues to rise, emphasizing the need for more effective strategies. 
The above population-wide preventive strategies may be also combined with targeted 
approaches in order to improve health gains. In fact, while it is necessary to achieve most of the 
population with strong general nutritional guidelines that have considerable potential to enhance 
public health in the complex, it is important to avoid inappropriately applying nutritional 
guidelines to population subgroups that may differ (i.e. genetically). It is noteworthy that a 
personalized nutritional intervention tailored to meet specific nutritional needs for a target 
population (e.g. people with similar risk factors/diseases or same age range) can be more 
effective to achieve a positive outcome. Moreover, in some cases the efficacy of appropriate 
nutritional intervention depends on when they begin (i.e. the life stage). For example, in 
subgroups of population “at higher risk” to develop CVD, such as children with primary 
hyperlipidemia, the treatment of risk factors should start as early as possible in childhood to 
prevent premature events later in life (Catapano et al. 2011; Weintraub et al. 2011). It is clear 
that effective intervention need strong and long-term public strategies that are able to early detect 
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chronic diseases, improve health care and prevent the risk factor exposure starting from early 
life and continuing with interventions for adults and the elderly. Furthermore, since most 
evidence on the relationship between diet/nutrition and chronic diseases is based on 
observational studies, there is specific demand for research aimed to identify the effect of 
personalized nutritional interventions designed to reduce specific risk factors and ameliorate 
well-being in target population groups. 
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1.2 CARDIOVASCULAR DISEASES AND ROLE OF DIETARY FAT  
In recent years, several studies have emphasized the role that several foods or dietary bioactive 
compounds play in the development and treatment of CVD. The CVDs are disorders of the heart 
or blood vessels supplying the heart (coronary heart disease, CHD), brain (cerebrovascular 
disease), arms or legs (peripheral arterial disease). They could be caused by blood clots (deep 
vein thrombosis and pulmonary embolism), or are due to heart muscle and valves damage from 
rheumatic fever caused by bacteria infection (rheumatic heart disease), or are present at birth 
(congenital heart disease). The main pathological process that leads to blood vessels damage is 
the atherosclerosis, an inflammatory process affecting medium-and large-sized blood vessels 
(Mendis et al. 2011). Major risk factors for CVDs and atherosclerosis, such as hyperlipidemia, 
hypertension, obesity and diabetes, could be potentially preventable and controlled by adopting 
healthy diet. Modulation of dietary fat intake is considered the cornerstone in the dietary 
management of CVD. The first evidence of the correlation between CVD and dietary fat intake 
came from the Seven Countries Study. This study showed that death rates from CHD during 10 
and 15 years of follow-up across 16 cohorts were positively associated with dietary intake of 
saturated fatty acids (SFA) and inversely associated with dietary intake of monounsaturated fatty 
acids (MUFA), mainly oleic acid. Furthermore, the variation in CHD death rates observed among 
different geographical regions was explained by differences in the amount of SFA and MUFA 
consumed. A strong associations between the replacement of dietary SFA with unsaturated fatty 
acids and lowered serum total cholesterol (TC) levels was also found (Keys 1965; Keys et al. 
1986). 
The early results of the Seven Countries Study and the consequent explosion of epidemiological 
and clinical trials, lead to the international dietary guidelines for CV prevention to specify the 
amount and type of dietary fatty acids to be consumed. Even if a lack of consensus exists 
regarding the effect of dietary fatty acid on CVD risk, the focus was on the importance of SFAs 
intake reduction due to their negative effect on low-density lipoprotein cholesterol (LDL-C) 
levels. According to the most recent American Heart Association guidelines, the intake of dietary 
SFA should be limited to 5-6% of total calories to lower LDL-C levels (Eckel et al. 2013). The 
long-held dogma that saturated fats per se cause CVD has lately been challenged by research 
findings. In fact, recent studies examining the association of dietary SFA with CVD morbidity 
and/or mortality have revealed inconclusive results, reporting either direct, inverse, or even no 
association (Hammad et al. 2016; Praagman et al. 2016; Siri-Tarino & Krauss 2016). The 
relationship between SFAs and CVD is complex, with numerous factors influencing their relative 
contributions to CVD risk. A critical aspect is what macronutrients should be suggested to replace 
SFA. Systematic review and meta-analysis of randomized controlled trials replacing SFA with 
polyunsaturated fatty acids (PUFA) found that the incidence of CVD events decreased by 19%, 
with 10% reduction in CVD risk with each 5% (of energy) replacement of SFA (Mozaffarian et 
al. 2010). Moreover, the substitution of SFAs with PUFAs has been associated with significant 
decreased in TC and LDL-C levels, and a decrease in the TC:HDL-C ratio (Mensink et al. 2003; 
Siri-Tarino & Krauss 2016). Similarly, when MUFA were used as replacements for SFA, 
reductions in plasma TC, LDL-C, and high-density lipoprotein cholesterol (HDL-C) levels were 
observed, even if the association of this substitution with CVD risk seems less clear (Siri-Tarino 
et al. 2010). In contrast, SFAs replacement with refined carbohydrates and added sugars has been 
associated with higher levels of triglyceride (TG) and small LDL particles and no effect on CVD 
(Siri-Tarino et al. 2010; Siri-Tarino & Krauss 2016). Considering these observations, currently 
the European Society of Cardiology Guidelines on CVD prevention suggest to limit SFA intake 
to a maximum of 10% of energy by replacing it with PUFAs (Perk et al. 2012). The 
cardioprotective effect of PUFAs are generally attributed to a reduction in serum TC and LDL-
C, which slows the progress of atherosclerosis and delays or prevents the onset of CVD and 
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cerebrovascular disease (Abdelhamid et al. 2016). The main sources of PUFA are plant and fish 
oils, with fish being rich in n-3 PUFA and plant oils rich in n-6 PUFA. A large number of studies 
highlighted the potential importance of restricting n-6 PUFA up to 10% of energy and trying to 
set the n-6/n-3 PUFA ratio as lower as possible, along with a particular emphasis on consuming 
adequate amounts of essential fatty acids (Hammad et al. 2016). 
Another important aspect when considering the most recent nutritional recommendations for 
CVD prevention regards to the shift of attention from the macronutrient composition of the diet 
to the intake of healthy foods or dietary patterns. Among the numerous dietary sources of 
unsaturated fats that could replace the energy deriving from SFAs, particular interest has been 
placed on vegetable oils, main sources of MUFA (e.g., extra virgin olive oil) and of good amount 
of PUFA. Since epidemiological evidence suggests a cardioprotective role of the plant sources of 
n-3 PUFA α-linolenic acid (ALA), products such as flaxseed, hempseed oil or canola oil have 
been considered as interesting healthy alternatives. Increased consumption of vegetable oils rich 
in MUFA and PUFA may improve the fatty acid imbalance typical of modern Western diets, high 
in SFA, and in the n-6/n-3 fatty acid ratio. The Mediterranean diet is an excellent example of the 
association between the adherence to a dietary pattern characterized by high unsaturated fat intake 
and the low prevalence of CVD. In particular, this dietary pattern is characterized by high intake 
of MUFA (16–29% MUFA out of 33-40% of energy from total fat), and low SFA (<8% of total 
fats), with extravirgin olive oil being the predominant source of fat (Hammad et al. 2016). The 
cardioprotective effect of the Mediterranean diet have been ascribed to its richness in food 
bioactives, such as the oleic acid and ALA, but also to antioxidants and polyphenols, that have 
been found to exert specific actions on the CV system, particularly on blood pressure, coagulation 
activity and endothelial function (Torres et al. 2015). 
The recent clinical trials of the “PREvención con DIeta MEDiterránea” (PREDIMED) study 
and the Lyon Diet Heart Study have robustly demonstrated the protective effects of diet rich in 
unsaturated fats, associated with the adherence to a Mediterranean-type dietary pattern, in 
primary and secondary prevention of CVD. The primary end point of PREDIMED study, a 
multicenter, 5-year randomized clinical trial, was to evaluate the effect of nuts or extra virgin 
olive oil consumption on major CV events (myocardial infarction, stroke and cardiovascular 
death) in 7447 adults with high risk but no CVD, adhering to a Mediterranean diet. Participants 
were randomized to three diet groups: two Mediterranean diets supplemented with either 
extravirgin olive oil or mixed Mediterranean nuts, and a control diet (advice to reduce dietary 
fat). After a median follow-up of 4.8 years, this study confirmed that, among persons at high CV 
risk, an energy-unrestricted Mediterranean diet supplemented with both extravirgin olive oil or 
nuts resulted in a substantial reduction in the risk of major CV events among high-risk persons, 
in comparison with  the control diet (Estruch et al. 2013). This is consistent with epidemiologic 
studies that showed a 26% reduced risk of all-cause mortality associated with extravirgin olive 
oil consumption (Buckland et al. 2012). On the basis of its MUFA content that had consistently 
demonstrated to benefit plasma lipid profile in clinical trials, the olive oil consumption (23 g/day) 
was issued with a health claim by U.S. Food and Drug Administration. More recently, the 
European Food Safety Authority released a health claim about the role of extravirgin olive oil 
polyphenols (5 mg/day) in protecting LDL from oxidation (EFSA Panel on Dietetic Products 
Nutrition and Allergies 2011). In addition to the MUFA contribution, in the PREDIMED study it 
was demonstrated that even the intake of dietary ALA, supplied mainly by walnuts and extra 
virgin olive oil, was inversely correlated to all-cause and CVD mortality (Sala‐Vila et al. 2016). 
The cardioprotective role of ALA intake, in the context of Mediterranean diet, was also 
investigated in the Lyon Diet Heart Study (de Lorgeril et al. 1994; de Lorgeril et al. 1999). This 
study was a randomized clinical trial designed to evaluate the effectiveness of a Mediterranean-
type diet high in ALA on measures of CHD recurrence rate, after a first myocardial infarction.  
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A total of 605 subjects who survived a myocardial infarction within 6 months of enrollment were 
randomly assigned to a control diet or to a Mediterranean-type diet where the use of olive oil was 
substituted with a canola oil–based margarine as the predominant fat. Compared with olive oil, 
this margarine contained a similar quantity of SFA (15%), less oleic acid (48% vs. 75%), and 
slightly greater amounts of linoleic acid (16.4% vs. 8.6%) and ALA (4.8% vs. 0.6%). After a 
follow-up of 27 months, the risk of cardiac death and nonfatal MI decreased by >60% in the 
intervention group. Although there were no differences in lipids and lipoproteins between the 
experimental and control groups, patients adhering to the Mediterranean-style diet had a 50–70% 
lower risk of recurrent heart disease after 46 months (de Lorgeril et al. 1994; de Lorgeril et al. 
1999). Other evidence from epidemiologic data demonstrated a beneficial role of ALA for the 
primary and secondary prevention of CVD that may be comparable to CVD benefits described 
for animal sources of n-3 PUFA (Hammad et al. 2016). Even limited, emerging research focused 
the attention on the potential cardioprotective effect of hempseed oil consumption, being a high 
source of both the essential fatty acids, i.e. the n-3 ALA and the n-6 linoleic acid (LA) (Rodriguez-
Leyva & Pierce 2010). In the whole, these data suggest that specific dietary pattern could be more 
appropriate than the single nutrient approach for predicting CVD risk. Despite dietary guidelines 
have advanced considerably through the “replacement of SFA with unsaturated fat message” 
instead of recommending decreasing SFAs alone, there is still a lack of evidence from well-
controlled clinical trials showing the optimal diet to maximally reduce CVD risk. 
 
1.2.1 Nuts consumption and cardiovascular diseases risk factors 
There are many interesting foods rich in unsaturated fatty acids and other bioactives that can 
replace dietary SFAs, in order to reduce CVD risk factors. Growing evidence support the 
importance to increase the consumption of nuts, to improve blood lipid profile and reduce risk 
factors for CVD. Nuts are nutrient-dense foods with one seed becoming hard at maturity and a 
thick, hard pericarp (Stern 1991). The most popular edible tree nuts are walnuts, hazelnuts, 
almonds, pistachios and macadamias, including peanuts that belong to the legume bean family 
but have a nutrient profile similar to other tree nuts. The healthy benefits of nuts derive from their 
high content of bioactives, in particular unsaturated fats (nearly one-half of the total fat content), 
mostly MUFAs. A sizeable proportion of PUFAs (predominantly LA) are present in walnuts, 
Brazil nuts and pine nuts, and walnuts are also a rich source of the plant n-3 ALA. Nuts contain 
also high-quality vegetable protein and often have a high content of the amino acid L-arginine, 
which is the substrate for endothelium-derived NO synthesis, a main regulator of vascular tone 
and blood pressure. Moreover, other bioactives with potential health benefits could be found in 
nuts (Table 1.1), such as vitamin E, minerals (potassium, copper, selenium, calcium, and 
magnesium), phytosterols, fibre and polyphenols (especially in the nut skin) (Alasalvar & Bolling 
2015; Ros 2015). The research proving the association between daily unsalted nut consumption 
and reduced risk factors for CHD, is so strong that in 2003 the U.S. Food and Drug Administration 
(FDA) issued a health claim reporting that the consumption of 1.5 oz/day (approximately 42.5 
g/day) of nuts, in particular walnuts, as part of a heart-healthy diet (low in saturated fat and 
cholesterol) can reduce the risk of heart disease (US Food and Drug Administration. Qualified 
Health Claims: Letter of Enforcement Discretion – Nuts and Coronary Heart Disease 2003). 
Subsequently, in 2011 the European Food Safety Authority (EFSA) claimed the positive effect 
of consumption of 30 g/day of walnuts, in the context of a balanced diet, as a contribute to the 
improvement of endothelium-dependent vasodilation in the general population (EFSA Panel on 
Dietetic Products 2011). The consumption of nuts is now recommended in the guidelines on 
lifestyle management to reduce CV risk by the American Heart Association/American College of 
Cardiology (Eckel et al. 2013). 
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Table 1.1 Average composition in macro- and micronutrients and selected phytochemicals of 
100 g of nuts. Adapted from Ros (2015) 
Notes: LA, linoleic acid; ALA, α-linolenic acid; PS, plant sterols; NR, not reported; Na, sodium; K, 
potassium; Ca, calcium; PP, polyphenols. 
 
The scientific evidence behind the recognition of nuts as “heart-healthy” foods derive from both 
epidemiological and clinical research suggesting a consistent inverse association between the 
frequency of nut intake and development of CHD risks and mortality. In fact, a recent report of 
two large prospective cohorts of 76464 women from the Nurses’ Health Study and 42 498 men 
form the Health Professionals Follow-up Study, with 24 and 30 years of follow-up respectively, 
showed a reduced CHD mortality for individuals of both sexes consuming nuts seven or more 
times per week. Remarkably, rates of death from cancer, CVD, heart and respiratory diseases 
were inversely related to frequency of nut consumption (Bao et al. 2013). Similar findings were 
also obtained from the elaboration of food frequency questionnaires from three large cohorts, 
including 71764 of Americans, African and European descent enrolled in the Southern 
Community Cohort Study and 134 265 Chineses from both Shanghai Women's Health Study and 
Shanghai Men's Health Study (Luu et al. 2015). The results, recently published in JAMA, 
demonstrated that consumption of nuts (including peanuts) was associated with decreased overall 
and CVD mortality even across different ethnic groups (blacks, whites and Asians) and among 
individuals from low socioeconomic status groups (Luu et al. 2015). Intervention studies have 
also provided new data suggesting health benefits of nut consumption. As previously discussed, 
findings from the PREDIMED demonstrated a beneficial effect of Mediterranean diets 
supplemented with mixed Mediterranean nuts (30 g/day: 15 g walnuts, 7.5 g almonds and 7.5 g 
hazelnuts) in the reduction of the rates of major CV events (Estruch et al. 2013). Moreover, 
compared to controls, the nut-supplemented group had reduced risk of cardiovascular and cancer 
mortality and those who consumed >3 servings nuts /week had the lowest rates of total mortality 
risk (Guasch-Ferré et al. 2013). Concurring with these findings, a recent 2-year vascular imaging 
study in a PREDIMED subcohort detected an anti-atherosclerotic effect of the Mediterranean 
diets versus the control diet, namely delayed progression of carotid intimamedia thickness and 
plaque, which was more pronounced with the nut-supplemented diet (Sala-Vila et al. 2014). 
Overall, a recent meta-analysis on 23 prospective studies, including a total of 179885 
partecipants, concluded that the consumption of 1 serving of nuts/d is associated with reduced 
risk of coronary artery disease and hypertension, but not with stroke or type 2 diabetes (Zhou et 
al. 2014).  
The beneficial effects of nuts were also evaluated in several short-term randomized clinical 
trials, mainly aimed to compared the effects of nut-enriched versus nut-free diets on the blood 
lipid profile in healthy or in hyperlipidemic subjects. A recent meta-analysis summarizing 
findings from 61 trials indicates that tree nuts intake (1 serving of 28.4 g nuts/day) has consistent 
lipid-lowering effect reducing levels of TC, LDL-C, apolipoprotein B, and TG. Moreover, the 
Nuts 
(100 g) 
Energy 
(kJ) 
Protein 
(g) 
Fibre 
(g) 
Fat 
(g) 
SFA 
(g) 
MUFA 
(g) 
PUFA 
(g) 
LA 
(g) 
ALA 
(g) 
PS 
(mg) 
Na 
(mg) 
K 
(mg) 
Ca 
(mg) 
Total PP 
(mg) 
Almonds 2418 21.3 8.8 50.6 3.9 32.2 12.2 12.2 0.00 120 1 728 248 287 
Brazil nuts 2743 14.3 8.5 66.4 15.1 24.5 20.6 20.5 0.05 NR 3 659 160 244 
Cashews 2314 18.2 5.9 46.4 9.2 27.3 7.8 7.7 0.15 158 12 660 37 233 
Hazelnuts 2629 15 10.4 60.8 4.5 45.7 7.9 7.8 0.09 96 0 680 114 687 
Macadamia  3004 7.9 6.0 75.8 12.1 58.9 1.5 1.3 0.21 116 5 368 85 126 
Peanuts 2220 25.8 8.5 49.2 6.8 24.4 15.6 15.6 0.00 220 18 705 92 396 
Pecans 2889 9.2 8.4 72 6.2 40.8 21.6 20.6 1.00 102 0 410 70 1816 
Pine nuts 2816 13.7 3.7 68.4 4.9 18.8 34.1 33.2 0.16 141 2 597 16 58 
Pistachios 2332 20.6 9.0 44.4 5.4 23.3 13.5 13.2 0.25 214 1 1025 107 1420 
Walnuts 2738 15.2 6.4 65.2 6.1 8.9 47.2 38.1 9.08 72 2 441 98 1558 
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major determinant of cholesterol lowering appeared to be nut dose rather than nut type, with 
stronger effects observed in trials providing ≥60 g nuts/d (Del Gobbo et al. 2015). Even if 
biomarker of oxidation were secondary outcomes in most of nut-supplementation studies, some 
evidence support the emerging role of nuts in reducing oxidative stress (López-Uriarte et al. 
2009). The favorable impact of nuts on lipid profile and oxidative stress appear attributable to 
their high content in bioactive compounds with antioxidant and lipid-lowering properties 
contained in both nut kernel and skin (i.e. vitamin E, polyphenols, phytosterols) (López-Uriarte 
et al. 2009; Alasalvar & Bolling 2015). Although whole nuts may be susceptible to oxidation 
because of their PUFA content – which is particularly high in walnuts – the potential antioxidant 
activity of the polyphenols, vitamin E, and other antioxidants contained in nuts and particularly 
in the skin, may counteract the pro-oxidant effects of fat, thus preventing potentially adverse 
effects of oxidation (López-Uriarte et al. 2009). 
Overall, because of their well-established effect in the reduction of coronary artery disease 
(Zhou et al. 2014), the consumption of whole nuts could be suggested as an excellent choice 
within heart-healthy snack foods especially for people with high CVD risk such as children with 
primary hyperlipidemia. 
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1.3 HYPERLIPIDEMIA AND DIETARY GUIDELINES SINCE PEDIATRIC AGE 
Among the classical risk factors for CVD, hyperlipidemia is considered the major determinant of 
the atherosclerotic progression and it is related to early CV events, especially in pediatric patients 
when inherited disorders occur (Groner et al. 2006; Haney et al. 2007). Hyperlipidemias are 
disorders of lipoprotein metabolism characterized by elevation in serum TC, LDL-C or TG 
concentrations. (Haney et al. 2007). These disorders, can occur as a result of a genetic defect in 
lipid metabolism pathways (primary or familial hyperlipidemia) or secondary to other diseases. 
It is estimated that the primary forms affect 0.5% to 2% of the population and up to 20% of 
survivors of premature myocardial infarction (Juonala et al. 2008). Through the congenital 
hyperlipidemias, the familial combined hyperlipidemia (FCHL) and the familial 
hypercholesterolemia (FH) are the two most common forms, estimated to affect more than 20 
million people worldwide (Feldman et al. 2015; Kavey 2015). While the FCHL is an autosomal 
multigenic inherited lipid disorder characterized by moderate-to-severe elevation in TG and non-
HDL-C, minimal elevation in LDL-C, and reduced HDL-C, the FH resulted in strongest 
manifestation. In fact, FH is caused by an autosomal dominant mutation in the genes encoding 
LDL receptor, PCSK9 or apolipoprotein B and results in normal levels of TG, reduced HDL-C 
but elevated LDL-C levels that exceed 400 mg/dL in case of homozygous form (Sniderman et al. 
2014; Feldman et al. 2015), evidences of xanthomas by age 5 and vascular disease before age 20 
(Haney et al. 2007). 
The atherosclerotic process begins early in life and may be present throughout the lifetime. For 
example, signs of fatty streaks, representing the earliest sign of atherosclerosis, have been 
observed already in fetal aortas and in children above 3 years of age (Narverud et al. 2014). Thus, 
compared with adult hyperlipidemic patients, children and adolescents affected by primary 
hyperlipidemia show a particularly higher risk to develop CVD later in life, mainly due to the 
chronic exposure to elevated LDL-C accumulating in the intima-media of large muscular arteries 
(Durrington 2003; Narverud et al. 2014). Several markers of atherosclerotic development are 
frequently reported in children with primary hyperlipidemia, including markers of inflammation, 
endothelial function, atherogenic lipids and related mediators (Narverud et al. 2014). In addition, 
in the early phase of atherosclerosis, systemic signs of enhanced oxidative stress have been 
detected. Increased oxidative stress results from the imbalance between an excessive reactive 
oxygen species (ROS) and/or deficiency of antioxidant defense mechanisms, and it is considered 
the main cause of cellular damages, endothelial dysfunction and atherosclerosis (Lum & Roebuck 
2001). Despite the scarce data available, hyperlipidemias, and in particular the primary forms, 
seem to be associated with increased markers of oxidative stress, evaluated by measuring 
oxidative DNA damage (DNA strand breaks in lymphocytes, urinary 8-hydroxy-2’-
deoxyguanosine concentrations), oxidative lipid damage (oxidized LDL, urine isoprostanes and 
malondialdehyde) and non-enzymatic or enzymatic antioxidants (Botto et al. 2002; Harangi et al. 
2002; Real et al. 2010; Ho et al. 2013; Pedro et al. 2013; Da Silva Pereira et al. 2013; Cortes et 
al. 2014; Narverud et al. 2014; Tangvarasittichai 2015). Moreover, a significant decrease of 
endothelial function found in hyperlipidemic children has been strongly correlated to prolonged 
exposure to ROS, which can inhibit endothelium nitric oxide release or synthase (Pignatelli et al. 
2009; Loffredo et al. 2013). Consistent with this is the demonstration that, in patients at risk of 
atherosclerosis, oxidative stress negatively correlated with endothelial function and antioxidant 
treatment was able to restore arterial dilatation (Cangemi et al. 2007; Del Bo’ et al. 2014). 
Although research in this field is growing, further studies are required to examine the utility of 
the most promising oxidative biomarkers to predict prognosis or response to treatment. 
Considering the evidence reported, it is clear that early diagnosis and treatment of 
hyperlipidemic children should be started as soon as possible to attenuate development of the 
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potential ongoing early atherosclerotic process and correlated risks of CVDs. Even if in the 
pediatric population the serum cholesterol concentrations is strongly influenced by age, gender, 
ethnicity and pubertal status, lowering of TC and LDL-C below the 75th percentile, 
corresponding to <170 and <110 mg/dl respectively, is considered the target therapy in 
hyperlipidemic children (Daniels & Greer 2008). However, there is still some reluctance to start 
an aggressive lipid-lowering drug therapy in pediatric age. In this context, healthy lifestyle, which 
includes appropriate dietary pattern in agreement with the expert panel guidelines for CV health 
and risk reduction (Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk 
Reduction in Children and Adolescents 2011), physical activity and weight loss in case of 
excessive body weight, is the cornerstone in the treatment of pediatric hyperlipidemia and 
represents an important target for CVD prevention (Haney et al. 2007; Catapano et al. 2011). 
Although the emphasis on reducing saturated fat, trans-fat, and cholesterol is to lower LDL-C, 
there is provocative evidence that other dietary constituents can reduce atherosclerosis in a 
manner independent of total cholesterol levels. In fact, in recent years several studies have 
emphasized the role of several food bioactive compounds in the CVD and atherosclerosis risk 
and progression. The effect of some bioactives such as PUFAs, phytosterols, vitamins and 
polyphenols was demonstrated to reduce or attenuate the atherosclerotic lesions by preventing 
the oxidation of LDL particles, reducing the inflammatory response, leukocyte migration, 
adhesion moleculelevels and blood pressure (Torres et al. 2015). Therefore, there is a need to 
establish appropriate recommendations on the intake of foods rich in these bioactives. 
Pediatric guidelines for the management of cholesterol in pediatric patients were firstly 
introduced in 1992 by the National Cholesterol Education Program (NCEP) Pediatric Panel 
Report (1992), then revised in 1998 by the American Academy of Pediatrics (1998). At that time, 
two different dietary regimens (STEP-I and STEP-II) were suggested to all children over the age 
of 2 years as part of a population-based approach to achieve lower cholesterol levels to acceptable 
range and thus, reduce CV risks. No restriction of fat or cholesterol was recommended for infants 
<2 years when rapid growth and development require high energy intake. In particular, for all 
healthy children (2-18 years) the STEP-I d iet was promoted as follow: total fat over several days 
≤30% of total energy intake and no less than 20% of total energy intake; saturated fatty acids 
(SFA) <10% of total energy intakes; and dietary cholesterol <300 mg per day. While, for children 
with high LDL–C levels or for those where a 3-month STEP-I diet did not result in a lower LDL–
C level, the Panel suggested to follow STEP-II dietary guidelines, consisting of: no more than 
30% and  no less than 20% of total energy from fat; <7% of total calories from SFA; ≤10% 
of calories from PUFA; and  no more than 200 mg per day of cholesterol (National 
Cholesterol Education Program 1992; American Academy of Ped iatrics 1998). Scientific 
evidence supported  the effectiveness of this approach in the reduction of the 
development of atherosclerosis in childhood  and  ad olescence. In particular, a decreased  
level of plasma TC and  LDL-C by <7--9% and  10--20% were found  respectively after  
STEP-I and  STEP-II d iet, compared  with the average American d iet (Yu-Poth et al. 1999).  
Despite the NCEP guidelines provided  the rationale for new d ietary prevention efforts 
initiated  early in life, guid elines for o ther nutrients needed  at ped iatric age were not 
addressed . For this reason, in 2011 the National Heart, Lung and  Blood  Institute 
(NHLBI) developed  new guidelines based  on the previous NCEP recommendations and 
Dietary Guidelines for Americans (2010), to create the CHILD-1 (Cardiovascular Health 
Integrated Lifestyle Diet–1), evidence-based recommendations for dietary changes to reduce CV 
risk in pediatric patients. CHILD-1 not only is built on the recommendations for achieving 
nutrient adequacy in growing children, but also added evidence regarding the efficacy of specific 
dietary and lifestyle changes in reducing CV risks. Because the focus of these guidelines was on 
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CV risk reduction, the review specifically evaluated dietary fatty acid and energy components as 
major contributors to hypercholesterolemia and obesity, as well as dietary composition and 
micronutrients as they affect hypertension. In accordance with previous NCEP, also the 
NHLBI developed  two-step regimens, the CHILD-1 and  CHILD-2, provid ing d ifferent 
recommend ations on the basis of severity of lip id  d iseases, as reported  in Table 1.2. In 
fact, the CHILD-1 represents the first stage in dietary change for children with a positive family 
history of early cardiovascular disease, obesity, primary hypertension or high-risk medical 
conditions that might ultimately require more intensive dietary change. The CHILD-1 guidelines 
confirmed the usefulness of a normocaloric diet administration not exceeding 25–30% of calories 
from fat, 8–10% from saturated fats, and 20% from MUFA and PUFA, avoiding trans fatty acids 
and providing not more than 300 mg per day of cholesterol and consuming adequate amounts of 
fiber. Moreover, specific dietary suggestions and supportive actions were provided for each child 
age range. For children with identified hypercholesterolemia and elevated lipid levels aged 2-21 
years, a more stringent CHILD-2 diet with SFA limited at ≤7% of calories and dietary cholesterol 
to 200 mg/day has been suggested. In addition, CHILD-2 was subdivided in two different 
regimens (CHILD-2 TG or CHILD-2 LDL) developed specifically for children older than 2 years 
with elevated TG or LDL-C levels. In particular, in children with an elevated TG level, reduction 
of simple carbohydrate intake in favor of complex carbohydrates, a reduced SFA intake, an 
increased intake of omega-3 from fish, physical activity and weight loss were suggested in order 
to decreased TG levels. While, in children with FH and abnormal LDL-C levels, a low-fat, low 
SFA CHILD-2 LDL diet was suggested, underlying the importance to replace the usual fat 
sources with plant sterols and/or plant stanol esters (>2 g/day) and to increase the intake of cereal 
enriched with water-soluble fiber psyllium (6 g/day for children 2–12 years and 12 g/d for those 
≥12 years). For all children, other life-style modifications have been recommended, including 1 
h/d of moderate-to-vigorous physical activity and the limitation of sedentary time (<2 h/day of 
TV/video) (Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction 
in Children and Adolescents: Summary Report 2011).  
In Europe, the evidence that diet is the main stay of treatment for hyperlipidaemia in childhood 
was also reported in the Guidelines for the management of dyslipidaemias (Catapano et al. 2011), 
developed by the European Society of Cardiology (ESC) and the European Atherosclerosis 
Society (EAS) These guidelines provided a review of evidence and recommendation for helping 
physicians in their management of diagnosis and treatment of dyslipidemia. However, despite the 
document provides a recommendation section on critical lifestyle and dietary modifications that 
should be adopted to control and prevent CVD since pediatric age, the guidelines were directed 
to the overall population of dyslipidaemic patients and not specifically to children at different age 
(Catapano et al. 2011). 
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Table 1.2 Evidence-Based Recommendations for Diet and Nutrition: comparison between CHILD-1, CHILD-2 LDL and CHILD-2 TG diet (Expert 
Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report 2011). 
 
Age CHILD-1 CHILD-2 LDL CHILD-2 TG 
Birth– 
6 
months 
 
• Infants should be exclusively breastfed (no supplemental formula or other foods) until the age of 6 months 
 
6 – 12 
months 
 
• Continue breastfeeding until at least 12 mo of age while gradually adding solids; transition to iron fortified formula until 12 months if reducing breastfeeding 
• Fat intake in infants <12 months of age should not be restricted without medical indication 
• Limit other drinks to 100% fruit juice (≤4 oz/d); no sweetened beverages; encourage water 
 
12 – 24 
months 
 
• Transition to reduced-fat (2% to fat-free) unflavored cow’s milk 
• Limit/avoid sugar-sweetened beverage intake; encourage water 
• Transition to table food with:  
      - Total fat: 30% of daily kcal/EER 
      - SFA fat: 8%–10% of daily kcal/EER  
      - MUFA and PUFA >20% of daily kcal/EER 
      - Cholesterol: 300 mg/day 
      - Avoid trans fat as much as possible 
Supportive actions: 
• The fat content of cow’s milk to introduce at 12–24 month of age should be decided together by parents and health care providers on the basis of the child’s growth, 
appetite, intake of other nutrient-dense foods, intake of other sources of fat, and potential risk for obesity and CVD 
• 100% fruit juice (from a cup), ≤ 4 oz/d 
• Limit sodium intake 
• Consider DASH-type diet rich in fruits, vegetables, whole grains, and low-fat/fat-free milk and milk products and lower in sugar 
2 – 10 
years 
 
• Primary beverage: fat-free unflavored milk 
• Limit/avoid sugar-sweetened beverages; encourage water 
• Encourage high dietary fiber intake from foods 
• Fat content: 
      - Total fat 25%–30% of daily kcal/EER 
      - SFA: 8%–10% of daily kcal/EER 
      - MUFA and PUFA:  >20% of daily kcal/EER 
      - Cholesterol: 300 mg/d 
      - Avoid trans fats as much as possible 
Supportive actions: 
• Teach portions based on EER for age/gender/age  
• Encourage moderately increased energy intake during periods of 
rapid growth and support DASH eating plan 
• Encourage dietary fiber from foods (age +5 g/die) 
• Limit naturally sweetened juice (no added sugar) to 4 oz/d 
• Limit sodium intake 
 
X 
X 
X 
• Fat content: 
    - Total fats: 25–30% of daily kcal/EER 
    - SFA: <7% of daily kcal/EER 
    - MUFA: 10% of daily kcal/EER 
    - Cholesterol: <200 mg/day 
    - Avoid trans fat as much as possible 
Supportive actions: 
• Children with FH >2 year: replacement of usual 
fat sources with plant sterols (>2 g/day)  
• Plant stanol esters as part of a regular diet 
• The water-soluble fiber psyllium can be added 
to a low-fat, low-SFA diet (6 g/day for children 
2–12 y of age and 12 g/d for those ≥12 y of age 
 
X 
X 
X 
• Fat content: 
  - Total fats: 25–30% of daily kcal/EER 
  - SFA: <7% of daily kcal/EER 
  - MUFA: 10% of daily kcal/EER 
  - Cholesterol: <200 mg/day 
  - Avoid trans fat as much as possible 
Supportive actions: 
• Replace simple with complex 
carbohydrates 
• No sugar-sweetened beverages 
• Increase dietary fish to increase PUFA 
ω-3 fatty acids 
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• As for all children, 1 h/d of moderate-to-vigorous physical activity 
and <2 h/day of sedentary screen  
• 1 h/d of moderate-to-vigorous physical activity 
and <2 h/day of sedentary screen time  
• 1 h/d of moderate-to-vigorous physical 
activity and <2 h/day of sedentary 
screen time  
11 – 21 
years 
 
• Primary beverage: fat-free unflavored milk 
• Limit/avoid sugar-sweetened beverages; encourage water 
• Encourage high dietary fiber intake from foods 
• Fat content: 
      - Total fat: 25%–30% of daily kcal/EER 
      - SFA:  8%–10% of daily kcal/EER 
      - MUFA and PUFA: >20% of daily kcal/EER 
      - Cholesterol: 300 mg/d 
      - Avoid trans fat as much as possible 
Supportive actions: 
• Teach portions based on EER for age/gender/activity 
• Encourage moderately increased energy intake during periods of 
rapid growth and/or regular 
• Moderate-to-vigorous physical activity 
• Advocate dietary fiber: goal of 14 g/1000 kcale 
• Limit naturally sweetened juice (no added sugar) to 4–6 oz/d 
• Limit sodium intake 
• Encourage healthy eating habits: breakfast every day, eating meals 
as a family, limiting fast-food meals 
• Support DASH-style eating plan  
 
 
X 
X 
X 
• Fat content: 
    - Total fats: 25–30% of daily kcal/EER  
    - SFA: <7% of daily kcal/EER 
    - MUFA: 10% of daily kcal/EER 
    - Cholesterol: <200 mg/day 
    - Avoid trans fat as much as possible 
Supportive actions: 
As for age 2-10 years 
 
X 
X 
X 
• Fat content: 
  - Total fats: 25–30% of daily kcal/EER  
  - SFA: <7% of daily kcal/EER 
  - MUFA: 10% of daily kcal/EER 
  - Cholesterol: <200 mg/day 
  - Avoid trans fat as much as possible 
 
Supportive actions: 
As for age 2-10 years 
Notes: CHILD-1, Cardiovascular Health Integrated Lifestyle Diet 1; CHILD-2 LDL, CHILD-2 for children with elevated LDL-C; CHILD-2 TG, CHILD-2 for 
children with elevated triglycerides; EER, indicates estimated energy requirement; FH, familiar hypercholesterolemia; MUFA, mono-unsaturated fat; PUFA, 
polyunsaturated fat; SFA, saturated fat. 
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1.4 IMMUNE FUNCTION AND THE ROLE OF NUTRITION 
A common denominator playing a role in the prevention of both chronic diseases and infections 
is a healthy and well-functioning immune system. This may be particularly critical for specific at 
risk target population groups such as children and the elderly.  
The immune system consists of a complex network of specialized cells organized to counteract 
the infection of harmful microorganisms or other non-self compounds. It is generally divided into 
two different systems on the base of the speed and specificity of its response: the innate and 
adaptive immunity. The innate immune response consists in a rapid, non-specific, non-
anticipatory and non-clonal response that plays a crucial role in the early first-line defense against 
intracellular growth microorganisms or malignant cells, through several mechanisms including 
the phagocytosis, the respiratory burst, release of proinflammatory cytokines or the natural killer 
(NK) cell activity. Moreover, the innate immune system has also a key role in the initiation and 
subsequent course of the acquired immunity, which is a more specialized and anticipatory 
response that becoming prominent after several days as antigen-specific T and B cells have 
undergone clonal expansion. Although innate and adaptive immune systems have been 
traditionally viewed as two separate entities, it has now become very clear that these are integrated 
and interconnected systems (Watson et al. 2010; Noakes & Michaelis 2013). 
An excessive or inappropriate innate immune response (i.e. a low NK activity) decrease the 
ability to counteract pathogenic organisms or cancer cells. Moreover, deviation in the 
programming of immune cells may lead to allergic reactions against harmless environmental 
factors or may result in an autoimmune response that is characterized by an immunological attack 
directed at the host’s tissues and followed by inflammatory processes in the affected organs 
(Nathan 2002; Schleinitz et al. 2010; Kiliç et al. 2013). Even if the inflammation is a protective 
response of the body against damaging insults, infectious agents and injuries that initiates healing, 
its chronification compromises even these healing processes. In fact, chronic inflammation can 
affect nearly all organs and tissues and persistence of an inflammatory environment seem to mark 
the development of onset of chronic degenerative conditions, including obesity, CVD, diabetes, 
autoimmune and neurodegenerative conditions (Kiliç et al. 2013; Ricordi et al. 2015). 
It is now widely recognized that diet and nutrient status are important factors contributing to 
immunocompetence. Dietary macro- and micronutrients are essential for the development, 
maintenance, and optimal functioning of the immune system. Immune competence can be easily 
dysregulated as a result of changes of nutritional status. Both deficiency and excess of a number 
of nutrients adversely affect the numbers and activity of immune cells (Kelley 2001; Watson et 
al. 2010). For example, malnutrition, due to insufficient intake of nutrients, is a striking example 
of the critical role that nutrition plays in innate immune responses. On the other hand, over-
nutrition and high intake of specific nutrients are associated with chronic inflammatory diseases, 
underlying the fact that nutrients must be present at appropriate levels to ensure proper immune 
function (Field et al. 2002; Watson et al. 2010; Calder & Parveen 2013). For example, evidence 
suggests that macronutrient excess can promote inflammatory responses in adipocytes and 
macrophages, in part through the activation of stress responses. Acute in vitro induction of 
hyperglycemia in healthy individuals and stimulation of monocytes with high glucose levels 
induces IL-6, IL-18 and TNF-α production (Esposito et al., 2002; Morohoshi et al., 1996). 
Similarly, excess extracellular and intracellular free fatty acids and triglycerides trigger 
endoplasmic reticulum stress responses or toll like receptor activation in adipocytes and 
macrophages (Ozcan et al., 2004, 2009; Schaeffler et al., 2009; Shi et al., 2006). In this context, 
it is noteworthy that certain dietary lipids are essential in the modulation of several immune 
functions. For example, n-3 long chain PUFAs (LC-PUFAs) is widely recommended to reduce 
inflammation in immune/inflammatory chronic diseases such as atherosclerosis, CVD, diabetes 
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and arthritis, and may be also beneficial in treating infectious diseases (Husson et al. 2016). 
However, although LC-PUFA have been applied in the resolution of diseases characterized by an 
overactivation of immune system due mainly to their anti-inflammatory properties, high amounts 
of PUFA could be responsible for an immunosuppressive state and for an increase in the 
susceptibility to infectious microorganisms. 
Recently, substantial research has also focused on the contribution of specific micronutrients to 
an optimum functioning of the immune system. Deficiencies in specific minerals or vitamins can 
cause an increased susceptibility to infection, leading to frequent and chronic infections 
controlled only through a nutritional rehabilitation treatment (Field et al. 2002; Afacan et al. 
2012). As an example, zinc is essential for the activity of many enzymes implicated in the immune 
activity and its deficiency, that affect one third of the world’s population, is a major risk factor 
for many diseased states that involve the immune systems such as pneumonia, diarrhea, malaria, 
HIV, etc. (Field et al. 2002; Caulfield et al. 2004; Gruber & Rink 2013) and has been associated 
with increased chronic inflammation and impaired innate immune activity (Wirth et al. 1989; 
Sheikh et al. 2010; Bao et al. 2010; Besecker et al. 2011). Similarly, there is much evidence that 
poor selenium intake impairs the initiation and regulation of inflammation and immune response 
leading to an ineffective activity against infection, and the benefits of increasing selenium intake 
through supplementation are clear (Huang et al. 2013). Regarding vitamins, the potential 
immunoregulation of vitamin D has attracted a lot of attention since it was discovered that all 
immuno cells express the vitamin D receptor (VDR) and, in most cell types, activation induces 
further VDR expression. In particular, experimental evidence has shown that some immune cells 
(NKT cells and CD8αα T cells) do require adequate vitamin D status and VDR signaling to 
develop and function normally. In addition, the evidence suggests that 1,25(OH)2-vitamin D and 
the VDR are important inhibitors of autoimmunity mediated by Th1 and Th17 cells (Harvey & 
Cantorna 2013). Even if vitamin D would be effective in autoimmune disease, it is unclear what 
dose, how often and/or what the 25(OH)-vitamin D blood levels should be achieved. Moreover, 
it is recognized that vitamins (i.e. A, B6, B9, B12, C, D, E) and minerals (i.e. iron, zinc, copper, 
and selenium) work in synergy to support the protective activities of the immune cells. Finally, 
all these micronutrients, with the exception of vitamin C and iron, are essential for antibody 
production (Field et al. 2002; Watson et al. 2010; Calder & Parveen 2013). Despite the importance 
of adequate nutrient intake, the current evidence is not sufficient to make a definite dietary 
recommendation for prevention or therapy, even in those with existing immune disease. In fact, 
many promising results have been achieved in in vitro experiments. Thus, in vivo approaches are 
needed to have results transferable to practical therapeutic options. Moreover, future 
investigations are need for a better understanding on the molecular mechanisms of action of 
nutrients on the immune system and the dose that could be considered safe for the overall 
metabolism. Currently, the achievement of an adequate nutrient intake is considered the best 
practice for promoting an optimal immune system function and prevent the risk of chronic 
degenerative diseases. 
  
1. Introduction 
24 
 
1.4.1 Immunomodulatory effect of LC-PUFA  
Dietary LC-PUFAs have been shown to influence immune system via different mechanisms, 
including the reduction of lymphocyte proliferation, and cytokine synthesis, the increase 
phagocytic activity or modification of NK cell activity (Watson et al. 2010). LC-PUFAs can 
influence the inflammatory response in either pro- or anti-inflammatory mediators. In particular, 
since the n-6 LC-PUFA arachidonic acid (ARA) is the precursor of eicosanoids, known to have 
a central role in inflammation, and since ARA metabolism is a long recognized target for anti-
inflammatory therapies, it has generally been assumed that n-6 LC-PUFA must, almost by 
definition, promote inflammation (Calder 2009). However, the mechanisms that participate in 
these processes are more complex and still poorly understood, since some ARA-derived 
eicosanoids have both pro- and anti-inflammatory roles (e.g. prostaglandin E2) and some others 
may be very important in resolving inflammation (e.g. lipoxin A4) (Calder 2009; Calder & 
Parveen 2013). 
On the contrary, there is evidence from both experimental models and clinical studies that n-3 
LC-PUFAs have anti-inflammatory and immunomodulatory effects, considered beneficial in 
treating infectious, autoimmune and inflammatory chronic diseases (Calder 2006; Watson et al. 
2010; Husson et al. 2016). Different mechanisms have been proposed. Extensive data 
demonstrated that increased consumption of n-3 LC-PUFAs, such as eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA), results in increased proportions of those fatty acids in 
inflammatory cell phospholipids, partly at the expense of ARA (Calder 2009). Since the same 
enzymes metabolize both n-3 and n-6 PUFAs, n-3 LC-PUFAs competitively inhibit the 
production of ARA, and thus ARA-derived proinflammatory eicosanoids, with a final anti-
inflammatory effect. Moreover, high intake of n-3 LC-PUFA from fish oils, decreases the 
production of inflammatory cytokines, other inflammatory agents (e.g. ROS) and the expression 
of adhesion molecules (Calder 2006; Calder 2009). 
Most often, the idea that n-3 LC-PUFAs diminish inflammatory cell functions is interpreted in 
a favorable way, with the conclusion that they are anti-inflammatory and thus will be beneficial 
to health. However, because these cells are among the cellular components of the immune system, 
a reduction in their activity could also compromise the immune response against microorganisms 
(McMurray et al. 2011; Husson et al. 2016). In fact, inflammatory cells recognize bacteria in a 
nonspecific way and destroy them by phagocytosis or via the production of superoxide and related 
ROS in the respiratory burst. Incorporation of n-3 LC-PUFAs into the cell membrane may change 
the membrane fluidity (Kelley 2001; Shaikh et al. 2015), with a consequent alteration in activity 
of cell’s actin skeleton that is accompanied by a reduction in phagocytosis of microorganisms by 
macrophages and antigen-presenting cells, phagolysosome formation, and NK cell activity (Thies 
et al. 2001; Rees et al. 2006; Mukaro et al. 2008; McMurray et al. 2011). The second consequence 
of the changed membrane fluidity is the inhibition of a clustering of surface proteins, which is 
involved in numerous signalling pathways in immune cell interactions (Bonilla et al. 2010). 
On the basis of current data, although n-3 LC-PUFAs are widely used in the treatment of 
diseases characterized by an overactivation of immune system (e.g. chronic inflammatory 
diseases), their intake could be both beneficial and deleterious in the prevention and control of 
infectious diseases (Anderson & Fritsche 2002; Watson et al. 2010; Husson et al. 2016). In fact, 
in healthy humans, the supplementation with EPA and DHA at daily dose of 0.5 g/day improves 
the outcome of infections caused by opportunistic extracellular pathogens that induce a strong 
inflammatory response (Husson et al. 2016). Thus, the beneficial effects of n-3 LC-PUFAs may 
result from their anti-inflammatory properties, which limit tissue damage associated with the 
pathogen and the inflammatory response. 
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Conversely, high amount of n-3 LC-PUFA could be responsible for an immunosuppressive state 
and for an increase in the susceptibility to infectious microorganisms. In fact, the anti-
inflammatory properties of n-3 LC-PUFA supplementation demonstrated to be detrimental in 
respiratory, systemic and ocular infections with intracellular pathogens (e.g. M. tuberculosis, 
Influenza A virus, Salmonella spp., L. monocytogenes, Herpes simplex virus), which need a strong 
inflammatory and immune cell responses to eradicate infected cells (Husson et al. 2016). This 
effect is particularly important to consider especially in immunocompromised patients and in 
infants and elderly, who are the major targets for n-3 LC-PUFA supplementation and, at the same 
time, the main groups at risk of sepsis.  
Overall, the review of published studies highlights that the effect of fatty acids on immune 
system function are conflicting due to multiple factors, including the type and amount of fatty 
acids consumed with the diet, the different supplementations and the target subjects enrolled in 
the study. Moreover, for obvious reasons, the altered resistance to infectious microorganisms has 
been analyzed especially in animal models or in vitro, using different microorganism to stimulate 
the host immune response. Therefore, it is pivotal to define the optimal n-3 LC-PUFA doses, 
timing of intake, and the characteristics of patients who might benefit from n-3 LC-PUFA 
supplementation. 
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2 AIM OF THE STUDY 
 
The aim of the present Ph.D. thesis was to evaluate the effect of specific foods and food bioactives 
in the modulation of risk factors for chronic-degenerative diseases in “at risk” groups of 
population, thorough both in vivo and ex vivo approaches. Thus, the research project has been 
subdived in two part, as described below. 
 
PART I 
In the first part we developed two different dietary interventions in a population of Italian children 
and adolescents affected by primary hyperlipidemia, a risk factor for future CV events. In 
particular, it was examined whether regular intake of food sources of unsaturated fats and other 
bioactives, i.e. hazelnuts and hempseed oil, were effective in the improvement of CV risk related 
biomarkers. In this context, three different activities were scheduled: 
- Characterization of FA composition of erythrocyte phospholipids to provide the first 
experimental data in this target population and to ascertain potential association with serum 
lipids and dietary factors;  
- Development of a dietary intervention study to investigate the effect of regular hazelnuts 
consumption in the modulation of markers of oxidative stress (DNA damage and ox-LDL) 
and lipid profile (serum lipids and FAs composition erythrocyte phospholipids); 
- Development of a dietary intervention study to evaluate the impact of a supplementation with 
hempseed oil rich in ALA on serum lipid profile and fatty acid composition of erythrocyte 
phospholipids. 
 
PART II 
The second part of the project was devoted to ex vivo investigations carried out at the Department 
of Physiology and Biochemistry of Nutrition of the Max Rubner-Institut (Karlsruhe, Germany). 
In particular, two different studies were developed on ex vivo immune cells from healthy subjects 
to investigated the immunomodulatory effect of LC-PUFAs (EPA and ARA) with vitamin D in 
the modulation of two mechanisms crucially involved in the innate immune response:  
- The activity of NK cells against target human cancer cell line (K562); 
- The phagocytic activity of monocytes and granulocytes against infectious agents (opsonised 
Escherichia coli). 
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3 DEVOLOPMENT OF DIETARY INTERVENTION STUDIES IN 
CHILDREN AND ADOLESCENT WITH PRIMARY HYPERLIPIDEMIA 
 
 
3.1 Subjects and Methods 
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3.1 CHARACTERISATION OF SERUM LIPID PROFILE AND FATTY ACID 
COMPOSITION OF ERYTHROCYTE PHOSPHOLIPIDS  
 
3.1.1 SUBJECTS AND METHODS 
Subject enrollment and study design 
Fifty-four children and adolescents with primary hyperlipidemia were recruited among pediatric 
patients cared at the Department of Health Science and Pediatrics of the University of Turin, after 
a screening for eligibility. Patients included in the study were aged 11 ± 3 (mean ± SD) years old 
and were affected by different types of hyperlipidemia: familial hypercholesterolemia (FH), 
familial combined hyperlipidemia (FCHL) or polygenic hypercholesterolemia (PHC). Diagnostic 
criteria of primary hyperlipidemia were based on accepted international standards (Guardamagna 
et al. 2011). FH was diagnosed in presence of LDL-C ≥ 95th percentile, parental LDL-C ≥ 190 
mg/dL, tendon xanthomas and/ or cardiovascular disease (phenotype IIA). FCHL was diagnosed 
in children showing TC and/or TG >90th age- and sex-specific percentile, with at least one parent 
affected by hypercholesterolemia, hypertriglyceridemia, or both (IIA, IV, or IIB phenotype, 
respectively), with concomitant individual and familial lipid phenotype variability. Children with 
LDL-C levels >90th percentile and a family history of dominant inherited hypercholesterolemia, 
but not fulfilling the biochemical international diagnostic criteria of FH or FCHL were diagnosed 
with PHC. 
Exclusion criteria were: secondary hyperlipidemia; obesity (body mass index (BMI) ≥ 90th 
percentile, age and sex matched); renal, endocrine and liver disorders; or chronic diseases requiring 
drug treatment (i.e. immunologic, neurologic, or oncohematologic disorders). Participants were 
not on lipid-lowering treatments (including functional foods) in the previous 3 months and were 
not smoking. 
At recruitment, children were on diet therapy and were selected only after demonstrating 
appropriate compliance with dietary instructions, provided by a trained nutritionist, in the previous 
2 months. Recruited subjects and their families were trained by a nutritionist to adhere to a properly 
dietary regimen, evaluated through a weekly food diary during the study period. Dietary 
recommendations were based on the cardiovascular health integrated lifestyle diet (CHILD-1) for 
children with identified dyslipidemia, as in the American Academy of Pediatrics (Expert Panel on 
Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: 
Summary Report 2011). The essential features were: 55% of daily energy from carbohydrate, 15% 
from protein, 30% from total fat (SFA <10%, MUFA and PUFA 20% of total energy), dietary 
cholesterol <200 mg/day, and 10-25 g/day of soluble fibre. In order to examine correct dietary 
habits, parents of the enrolled children, and probands themselves, were asked to fill in a weekly 
food diary to be provided at time of the visit. Detailed instructions on how to collect diet records 
were comprehensively explained by a nutritionist. The nutritional evaluation of macronutrients and 
FA content of the diet registered was performed with MètaDieta® Software using the Italian Food 
Composition Tables (Carnovale & Marletta 2000). 
All subjects enrolled underwent a medical examination in the morning between 8 and 10 a.m. on 
the day of recruitment. Physical parameters including height, weight and blood pressure were 
measured. Fasting blood samples were drawn by venipuncture for the analysis of the lipid profile 
and the fatty acid (FA) composition of red blood cell (RBC) phospholipids. 
The study protocol complied with the principles of the Declaration of Helsinki, and was approved 
by the ethics committee of the City of Health and Science University Hospital of Turin 
(EC:CS377). The study purpose and protocol were exhaustively explained to all participants and 
their parents, who signed an informed consent before study enrollment. The trial was registered 
under ISRCTN.com (identifier no. ISRCTN12261900). 
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Physical evaluation 
Height and weight were measured to the nearest 0.1 cm and 0.1 kg respectively (Wunder SA.BI. 
S.r.l. Italy), with the patients wearing hospital gowns and had bare feet. BMI was calculated as 
body weight in kilograms divided by height squared in meters (kg/m2). Systolic and diastolic 
blood pressure was measured with a mercury sphygmomanometer during the medical 
examination. 
 
Blood samples collection and separation 
Venous blood samples of 2.5 ml were drawn into vacutainer tubes containing lithium heparin (to 
obtain plasma and RBCs) or silicon (to obtain serum). Plasma and serum were separated by 
centrifugation at 1400 g for 15 min at 4°C. Plasma was stored at -80°C for further analysis, while 
serum was immediately analysed. The buffy layer of white blood cells was removed using a pipette, 
and RBCs were washed twice in an equal volume of a physiologic solution (0.9% NaCl, w/v). Two 
aliquots (0.5 ml) of RBCs were stored at -80°C until the analysis. 
 
Analysis of serum lipid profile 
Serum levels of TC, HDL-C and TG were directly determined by an automatic biochemical analyzer 
(Olympus AU2700, Japan), while the LDL-C concentration was estimated using the Friedewald 
formula (LDL= TC-(HDL+TG/5). Non-high density lipoprotein cholesterol (non–HDL-C) was 
calculated as TC minus HDL-C.  
 
Analysis of FA composition of RBC phospholipids 
FAs extraction from RBC phospholipid was performed in accordance to the method previously 
described by Simonetti et al. (2002). Briefly, 1 ml of distilled water, 300 mg of RBC, 2.5 ml of 
butylated hydroxitoluene (110 µg/ml in methanol), and 5 ml of chloroform were transferred into 
10 ml plastic tubes. The mixtures were shaken on vortex for 3 min and centrifuged at 1200 g x for 
10 min. The chloroform phase was transferred into 10 ml plastic tubes. An aliquot of 2.5 ml 
chloroform was added to the tubes containing RBCs to perform the second extraction by vortexing 
for 3 min, and, after centrifugation at 1200 g x for 10 min, the supernatant was transferred into the 
corresponding tube. The chloroform phase was eluted on a silica cartridge (Sep-Pack PlusSilica, 
Waters), which was then evaporated under nitrogen steam. The silica phase was transferred into 
pyrex glass tubes, and 2.5 ml of a toluene/methanol (1:4 v/v) mixture and 200 µl of acetyl chloride 
were added. After 1 h in an oven at 100°C, 5 ml of K2CO3 (6% w/v in water) was added to the 
silica. After centrifugation at 1200 g x 10 min, the supernatant was transferred into amber glass 
vials, dried under nitrogen and resuspended in 100 µl of hexane before gas chromatography 
analysis.  
The analysis of FA methyl esters extracts was performed by gas chromatography, as described 
by Ackman (1986) partly modified. Separations were performed with a 30 m 0.32 mm i.d. 
Omegawax 320 capillary column, under these conditions: initial isotherm, 140°C for 5 min; 
temperature gradient, 2°C/min to 210°C; final isotherm, 210°C for 20 min. The injector 
temperature was 250°C. Injection volume was 1 µl with a split ratio of 1/100, and the flame 
ionization detector temperature was 250°C. Carrier and makeup gas were hydrogen and nitrogen, 
respectively. FA retention times were obtained by injecting the Omegawax test mix as standard. 
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Statistical analysis 
Statistical analysis was carried out by R statistic software (version 3.1.2). One way repeated-
measures analysis of variance (ANOVA) was used to compare the data obtained from subjects 
stratified by sex and by type of hyperlipidemia; post-hoc analysis of differences between paired 
data was assessed, when appropriate, by the Least Significant Difference. Differences in serum 
lipid concentrations, anthropometric data and the proportion of FA composition of RBCs in relation 
to different lipid disorders was evaluated by non-parametric Wilcoxon-Mann-Whitney test with 
Benjamini-Hochberg correction. The relationship among variables was assessed by Kendall and 
Spearman rank, non-parametric correlation tests. This approach was used to achieve the 
significance level and the trend (direct or inverse) of the data correlation. The level of statistical 
significance was set at p≤ 0.05; data are presented as a mean and standard deviation (SD). 
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3.1.2 RESULTS  
The results reported in this section have been recently published (Deon et al. 2016). 
 
Subjects characteristics 
The main subject features are summarized in Table 3.1 and reported in our publication (Deon et 
al. 2016). The cohort of children and adolescents included 54 hyperlipidemic subjects aged 
between 6-17 years old: 14 patients were affected by FH (7 F), 21 by FCHL (12 F) and 19 by PHC 
(7 F). Five subjects were slightly overweight and the mean of blood pressure levels were in the 
normal range.  
Table 3.1 Subject characteristics (n = 54). 
 
Parameter Value 
Age, years  11 ± 3 
Sex, M/F 28/26 
Weight, kg 47.9 ± 16.4 
Height, cm 149.1 ± 16.1 
BMI, kg/m2 20.9 ± 4.0 
Systolic blood pressure, mmHg 104.5 ± 10.1 
Diastolic blood pressure, mmHg 66.6 ± 7.4 
Notes: BMI, body mass index. Values are reported as 
mean ± SD. 
 
Serum lipid profile and RBC phospholipid composition 
Serum lipid profile and FA composition of RBC phospholipids were analysed in all patients and 
classified according to sex and clinical diagnosis (Table 3.2). 
Mean of serum lipid parameters exceeded the 90th percentiles (age and sex related), except for 
HDL-C, showing normal concentrations. The RBC phospholipid composition was 
SFA>PUFA>MUFA and all patients showed a low omega-3 index value (≤ 4%), that is associated 
with a high risk of mortality for CVD (Harris & Von Schacky 2004).  
No significant serum lipid concentration difference was observed between males and females, 
while sex-related differences were detected in the phospholipid composition of RBCs. In fact, 
females showed significantly higher proportion of the SFA stearic acid and lower concentration of 
the n-6 PUFA dihomo-γ-linolenic acid (DGLA) in RBCs phospholipids (p= 0.031 and 0.050, 
respectively). Moreover, we found a trend toward lower level of MUFA and MUFA/SFAs ratio in 
RBCs of females with respect to males (p= 0.052 and 0.056, respectively). 
A further analysis considering the type of primary hyperlipidemia revealed that children with FH 
had higher levels (p <0.001) of serum TC, LDL-C and non-HDL-C, and lower serum HDL/LDL 
ratio if compared to children with FCHL or PHC, that is due to the different diagnosis considered. 
Finally, significantly lower levels of MUFA vaccenic acid and the n-6 PUFA γ-linolenic acids in 
RBC phospholipids were detected in FH as compared to PHC children (p= 0.036 and 0.027, 
respectively). 
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Table 3.2 Serum lipid concentrations and RBC phospholipid FAs composition in hyperlipidemic children and adolescents (n= 54), according to sex 
and type of hyperlipidemia. 
 
Lipid profile 
All subjects  Sex  Hyperlipidemia 
  Male Female   FH FCHL PHC  
n = 54  n = 28 n = 26 p value  n = 14 n = 21 n = 19 p value 
Serum lipids (mg/dl)           
TC 232.4 ± 55.6  226.0 ± 56.7 239.2 ± 54.8 0.385  288.2 ± 67.1a 214.2 ± 38.3b 211.4 ± 30.8b < 0.001 
TG 90.9 ± 51.9  94.0 ± 53.4 84.9 ± 50.3 0.658  73.6 ± 31.3 102.3 ± 67.6 91.1 ± 42.1 0.282 
HDL-C 58.8 ± 15.4  58.6 ± 15.6 60.2 ± 14.6 0.912  55.0 ± 10.6 57.8 ± 19.6 62.7 ± 12.7 0.340 
LDL-C 156.3 ± 58.4  149.1 ± 60.9 163.3 ± 56.8 0.355  219.9 ± 69.5a 137.3 ± 36.5b 130.3 ± 28.0b < 0.001 
HDL/LDL ratio 0.4 ± 0.2  0.4 ± 0.2 0.4 ± 0.2 0.502  0.3 ± 0.1a 0.5 ± 0.2b 0.5 ± 0.2b < 0.001 
Non-HDL-C 173.6 ± 59.4  167.4 ± 61.7 179.0 ± 58.1 0.433  233.2 ± 71.0a 156.5 ± 42.5b 148.6 ± 31.4b < 0.001 
RBC phospholipid FAs (%)          
Total SFAs 48.99 ± 2.23  48.66 ± 2.51 49.44 ± 1.84 0.261  49.23 ± 2.87 49.35 ± 1.53 48.43 ± 2.35 0.389 
Total MUFAs 18.45 ± 0.91  18.68 ± 0.84 18.12 ± 0.87 0.052  18.07 ± 0.77 18.59 ± 0.86 18.58 ± 1.02 0.197 
Total PUFAs 32.55 ± 2.14  32.65 ± 2.55 32.44 ± 1.67 0.729  32.70 ± 2.81 32.06 ± 1.61 32.99 ± 2.10 0.383 
MUFAs/SFAs ratio 0.38 ± 0.03  0.39 ± 0.03 0.37 ± 0.03 0.056  0.37 ± 0.03 0.38 ± 0.02 0.39 ± 0.03 0.296 
PUFAs/SFAs ratio 0.67 ± 0.08  0.68 ± 0.09 0.66 ± 0.06 0.452  0.67 ± 0.11 0.65 ± 0.05 0.68 ± 0.08 0.391 
PUFAs n-3/n-6 0.19 ± 0.06  0.18 ± 0.03 0.20 ± 0.05 0.758  0.19 ± 0.05 0.20 ± 0.07 0.19 ± 0.04 0.871 
LC-PUFAs n-3/n-6 0.33 ± 0.09  0.31 ± 0.05 0.34 ± 0.09 0.633  0.33 ± 0.09 0.34 ± 0.11 0.32 ± 0.08 0.822 
Omega-3 index 3.76 ± 1.04  3.54 ± 0.55 3.80 ± 1.08 0.770  3.81 ± 0.87 3.84 ± 1.24 3.62 ± 0.95 0.789 
Saturated           
14:0 (myristic acid) 0.41 ± 0.08  0.40 ± 0.09 0.42 ± 0.08 0.336  0.42 ± 0.10 0.4 ± 0.07 0.4 ± 0.08 0.789 
15:0 (pentadecanoic acid) 0.16 ± 0.03  0.16 ± 0.03 0.17 ± 0.03 0.152  0.16 ± 0.03 0.16 ± 0.02 0.16 ± 0.03 0.963 
16:0 (palmitic acid) 24.05 ± 1.38  24.02 ± 1.52 24.08 ± 1.23 0.864  24.4 ± 1.56 24.06 ± 1.10 23.78 ± 1.52 0.625 
17:0 (margaric acid) 0.46 ± 0.17  0.46 ± 0.16 0.45 ± 0.19 0.803  0.42 ± 0.22 0.44 ± 0.19 0.51 ± 0.11 0.387 
18:0 (stearic acid) 15.47 ± 1.47  15.06 ± 1.40a 15.92 ± 1.44b 0.031  15.61 ± 2.10 15.68 ± 1.16 15.15 ± 1.24 0.593 
20:0 (arachidic acid) 0.56 ± 0.15  0.58 ± 0.20 0.55 ± 0.05 0.579  0.54 ± 0.07 0.55 ± 0.05 0.6 ± 0.23 0.610 
22:0 (behenic acid) 1.99 ± 0.28  1.98 ± 1.29 1.99 ± 1.27 0.988  1.94 ± 0.32 2.02 ± 0.24 1.98 ± 0.29 0.607 
23:0 (tricosanoic acid) 0.31 ± 0.06  0.31 ± 0.05 0.31 ± 0.06 0.935  0.30 ± 0.07 0.32 ± 0.05 0.31 ± 0.05 0.576 
24:0 (lignoceric acid) 5.59 ± 0.75  5.7 ± 0.84 5.46 ± 0.63 0.242  5.45 ± 0.83 5.73 ± 0.63 5.54 ± 0.81 0.583 
Monounsaturated           
16:1n-9 (hypogeic acid) 0.11 ± 0.03  0.11 ± 0.01 0.11 ± 0.04 0.524  0.11 ± 0.04 0.11 ± 0.03 0.11 ± 0.01 0.934 
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16:1n-7 (palmitoleic acid) 0.24 ± 0.07  0.24 ± 0.07 0.23 ± 0.07 0.561  0.23 ± 0.08 0.23 ± 0.08 0.25 ± 0.05 0.795 
18:1n-9 (oleic acid) 11.09 ± 0.94  11.16 ± 0.89 11.02 ± 1.01 0.569  11.19 ± 1.16 10.95 ± 0.91 11.18 ± 0.83 0.719 
18:1n-7 (vaccenic acid) 1.08 ± 0.11  1.07 ± 0.10 1.09 ± 0.12 0.392  1.02 ± 0.07a 1.08 ± 0.11ab 1.12 ± 0.10b 0.036 
20:1n-9 (eicosenoic acid) 0.20 ± 0.08  0.21 ± 0.10 0.19 ± 0.02 0.474  0.18 ± 0.02 0.19 ± 0.02 0.22 ± 0.12 0.361 
24:1n-9 (nervonic acid) 5.73 ± 0.92  5.9 ± 1.14 5.56 ± 0.56 0.179  5.34 ± 1.11 6.02 ± 0.60 5.70 ± 0.99 0.240 
n-6 Polyunsaturated           
18:2n-6 (linoleic acid) 10.70 ± 1.08  10.72 ± 1.06 10.68 ± 1.13 0.916  10.49 ± 0.77 10.78 ± 1.13 10.78 ± 1.24 0.795 
18:3n-6 (γ-linolenic acid) 0.06 ± 0.02  0.06 ± 0.02 0.06 ± 0.02 0.193  0.06 ± 0.02a 0.06 ± 0.02a 0.07 ± 0.02b 0.027 
20:2n-6 (eicosadienoic acid) 0.23 ± 0.07  0.24 ± 0.09 0.22 ± 0.05 0.222  0.20 ± 0.06 0.23 ± 0.03 0.26 ± 0.10 0.138 
20:3n-6 (DGLA) 1.91 ± 0.38  2.01 ± 0.46a 1.81 ± 0.24b 0.050  1.75 ± 0.26 1.95 ± 0.37 1.99 ± 0.44 0.137 
20:4n-6 (ARA) 11.05 ± 1.14  10.89 ± 1.29 11.23 ± 0.95 0.270  11.43 ± 1.23 10.84 ± 0.86 11.01 ± 1.33 0.446 
22:4n-6 (adrenic acid) 1.93 ± 0.49  1.92 ± 0.53 1.94 ± 0.44 0.867  1.9 ± 0.53 1.76 ± 0.27 2.14 ± 0.58 0.114 
Total PUFA n-6 25.89 ± 1.58  26.15 ± 1.37 25.85 ± 1.50 0.815  25.83 ± 1.69 25.62 ± 1.58 26.25 ± 1.51 0.457 
Total LC-PUFAs n-6 14.90 ± 1.46  15.07 ± 1.19 14.82 ± 1.64 0.681  15.08 ± 1.65 14.56 ± 1.16 15.14 ± 1.59 0.392 
n-3 Polyunsaturated           
18:3n-3 (α-linolenic acid) 0.09 ± 0.04  0.09 ± 0.02 0.09 ± 0.02 0.827  0.09 ± 0.04 0.09 ± 0.04 0.10 ± 0.03 0.291 
20:5n-3 (DPA) 0.36 ± 0.21  0.38 ± 0.21 0.33 ± 0.22 0.402  0.37 ± 0.29 0.35 ± 0.22 0.36 ± 0.12 0.988 
22:5n-3 (DPA) 1.10 ± 0.20  1.13 ± 0.21 1.07 ± 0.17 0.207  1.08 ± 0.20 1.04 ± 0.19 1.18 ± 0.19 0.130 
22:6n-3 (DHA) 3.40 ± 0.89  3.41 ± 0.96 3.38 ± 0.82 0.888  3.43 ± 0.67 3.49 ± 1.05 3.26 ± 0.86 0.781 
Total PUFAs n-3 4.95 ± 1.17  4.68 ± 0.63 5.02 ± 1.21 0.632  4.98 ± 0.99 4.97 ± 1.39 4.90 ± 1.06 0.976 
Total LC-PUFAs n-3 4.86 ± 1.17  4.59 ± 0.63 4.93 ± 1.21 0.637  4.89 ± 0.99 4.88 ± 1.39 4.80 ± 1.06 0.970 
Notes: FH, familiar hypercholesterolemia; FCHL, familiar combined hyperlipidemia; PHC, polygenic hypercholesterolemia; TC, total cholesterol; TG, triglycerides; 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SFAs, saturated fatty acids; MUFAs, monounsaturated fatty acids; PUFAs, 
polyunsaturated fatty acids; LC-PUFAs, long chain polyunsaturated fatty acids (C ≥20, double bonds ≥ 3); omega-3 index, sum of EPA + DHA; DGLA, dihomo-γ-
linolenic acid; ARA: arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA: docosahexaenoic acid. 
Values are reported as mean ± SD. a,b Data with different letters are significantly different (p ≤0.05). 
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Correlation between RBC phospholipid composition and serum lipid profile 
Correlations between serum lipid levels and RBC phospholipid composition are reported in Table 
3.3. Lower RBC MUFA levels correlated with higher serum TC levels (p= 0.032) and HDL/TG 
ratio (p= 0.025), but lower serum TG levels (p= 0.005). A positive correlation between serum 
HDL-C and PUFA n-6 levels (p= 0.048) was also detected. 
 
 
Table 3.3 R-value of correlation between RBC phospholipid FAs and serum lipid concentrations 
(n= 54).  
 
RBC phospholipid FAs 
Serum lipids 
TC HDL-C LDL-C TG HDL/LDL 
Total SFAs 0.095 -0.001 0.095 -0.077 -0.051 
Total MUFAs -0.290* -0.138 -0.274 0.371* 0.064 
Total PUFAs 0.020 0.072 0.021 -0.137 0.030 
MUFAs/SFAs ratio -0.208 -0.057 -0.210 0.262 0.073 
PUFAs/SFAs ratio -0.025 0.029 -0.015 -0.058 0.021 
Total PUFAs n-3 0.104 -0.155 0.151 -0.068 -0.200 
Total PUFAs n-6 0.023 0.275* -0.028 -0.155 0.198 
PUFAs n-3/n-6 0.085 -0.220 0.151 -0.039 -0.231 
Total LC-PUFAs n-3 0.105 -0.168 0.159 -0.064 -0.213 
Total LC-PUFAs n-6 0.174 0.207 0.120 -0.197 0.063 
LC-PUFAs n-3/n-6 -0.020 -0.229 0.059 0.006 -0.181 
Omega-3 index 0.085 -0.203 0.160 -0.080 -0.233 
Notes: TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; SFAs, saturated fatty acids; MUFAs monounsaturated fatty acids; PUFAs, 
polyunsaturated fatty acids; LC-PUFAs, long chain polyunsaturated fatty acids; omega-3 index, sum of EPA 
+ DHA. 
*Significantly different by Kendall and Spearman correlations for multiple comparisons (p ≤0.05). 
 
Food diary analysis and correlation between dietary factors, RBC phospholipid FAs and serum 
lipids 
Complete and detailed weekly food diaries were obtained from 23 (7 F) out of 54 children, and 
were used to calculate mean daily energy and macronutrient intake. Results showed a mean daily 
total energy intake of 1208 ± 151 kcal suggesting a possible overall underestimation of food intake 
(e.g. in terms of portion size declared). Macronutrients distribution, expressed as percentage of 
daily energy intake, was: 16.7 ± 2.8% protein, 58.6 ± 6.1% carbohydrate and 24.7 ± 6.4% fat 
(saturated: 7.4 ± 2.1%, monounsaturated: 10.3 ± 4.8%, polyunsaturated: 2.6 ± 0.5%). Estimated 
cholesterol intake was 136.2 ± 47.2 mg/day, while fibre intake was 14.0 ± 5.3 g/day, confirming 
previous data (Guardamagna et al. 2013; Guardamagna et al. 2014). Correlations between dietary 
factors, the RBC phospholipid composition and serum lipid profile are reported in Table 3.4. An 
inverse association was found between the dietary intake of cholesterol and n-6 PUFA and n-6 LC-
PUFA levels in RBC phospholipids (p= 0.001 and 0.017, respectively). The fibre intake was 
directly associated with RBC MUFA/SFA ratio (p= 0.035)
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Table 3.4 R-value of correlation between dietary factors, RBC phospholipid FAs and serum lipids (n= 23). 
 
 Dietary factors 
 Energy Protein CHO Total Fat SFAs MUFAs PUFAs PUFAs n-3 PUFAs n-6 Cholesterol Fiber 
Serum lipids            
TC -0.265 -0.202 0.302 -0.204 -0.196 -0.221 -0.376 0.011 -0.083 -0.386 -0.210 
HDL-C -0.381 -0.126 0.163 -0.149 0.118 -0.102 -0.034 -0.087 -0.182 -0.254 -0.203 
TG -0.013 -0.101 -0.210 0.249 0.402 0.123 0.181 -0.007 0.099 0.180 0.104 
LDL-C -0.219 -0.243 0.187 -0.079 -0.147 -0.118 -0.339 0.204 -0.027 -0.280 -0.214 
HDL/LDL ratio -0.252 0.012 -0.012 -0.049 0.167 0.017 0.147 -0.081 -0.113 -0.061 -0.074 
RBC phospholipid FAs            
Total SFAs -0.145 -0.108 0.150 -0.096 -0.297 -0.105 -0.010 -0.350 0.083 0.265 -0.235 
Total MUFAs 0.103 -0.137 -0.142 0.123 0.547 0.292 0.409 0.265 0.282 0.360 0.493 
Total PUFAs -0.059 0.174 -0.044 0.049 0.081 -0.047 -0.203 0.277 -0.216 -0.485 -0.012 
MUFAs/SFAs ratio 0.193 -0.056 -0.150 0.123 0.504 0.271 0.324 0.340 0.212 0.088 0.525* 
PUFAs/SFAs ratio 0.072 0.146 -0.093 0.069 0.164 0.027 -0.108 0.321 -0.128 -0.407 0.131 
Total PUFAs n-3 0.360 0.434 -0.397 0.181 -0.039 0.027 0.017 0.105 0.039 0.137 0.135 
Total PUFAs n-6 -0.164 -0.105 0.115 0.029 -0.076 -0.054 -0.282 0.201 -0.243 -0.762* -0.245 
PUFAs n-3/n-6 0.363 0.429 -0.409 0.167 -0.059 0.010 0.029 0.078 0.049 0.260 0.150 
Total LC-PUFAs n-3 0.360 0.434 -0.397 0.181 -0.039 0.027 0.017 0.105 0.039 0.137 0.135 
Total LC-PUFAs n-6 0.002 0.071 -0.201 0.118 0.108 0.051 -0.108 0.225 -0.157 -0.522* -0.142 
LC-PUFAs n-3/n-6 0.368 0.463 -0.390 0.135 -0.083 -0.034 0.007 0.020 0.034 0.390 0.176 
Omega-3 index 0.358 0.441 -0.350 0.127 -0.076 -0.032 -0.010 0.081 0.029 0.265 0.154 
Notes: CHO, carbohydrates; SFAs, saturated fatty acids; MUFAs monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids;TC, total 
cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LC-PUFAs, long 
chain polyunsaturated fatty acids; omega-3 index, sum of EPA + DHA. *Significantly different by Kendall and Spearman correlations for 
multiple comparisons (p≤0.05). 
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3.2 EFFECT OF REGULAR HAZELNUT INTAKE ON MARKERS OF OXIDATIVE 
STRESS, SERUM LIPID PROFILE AND FATTY ACID COMPOSITION OF 
ERYTHROCYTE PHOSPHOLIPIDS 
 
3.2.1 SUBJECTS AND METHODS 
Study design 
A total of 66 children and adolescents with primary hyperlipidemia (31 females; mean age: 11.6 ± 
2.6 years) were selected as previously reported (see Study 3.1). The process of patient selection 
and allocation to the different study groups is depicted in Figure 3.1. 
The intervention study was an 8-week randomized, single blind, controlled, three-arm, parallel-
group (Figure 3.1). Patients were assigned to their treatment groups according to a randomization 
list obtained through the investigating center database. Patients were allocated to receive the 
different treatments by a pediatrician who was not involved in the study and did not participate to 
sample analysis. Each patient was randomized to one of the three treatment groups with a 1:1:1 
ratio (22 subjects per group): group 1 was treated with one daily portion of hazelnuts with skin 
(HZN+S); group 2 with one daily portion of hazelnuts withot skin (HZN-S); while group 3 
(control) received no treatment. At the beginning of the study, patients assigned to treatment groups 
received a hazelnut (HZN) supply sufficient for the complete duration of treatment, portioned into 
pre-weighed packages, and were asked to consume one portion per day for 8 consecutive weeks. 
The control group was advised to follow a nut-free diet for the subsequent 8 weeks. At enrollment, 
all children and their parents received nutritional recommendations based on CHILD1 dietary 
guidelines, as report in the previous study (Expert Panel on Integrated Guidelines for 
Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report 2011).  
For the duration of the study, all participants were encouraged to maintain the same dietary and 
lifestyle habits (as assessed before enrollment) and to refrain from consuming any other kind of 
nuts (a list of prohibited foods was provided). In order to check the compliance to the dietary 
instructions, subjects and their families were asked to fill in weekly food diaries, before and after 
enrollment in the study. A nutritionist provided detailed instructions to patients and their parents 
on how to record food intake. Moreover, patients and their parents were periodically interviewed 
to verify their compliance to dietary recommendations and actual intake of nuts. In order to 
estimate the average daily energy and nutrient intake, dietary records were analyzed with 
MètaDieta® Software using the Italian Food Composition Tables (Carnovale & Marletta 2000). 
At baseline and at the end of the study, each patient underwent a medical examination after an 
overnight fast, during which blood samples and the physical parameters (including height, weight, 
BMI, blood pressure) were obtained. Blood samples was used for the analysis of serum lipid 
profile, the RBC phospholipid composition, the DNA damage and oxidized LDL-C (ox-LDL) 
levels. Participants in the HZN groups were asked to give back any uneaten HZN package at the 
last visit. Compliance was assessed by weighing the eventual packages returned, and by analysing 
weekly food diaries filled at baseline and during the study. 
 
Hazelnut preparation  
Italian roasted HZNs Corylus avellana L., (cultivar ‘Tonda Gentile delle Langhe’, from Piedmont, 
Italy), were provided peeled (HZN-S) or unpeleed (HZN+S), in pre-weighed vacuum packed 
portions. The amount of HZNs per portion was calculated on the basis of the doses that are 
generally advised to adults, adjusted on children body weight (0.43 g/kg of body weight on average, 
corresponding to portions of 15 to 30 g).  
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Figure 3.1 CONSORT study flow-chart showing the process of patient selection and enrollment, 
allocation to the three study groups, and rate of patients completing the study.  
 
 
 
 
Notes: HZN+S: group treated with hazelnuts with skin; HZN-S: group treated with hazelnuts without skin. 
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Fat and bioactive composition of hazelnuts 
HZNs composition in terms of total fat, sterols and tocopherols content was determined using 
standardized methods. The HZN oil was extracted using a cold-pressing method. The recovered 
oil was clarified and stored at -18°C until analyses. Fatty acids composition was obtained through 
the analysis of derived methyl esters by gas-chromatography, following the method described by 
Ficarra et al. (2010). The fatty acid concentration (expressed as mg of fatty acid/g of oil) was 
calculated according to AOAC 963.22 method. The content of minerals was measured by 
inductively coupled plasma mass spectroscopy (ICP-MS; Varian 820 ICP-MS) (Del Bo’ et al. 
2013). Polyphenol compounds were extracted following the method suggested by Ghirardello et 
al. (2016). The total phenolic content was assessed by spectrophotometry by means of the modified 
Folin–Ciocalteu method, and was expressed as mg of gallic acid equivalents (GAE) per g of 
sample. Polyphenol composition was determined using a Thermo-Finnigan Spectra-System HPLC 
equipped with a Finnigan Surveyor PDA Plus detector. The separation was achieved at 22 °C on a 
C18 RP Lichrospher 250 × 4.6 mm, 5-µm column equipped with a C18 RP Lichrospher 5-µm 
guard column. The mobile phase was trifluoroacetic acid/ultrapure water (solvent A) and methanol 
(solvent B); the flow rate was 0.8 mL min-1, and the injection volume was 20 µL. The PDA spectra 
were recorded over a wavelength (λ) range of 200 to 600 nm, and quantification was performed 
recording the peak area at a maximum λ of each compound. Identification was achieved by 
comparing the retention times and spectra of our samples with those of authentic standards. In 
addition, the antioxidant capacity (radical scavenging activity) of the HZN extracts was evaluated 
according to method of Ghirardello et al. (2016). The radical scavenging activity was measured by 
the discoloration of the purple-coloured methanol solution of the 2,2-diphenyl-1-picrylhydrazyl 
radical recorded at 515 nm. The results were expressed as µmoles of Trolox equivalent (TE) per g 
of sample.  
 
Chemicals 
Normal-melting-point (NMP) agarose, low-melting-point (LMP) agarose, EDTA, Na2EDTA, 
Tris–acetate–EDTA buffer, dimethyl sulfoxide (DMSO), phosphate-buffered saline (PBS), RPMI-
1640 medium, Histopaque 1077, fetal bovine serum (FBS), hydrogen peroxide (H2O2), ethidium 
bromide, N-lauroylsarcosine sodium salt, Triton X-100, Trizma base, sodium hydroxide (NaOH), 
bovine serum albumin (BSA) and sodium chloride (NaCl) were obtained from Sigma–Aldrich (St 
Louis, MO, USA). Formamidopyrimidine-DNA glycosylase (FPG) was kindly provided by Prof. 
Andrew Collins from the University of Oslo. 
 
Blood sample collection, separation and storage 
Fasting blood samples were collected into vacutainers containing lithium heparin as anticoagulant 
[(to obtain plasma, RBCs and peripheral blood mononuclear cells (PBMCs)] or silicon (to obtain 
serum). Plasma, serum and RBCs were separated as previously reported (see study 3.1).  
PBMCs were isolated from heparin whole blood by density gradient using Histopaque 1077. A 
total of 100 μl of whole blood was gently mixed with 900 μl of cold RPMI medium in microfuge 
tubes. Then, 100 μl Histopaque 1077 was carefully added to the bottom of the tube and centrifuged 
at 200 ×g for 4 min at room temperature. The PBMCs were removed and washed with PBS, and 
centrifuged for 10 s at 5000 ×g at room temperature to pellet the cells. The supernatant was poured 
off and the pellet resuspended in 50 μl of PBS and used immediately for the determination of ex-
vivo resistance to H2O2-induced DNA strand breaks. A different batch of isolated PBMC was 
diluted into an appropriate freezing medium composed of 50% FBS, 40% RPMI and 10% DMSO 
as a cryoprotectant and stored at -80°C for the subsequent determination of endogenous DNA 
damage. 
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Evaluation of DNA damage through comet assay 
The alkaline comet assay was performed for the determination of ex-vivo resistance to H2O2-
induced DNA strand breaks and the determination of endogenous DNA damage as previously 
reported (Collins et al. 1996; Riso et al. 1999; Guarnieri et al. 2008). The main steps of comet assay 
are summarized in Figure 3.2. 
Briefly, PBMCs suspension was mixed with LMP agarose (1.5% wt/vol) in Tris–acetate–EDTA 
buffer (pH 7.4, at 37°C) and pipetted onto a fully frosted microscope slide (Richardsons Supply 
Co. Ltd, London, UK) already precoated with NMP agarose (1% wt/vol in Tris–acetate–EDTA 
buffer). Each slide provided two gels containing ~104 cells.  
Cell resistance against oxidatively induced DNA damage was measured by treating the cells with 
H2O2. Two slides prepared for each subject: one slide was treated with H2O2 (500 µmol/l in PBS) 
for 5 min at room temperature in the dark, whereas the other one slide was treated for 5 min with 
a solution of PBS alone (without H2O2; control slide). Following the oxidative treatment, slides 
were immersed in a lysis buffer (2.5 M NaCl, 0.1 M Na2EDTA, 10 mM Tris, 1% N-
lauroylsarcosine sarcosine sodium salt, pH 10 with NaOH; 1% Triton X-100 and 1% DMSO) for 
1 h at 4°C in the dark. Slides were then transferred in a horizontal electrophoresis tank containing 
an alkaline electrophoresis buffer (0.3 M NaOH, 1 mM Na2EDTA) and kept for 40 min at 4°C. 
Then, electrophoresis was carried out (25 V, 300 mA, 20 min) in the same alkaline solution at 4 
°C in the dark. The samples were subsequently washed in a neutralizing buffer (0.4 M Tris–HCl, 
pH 7.5) for 15 min at 4°C in the dark, stained with ethidium bromide (2 μg/ml) for 20 min, washed 
in PBS, drained and coverslipped. 
 
Figure 3.2 Comet assay steps for the evaluation of cell resistance against H2O2 insult (a) and 
endogenous DNA damage (b) in PBMCs. 
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The detection of endogenous oxidized DNA bases was performed in cryopreserved PBMCs, as 
previously reported (Collins et al. 1996; Riso et al. 2009) by means of the enzyme 
formamidopyrimidine DNA glycosylase (FPG), able to detect the oxidized purines (mainly 8-oxo-
7,8-dihydroguanine). For this present study, cryopreserved PBMCs were used. In brief, 
cryopreserved PBMCs were rapidly thawed at 37°C and washed with fresh RPMI medium and 
cold PBS. Cell suspension was embedded in LMP agarose (1.5% wt/vol in Tris–acetate–EDTA 
buffer at pH 7.4, 37°C) and pipetted on fully frosted slides previously precoated with NMP agarose 
(1% wt/vol in Tris–acetate–EDTA buffer). After the lysis phase (2.5 M NaCl, 0.1 M Na2EDTA, 
10 mM Tris, 1% N-lauroylsarcosine sarcosine sodium salt, pH 10 with NaOH; 1% Triton X-100 
and 1% DMSO, for 1 h at 4°C in the dark), slides were washed three times in a buffer (40 mM 
HEPES, 0.1 M KCl and 0.5 mM EDTA, pH 8.0 with KOH), for 5 min each. Then, one slide was 
treated with a solution of FPG enzyme (100 ng/ml in enzyme buffer: 40 mM HEPES, 0.1 M KCl, 
0.5 mM EDTA and 0.2 mg/ml bovine serum albumin, pH 8.0 with KOH), while the other slide 
(control) with buffer without FPG. Incubation was performed at 37°C for 45 min. The slides were 
then transferred to electrophoresis buffer and processed as previously described (see oxidatively 
induced DNA damage). 
One hundred images of nucleoids, or comets, per slide were electronically captured at 20 x 
magnification using an epifluorescence microscope (Olympus CX 41; Olympus Italia) attached to 
a high sensitivity CCD video camera (CFW 1808M; Scion Corporation, Germany) and to a 
computer equipped with an image analysis system (Cometa 1.5; Immagini e Computer, Bareggio, 
Milan, Italy). The level of DNA damage was calculated as the percentage of DNA in the tail. For 
each subject, the percentage of DNA in tail of control cells (slides not treated with H2O2 or FPG) 
was subtracted from the percentage of DNA in tail obtained by incubating the cells with H2O2 or 
FPG.  
 
Analysis of oxidized-LDL 
The serum ox-LDL concentration was measured by an ELISA kit (Mercodia, Uppsala, Sweden), 
according to the manufacturer instructions. The absorbance was evaluated at 450 nm using a plate 
reading spectrophotometer (mod. F200 Infinite, TECAN Milan, Italy). Each sample was 
determined in duplicate. The analysis was performed in a subsample of 40 subjects, belonging to 
HZN+S and control groups. 
 
Analysis of serum lipids and FA composition of phospholipids in RBCs  
Serum lipid concentrations (TC, HDL-C, TG, LDL-C and non-HDL-C) and RBCs phospholipids 
fatty acids analysis were performed as previously described in detail (see study 3.1). 
 
Statistical analysis 
Sample size was calculated taking into account the expected variation in the primary endpoints 
considered. In particular, 16 subjects per group were estimated to be sufficient to detect significant 
differences in DNA damage after HZN interventions, with a power of 80% and p=0.05. All data 
are presented as mean ± standard deviation (SD). 
One-way ANOVA was used to compare the three groups (HZN+S, HZN-S and control group) at 
baseline. Two-way ANOVA was used to compare the effect of dietary treatment (HZN+S, HZN-
S or control group) and time (baseline vs. 8 weeks) on the levels of DNA damage and ox-LDL. 
Differences were considered significant at p≤0.05; post-hoc analysis of the differences between 
treatments was assessed by the Least Significant Difference test considering p≤0.05 for statistical 
significance. Regression analysis was used to verify correlations between the variables under study 
at baseline and percent changes observed between pre-to-post intervention in the three groups. 
Statistical analysis was performed using STATISTICA software (Statsoft Inc, Tulsa, OK, USA). 
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3.2.2 RESULTS 
Characterization of hazelnuts 
The fat and bioactives composition of 100 g of HZN+S and HZN-S are reported in Table 3.5. The 
major components of HZNs was fat, with a high prevalence of MUFAs, in particular oleic acid. 
Furthermore, HZNs contained phytosterols, tocopherols (mainly α-tocopherol), minerals (mainly 
potassium, phosphorus, magnesium and calcium). In HZN+S, small amounts of polyphenols (about 
13 mg, three-fold higher than in HZN-S) were also detected. Moreover, the HZN+S exhibited a 
higher phenolic content (3.9 mg GAE/g), and total antioxidant capacity (18.2 μmol TE/g) than 
HZN-S (0.8 mg GAE/g and 2.2 μmol TE/g, respectively). 
 
Table 3.5 Characterization of fat and bioactives composition of hazelnut Corylus avellana L. 
‘Tonda Gentile delle Langhe’. 
 
 HZN+S HZN-S 
Total fats (%)  48.5 52.9 
Fatty acids (%)   
14:0 (myristic acid) 0.03 0.03 
16:0 (palmitic acid)  5.85 6.02 
16:1 cis-9 (palmitoleic acid)  0.23 0.22 
17:0 (margaric acid)  0.05 0.05 
18:0 (stearic acid)  2.46 2.7 
18:1 trans-9 (elaidic acid)  0.02 0.02 
18:1 cis-9 (oleic acid)  83.94 84.52 
18:2 cis-9, cis-12 (linoleic acid)  6.93 5.97 
20:0 (arachidic acid)  0.13 0.13 
20:1 cis-13 (paullinic acid)  0.13 0.12 
18:3 cis-6, cis-9, cis-12 (γ-linolenic acid) 0.1 0.1 
22:0 (behenic acid)  0.02 0.02 
20:4 cis-5, cis-8, cis-11, cis-14 
(arachidonic acid)  
0.03 0.03 
Sterols (%)   
Cholesterol  0.1 0.1 
Campesterol  4.2 4.1 
Campestenol  0.2 0.2 
Stigmasterol  0.9 0.9 
Delta-7-campesterol  - 0.1 
Delta-5.23-stigmastadienol  0.4 0.2 
Chlerosterol  0.9 1 
β-Sitosterol  81.4 82 
Sitostanol  2.4 2 
Delta-5-avenasterol  4.9 5.5 
Delta-5.24-stigmastadienol  0.7 0.9 
Delta-7-stigmastenol  2.7 1.9 
Delta-7-avenasterol  1.2 1.1 
Total sterols (mg/100g) 147.4 147.4 
Tocopherols and tocotrienols (mg/100 g)   
α-Tocopherol  22.9 32.3 
β-Tocopherol 0.5 0.6 
γ-Tocopherol  1.1 0.6 
Total tocopherols  24.4 33.5 
Minerals (mg/100 g)   
Magnesium 141.0 142.0 
Potassium 597.0 595.0 
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Calcium 119.0 118.0 
Manganese 1.75 1.6 
Iron 3.4 3.1 
Zinc 1.8 1.8 
Phosphorus 418.0 424.0 
Copper 1.4 1.5 
Polyphenols (mg/100 g)   
Gallic acid 2.9 1.9 
Procyanidin B1 1.7 1.2 
Epigallocatechin 1.3 - 
Procyanidin B2 2.8 - 
Epigallocatechin gallate 1.7 - 
Gallocatechin gallate 1.9 1.3 
Epicatechin gallate 0.4 - 
Total phenolic content (mg GAE/g) 3.9 0.8 
Total antioxidant capacity (μmol TE/g) 18.2 2.2 
Notes: HZN+S, hazelnut with skin; HZN-S, hazelnuts without skin. 
The phenolic content (Folin–Ciocalteu method) was expressed as mg of gallic acid 
equivalents (GAE) per g of sample. The antioxidant capacity (radical scavenging 
activity) is expressed as µmoles of trolox equivalent (TE) per g of sample. 
 
Subjects characteristics 
Of the 90 hyperlipidemic children and adolescents initially screened for the study, 24 subjects did 
not meet the eligibility criteria. The remaining 66 eligible children agreed to participate to the 
experimentation. Six participants (4 females) dropped out from the study due to personal reasons, 
not related to the study. Thus, 60 hyperlipidemic children and adolescents (M/F, 34/26) 
successfully completed the 8-week intervention and were included in the data analysis (Figure 
3.1). The study was performed between January and October 2015. 
Main features of the three groups of patients at baseline and after treatment are reported in Table 
3.6. Age ranged from 6.7 to 17.5 years, with a mean age ± SD of 11.6 ± 2.6 years. Mean serum 
lipid levels exceeded the 90th age and sex related percentiles, with the exclusion of HDL-C values, 
which were in the normal range. Body weight was in the normal range, except for five subjects 
presenting mild overweight, BMI remained unchanged throughout the treatment period. Blood 
pressure levels were in the normal range at baseline and during the entire study period. HZN 
consumption was appreciated and well tolerated by all patients. 
 
Table 3.6 Main sample features at baseline and after 8 weeks of intervention. 
 
 
Variables 
Control (n=18)  HZN+S (n=22)  HZN-S (n=20) 
Baseline Week 8  Baseline Week 8  Baseline Week 8 
Age (years) 12.2 ± 2.3 12.4 ± 2.3  10.8 ± 2.5 11.0 ± 2.5  11.8 ± 2.8 12.0 ± 2.8 
Sex (M/F) 13/5  12/10  9/11 
Weight (kg) 49.5 ± 16.5 50.0 ± 16.6  44.4 ± 15.3 45.0 ± 15.3*  47.8 ± 16.6 48.4 ± 16.5* 
Height (cm) 151.8 ± 15.6 152.9 ± 16.0*  145.8 ± 14.6 146.6 ± 14.5*  151.2 ± 17.2 151.9 ± 17.0* 
BMI (kg/m2) 20.9 ± 3.9 20.8 ± 4.0  20.4 ± 4.0 20.3 ± 4.0  20.3 ± 3.7 20.3 ± 3.5 
SBP 
(mmHg) 
106.8 ± 9.8 109.0 ± 7.5  103 ± 9.9 105.2 ± 9.3  102.8 ± 10.3 102.5 ± 10.3 
DBP 
(mmHg) 
68.0 ± 5.1 67.1 ± 6.9  65.6 ± 6.6 66.5 ± 7.0  65.1 ± 9.3 66.3 ± 7.4 
Notes: BMI, body mass index; HZN+S, group treated with hazelnut with skin; HZN-S, group treated with 
hazelnuts without skin. 
Values are expressed as mean ± SD. * Significantly different as compared to baseline (p≤ 0.05). 
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Energy and nutrient intake at baseline and during the study period are reported in Table 3.7. A 
significant increase of total fat (p <0.001), MUFA (p <0.05), and PUFA (p <0.001) intake and a 
reduction of carbohydrates (p <0.01), but not of total energy intake was registered following HZN 
treatments. No differences between baseline and the end of the study were observed in the control 
group. 
 
Table 3.7 Daily energy and nutrient intakes assessed by patient food diaries, before and after 8 
weeks of treatment. 
 
 
Variables 
Control (n=18) HZN+S (n=22) HZN-S (n=20) 
Baseline Week 8 Baseline Week 8 Baseline Week 8 
Energy (kcal) 1126.5 ± 281 1163.5 ± 14 1093.2 ± 194.7 1199.3 ± 180.1 1241.0 ± 210.2 1358.7 ± 211.0 
Protein (% E) 17.0 ± 2.6 16.4 ± 2.9 17.5 ± 2.9 16.9 ± 2.6 16.5 ± 2.4 16.3 ± 2.3 
CHO (% E) 50.7 ± 4.3 50.3 ± 3.9 51.2 ± 3.8 46.9 ± 3.6* 52.6 ± 3.9 48.6 ± 4.2* 
Total fat (% E) 32.5 ± 3.0 33.3 ± 3.1 31.2 ± 2.9 36.2 ± 1.9* 30.9 ± 2.5 35.2 ± 2.8* 
SFA (% E) 10.1 ± 2.6 10.0 ± 2.2 9.4 ± 1.4 9.6 ± 1.6 8.9 ± 1.9 8.6 ± 1.9 
MUFA (% E) 14.7 ± 1.9 15.5 ± 3.0 13.1 ± 3.3 17.8 ± 6.5* 7.9 ± 2.5 9.0 ± 2.1* 
PUFA (% E) 3.5 ± 0.9 3.3 ± 0.5 4.1 ± 2.3 7.6 ± 3.3* 3.3 ± 1.4 6.8 ± 3.5* 
ω-3 (% E) 0.6 ± 0.1 0.6 ± 0.1 0.7 ± 0.5 1.3 ± 0.6* 0.5 ± 0.3 1.0 ± 0.7* 
ω-6 (% E) 2.2 ± 0.8 2.1 ± 0.4 2.8 ± 2.0 6.0 ± 2.8* 2.1 ± 1.2 5.4 ± 2.9* 
Fibers (g) 9.0± 2.6 9.9 ± 2.5 10.1 ± 2.1 10.5 ± 2.9 11.9 ± 4.8 14.1± 5.3 
Cholesterol (mg) 137.5 ± 35.9 138.8 ± 59.1 129.9 ± 39.9 123.6 ± 39.3 133.6 ± 44.8 128.8 ± 45.2 
Notes: HZN+S, group treated with hazelnut with skin; HZN-S, group treated with hazelnuts without skin; 
CHO, carbohydrate; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, 
saturated fatty acids. Values are expressed as mean ± SD. * Significantly different as compared to baseline 
(p≤ 0.05). 
 
 
Effect of hazelnuts on endogenous and oxidatively-induced DNA damage 
At baseline, hyperlipidemic children showed a mean percentage of endogenous and oxidatively 
induced DNA damage of 14.8 ± 5.6%, and 36.4 ± 11.7%, respectively. The regular intake of 
hazelnuts was associated with the reduction (time x treatment interaction, p= 0.0006) of the level 
of endogenous DNA damage by 18.9% (from 14.7 ± 5.1% at baseline, to 10.5 ± 4.1% after 8 weeks; 
p= 0.0029) and 22.5% (from 13.9 ± 3.3% at baseline, to 10.1 ± 4.7% after 8 weeks; p= 0.007), 
respectively after HZN+S and HZN-S intake (Figure 2a). On the contrary, an increase of 26.8% 
(from 15.7 ± 7.9 at baseline, to 18.9 ± 9.7 after 8-weeks; p= 0.04) in FPG-sensitive sites was 
registered in the control group at the end of the study period (Figure 3.3-A). 
With regard to cell protection against oxidative stress, HZN+S treatment significantly decreased 
(time effect, p= 0.002) the level of oxidatively-induced DNA strand breaks by 16% (from 36.6 ± 
12.4 at baseline, to 28.7 ± 12.2% after 8 weeks; p= 0.02) (Figure 3.3-B).  
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Figure 3.3 Levels of endogenous (A) and oxidatively-induced (B) DNA damage, evaluated at 
baseline and after 8 weeks of treatment, in the control, HZN+S and HZN-S groups. * Significantly 
different as compared to baseline (p< 0.05). 
 
 
 
 
 
 
  
A) 
B) 
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Effect of hazelnuts on oxidized LDL levels  
Mean baseline ox-LDL levels in hyperlipidemic children were 54.4 ± 15.4 U/L, and did not 
significantly change in the control or HZN+S groups after intervention (Figure 3.4). 
 
 
Figure 3.4 Levels ox-LDL, evaluated at baseline and after 8 weeks of treatment, in the control and 
HZN+S groups. * Significantly different as compared to baseline (p< 0.05). 
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Effect of hazelnuts on serum lipid profile 
The serum lipoprotein concentrations are reported in Table 3.8. 
The two-way ANOVA applied, considering time and treatments as dependent factors, revealed a 
significant effect of HZN treatment on serum LDL-C, HDL/LDL ratio and non-HDL-C (p≤0.001). 
In particular, both HZN+S and HZN-S significantly reduced the concentrations of LDL-C (-6.3%, 
p=0.005; and -6.0%, p=0.01, respectively), while increasing HDL-C/LDL-C ratio (+10.8%, 
p=0.007; and +10.2%, p=0.008, respectively), with respect to baseline. In addition, HZN-S reduced 
non-HDL-C (-6.2%, p=0.008). Serum lipid composition did not change over the study period. 
 
Effect of hazelnuts on fatty acid composition of phospholipids in RBC membranes 
The FA composition of phospholipids in RBC membranes at baseline and at the end of treatment 
are reported in Table 3.9. 
The two-way ANOVA revealed a significant time x treatment interaction in terms of total 
MUFAs, oleic acid and MUFAs/SFAs ratio (p≤0.01), being the levels of MUFA and MUFA/SFA 
ratio after HZN were significantly different from those registered in the control group (p<0.01 and 
p=0.005, respectively). In particular, compared to baseline, both HZN+S and HZN-S treatments 
increased the level of MUFAs (+4.5%, p=0.0001; and +4.5%, p=0.0002), oleic acid (+4.0%, 
p=0.02; and HZN-S: +5.2%, p=0.004) and MUFAs/SFAs ratio (+5.7%, p=0.003; and +6.4%, 
p=0.002, respectively). The levels of palmitoleic and linoleic acids also decreased (-9.8%, p=0.004; 
-4.8%, p=0.002, respectively) after 8-week of HZN-S consumption, while no effects were observed 
in the HZN+S group. 
The significant time x treatment interaction revealed in the control group differently from HZN 
treatments, time x treatment interaction revealed a significant increase of SFAs (+2.9%, p =0.04) 
and a decrease of PUFA n-6 (-2.7%, p =0.04) was evident at the end of the study, as compared to 
baseline. In particular, the margaric acid levels increased (+14.2%, p =0.05), while eicosenoic acid 
and dihomo-γ-linolenic acid decreased (-10.2%, p =0.01; -3.3%, p=0.04, respectively). 
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Table 3.8 Serum lipid profile at baseline and after 8-weeks of each treatment. 
 
Serum lipid profile Control (n=18)  HZN+S (n=22)  HZN-S (n=20) 
(mg/dl) Baseline Week 8  Baseline Week 8  Baseline Week 8 
TC  210.3 ± 50.0 204.1 ± 44.9  215.8 ± 42.0 210.5 ± 41.8  221.6 ± 55.6 212.3 ± 52.3 
TG  76.5 (35-185) 77.5 (38-165) 67.0 (32 - 194) 58.5 (37 - 159) 61.5 (46-300) 70 (41-264) 
HDL-C  55.4 ± 14.9 55.5 ± 12.2  62.0 ± 13.6 63.2 ± 14.3  61.0 ± 16.2 62.4 ± 16.9 
LDL-C  136.7 ± 45.2 131.9 ± 45.4  141.9 ± 46.8 132.7 ± 44.1* 141.4 ± 57.3 132.6 ± 55.3* 
HDL/LDL ratio 0.45 ± 0.24 0.49 ± 0.31  0.49 ± 0.19 0.53 ± 0.21*  0.50 ± 0.24 0.55 ± 0.27* 
HDL/TG ratio 0.76 ± 0.41 0.82 ± 0.41  1.03 ± 0.50 1.06 ± 0.52  0.9 ± 0.5 0.9 ± 0.5 
Non-HDL-C 154.9 ± 47.5 148.6 ± 46.9  153.8 ± 46.5 147.3 ± 46.7  162.4 ± 59.4 151.7 ± 56.1* 
Notes: HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; MUFAs: 
monounsaturated fatty acids; Values are expressed as mean ± SD or median (min-max). * Significantly different as compared to baseline (p< 0.05).  
 
 
Table 3.9 Fatty acid composition of phospholipids in RBC membranes before and after each treatment. 
 
RBC phospolipid composition Control (n=18)   HZN+S (n=22)   HZN-S (n=20) 
(%) Baseline Week 8   Baseline Week 8   Baseline Week 8 
Total SFAs 48.52 ± 2.79a 49.85 ± 5.06*b 49.23 ± 2.23ab 48.81 ± 3.01ab 49.73 ± 1.61b 48.97 ± 2.05ab 
Total MUFAs 18.57 ± 1.07a 18.49 ± 1.52a  18.3 ± 0.75a 19.10 ± 0.94*b 18.41 ± 0.95a 19.23 ± 1.01*b 
Total PUFAs 32.91 ± 2.75 31.67 ± 6.10  32.47 ± 2.12 32.09 ± 3.03  31.85 ± 1.97 31.80 ± 2.10 
MUFAs/SFAs ratio 0.38 ± 0.04ab 0.37 ± 0.03a  0.37 ± 0.03a 0.39 ± 0.04*b  0.37 ± 0.02a 0.39 ± 0.03*b 
PUFAs/SFAs ratio 0.68 ± 0.10 0.64 ± 0.15  0.66 ± 0.07 0.66 ± 0.12  0.64 ± 0.06 0.65 ± 0.07 
Total PUFAs n-3 5.16 ± 1.28 4.79 ± 1.53  4.73 ± 0.77 4.60 ± 0.78  4.82 ± 0.91 4.93 ± 0.93 
Total PUFAs n-6 25.90 ± 1.26 25.19 ± 4.46* 26.08 ± 1.88 25.8 ± 2.19  25.58 ± 1.38 25.30 ± 1.48 
PUFAs n-3/n-6 0.20 ± 0.05 0.19 ± 0.06  0.18 ± 0.04 0.18 ± 0.04  0.19 ± 0.04 0.20 ± 0.04 
Total LC-PUFAs n-3 5.08 ± 1.28 4.7 ± 1.52  4.64 ± 0.78 4.52 ± 0.77  4.72 ± 0.90 4.85 ± 0.93 
Total LC-PUFAs n-6 14.89 ± 1.47 14.23 ± 3.58  15.02 ± 1.64 14.73 ± 1.92  14.69 ± 1.32 14.95 ± 1.62 
LC-PUFAs n-3/n-6 0.34 ± 0.08 0.33 ± 0.08  0.32 ± 0.08 0.31 ± 0.07  0.32 ± 0.07 0.33 ± 0.07 
Omega-3 index 3.94 ± 1.09 3.66 ± 1.24  3.57 ± 0.74 3.49 ± 0.70  3.63 ± 0.79 3.76 ± 0.83 
SFAs (%)         
14:0 (myristic acid) 0.38 ± 0.07 0.40 ± 0.24  0.39 ± 0.09 0.39 ± 0.08  0.42 ± 0.08 0.39 ± 0.08 
15:0 (pentadecanoic acid) 0.16 ± 0.03 0.16 ± 0.04  0.16 ± 0.03 0.16 ± 0.03  0.16 ± 0.03 0.16 ± 0.03 
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16:0 (palmitic acid) 23.83 ± 1.07 24.40 ± 2.80  24.01 ± 1.43 24.08 ± 1.72  24.17 ± 1.50 23.63 ± 1.28 
17:0 (margaric acid) 0.46 ± 0.13a 0.51 ± 0.34*b  0.38 ± 0.19c 0.41 ± 0.16cd  0.47 ± 0.14ab 0.43 ± 0.12ad 
18:0 (stearic acid) 15.02 ± 1.53 15.17 ± 1.63  15.56 ± 1.02 15.21 ± 1.66  15.95 ± 1.36 15.77 ± 1.28 
20:0 (arachidic acid) 0.63 ± 0.25 0.60 ± 0.09  0.56 ± 0.05 0.57 ± 0.07  0.55 ± 0.07 0.55 ± 0.07 
22:0 (behenic acid) 2.07 ± 0.36 2.19 ± 0.26  2.06 ± 0.22 1.99 ± 0.35  2.03 ± 0.25 2.04 ± 0.26 
23:0 (tricosanoic acid) 0.30 ± 0.05 0.32 ± 0.07  0.33 ± 0.06 0.32 ± 0.07  0.31 ± 0.05 0.33 ± 0.12 
24:0 (lignoceric acid) 5.68 ± 0.81 6.09 ± 0.85  5.78 ± 0.81 5.69 ± 1.11  5.65 ± 0.85 5.68 ± 0.84 
MUFAs (%)         
16:1n-9 (hypogeic acid) 0.11 ± 0.02 0.11 ± 0.03  0.10 ± 0.02 0.11 ± 0.04  0.11 ± 0.03 0.10 ± 0.02 
16:1n-7 (palmitoleic acid) 0.22 ± 0.06 0.22 ± 0.16  0.24 ± 0.09 0.23 ± 0.08  0.26 ± 0.07 0.24 ± 0.07* 
18:1n-9 (oleic acid) 10.86 ± 1.09 10.88 ± 1.39  10.89 ± 0.79 11.31 ± 1.06* 10.93 ± 0.85 11.48 ± 0.95* 
18:1n-7 (vaccenic acid) 1.08 ± 0.07 1.05 ± 0.08  1.06 ± 0.11 1.08 ± 0.13  1.09 ± 0.11 1.08 ± 0.07 
20:1n-9 (eicosenoic acid) 0.23 ± 0.13a 0.19 ± 0.07*b  0.19 ± 0.02b 0.2 ± 0.03ab  0.19 ± 0.02b 0.20 ± 0.03ab 
24:1n-9 (nervonic acid) 6.06 ± 1.21 6.05 ± 0.88  5.82 ± 0.80 6.16 ± 1.10  5.83 ± 0.79 6.12 ± 0.78 
ω-6 PUFAs (%)         
18:2n-6 (linoleic acid) 10.68 ± 1.12a 10.69 ± 1.52a  10.78 ± 0.99a 10.79 ± 1.16a  10.59 ± 1.06a 10.06 ± 0.97*b 
18:3n-6 (γ-linolenic acid) 0.06 ± 0.02 0.06 ± 0.03  0.06 ± 0.02 0.06 ± 0.02  0.06 ± 0.02 0.06 ± 0.03 
20:2n-6 (eicosadienoic acid) 0.27 ± 0.10 0.23 ± 0.04  0.22 ± 0.03 0.23 ± 0.03  0.24 ± 0.03 0.23 ± 0.04 
20:3n-6 (DGLA) 1.91 ± 0.43 1.82 ± 0.48*  1.87 ± 0.37 1.81 ± 0.39  1.94 ± 0.38 1.88 ± 0.41 
20:4n-6 (arachidonic acid) 11.11 ± 1.01 10.62 ± 2.69  11.18 ± 1.41 10.93 ± 1.31  10.89 ± 0.98 11.09 ± 1.15 
22:4n-6 (adrenic acid) 1.88 ± 0.57 1.78 ± 0.61  1.97 ± 0.49 2.00 ± 0.77  1.86 ± 0.42 1.98 ± 0.60 
ω-3 PUFAs (%)         
18:3n-3 (α-linolenic acid) 0.08 ± 0.03 0.08 ± 0.04  0.08 ± 0.02 0.08 ± 0.03  0.10 ± 0.04 0.09 ± 0.03 
20:5n-3 (EPA) 0.35 ± 0.13 0.33 ± 0.16  0.36 ± 0.22 0.33 ± 0.14  0.34 ± 0.17 0.34 ± 0.17 
22:5n-3 (DPA) 1.14 ± 0.27 1.05 ± 0.35  1.07 ± 0.14 1.03 ± 0.19  1.09 ± 0.16 1.09 ± 0.15 
22:6n-3 (DHA) 3.58 ± 0.99 3.33 ± 1.17  3.22 ± 0.60 3.17 ± 0.59  3.29 ± 0.68 3.42 ± 0.71 
Notes: DGLA, dihomo-γ-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; LC-PUFAs, long chain 
polyunsaturated fatty acids (C ≥20, double bonds ≥3); MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; ω-6, omega-6; ω-3, omega-
3; RBC, red blood cell; SFAs, saturated fatty acids. Omega-3 index: sum of EPA + DHA. Values are expressed as mean ± SD. 
* Significantly different as compared to baseline (p< 0.05). Data with different letters within the same row differ significantly (p<0.05). 
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Correlation between serum lipid profile and markers of oxidative stress 
At baseline, a positive correlation between LDL-C concentrations and H2O2-induced DNA 
damaged (r= 0.34, p=0.04) was detected. Furthermore, serum TC, LDL-C and non-HDL-C levels 
were directly related to ox-LDL (r= 0.84, p<0.001; r= 0.85, p <0.001; r= 0.87, p <0.001, 
respectively) in the subgroup of subjects analyzed (n=40).  
Interestingly, the analysis of correlation performed on percentage changes (post-to-pre 
intervention) registered for the variables under study confirmed a direct association between ox-
LDL concentrations and the levels of TC, LDL-C and non-HDL in both control (r= 0.57, p =0.014; 
r= 0.73, p=0.001; r= 0.72, p= 0.001, respectively) and HZN+S group (r= 0.60, p= 0.004; r= 0.56, 
p= 0.008; r= 0.69, p< 0.001, respectively).  
Moreover, an inverse correlation between the percentage variation in endogenous DNA damage 
and changes in TC, HDL-C and non-HDL concentrations (r= -0.67, p= 0.002; r= -0.64, p= 0.004; 
r= -0.54, p= 0.020, respectively) were observed following HZN-S treatment. 
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3.3 EFFECT OF HEMPSEED OIL SUPPLEMENTATION ON SERUM LIPIDS 
PROFILE AND FATTY ACID COMPOSITION OF ERYTHROCYTE 
PHOSPHOLIPIDS  
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3.3.1 SUBJECTS AND METHODS 
 
Study design 
The study was an 8-week randomized, single blind, controlled, two-arm parallel-group. A total of 
36 hyperlipidemic children and adolescents were selected as previously reported (see Study 3.1) 
and randomly assigned to 1 of the 2 treatment groups of 18 participants each. Patients assigned to 
the first group (control) were asked to maintained their diet based on CHILD1 guidelines 
throughout the 8 week of study period (without dietary supplements). Whereas, subjects assigned 
to group supplemented with hempseed oil (HSO) additionally receive 3 g/day of HSO supplement 
(4 capsules), providing 700 mg/die of ALA and other bioactives. In Table 3.10 is reportented the 
nutritional composition of the study supplement, according to the manufacturer’s specification. 
The study supplement AlfaLife®, produced by hempseed Cannabis sativa L., was prepared as 
gelatine-soft gel capsules and was kindly provided by Freia Farmaceutici Srl (Milan, Italy).  
All individuals involved in the trial, including doctors, research staff and parents of children, 
were aware of the specific product administered. At the beginning of the study, patients allocated 
to HSO group received a supply of supplement sufficient for the complete duration of treatment. 
For the duration of the experiments, all participants were encouraged to maintain the same dietary 
and lifestyle habits (as assessed before enrollment) and to abstain from consuming any other kind 
of supplements and ALA-rich products during the intervention (a list of prohibited foods was 
provided). In order to check the compliance to the dietary instructions, subjects and their families 
were asked to fill in weekly food diaries, before and after enrollment in the study. A nutritionist 
provided detailed instructions to patients and their parents on how to record food intake. Daily 
energy and nutrient intake were analyzed with MètaDieta® Software using the Italian Food 
Composition Tables (Carnovale & Marletta 2000). Compliance was also assessed by counting the 
eventual capsules returned. 
At beginning and at the end of the intervention period, each patient underwent a medical 
examination after an overnight fast, during which blood samples and the physical parameters 
(including height, weight, BMI and blood pressure) were obtained. The analysis of serum lipid 
concentrations (TC, HDL-C, TG, LDL-C and non-HDL-C) and FA composition of RBC 
phospholipids were performed as previously reported (see Study 3.1). Participants in the HSO 
group were asked to give back any left-over capsules at the last visit.  
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Table 3.10 Nutritional composition of HSO supplement, according to the manufacturer 
specifications. 
 
Hampseed oil 
100 g* 
Daily dose 
supplement (4 capsules, 3 g) 
Energy, kcal 896 27 
Carbohydrates, g - - 
Protein, g - - 
Total Fats, g > 99.5 3 
Total SFAs, g 10.4 0.3 
Total MUFAs, g 11.8 0.4 
Oleic acid, g 9.0 0.3 
Total PUFAs, g 75.5 2.3 
ALA 23.0 0.7 
EPA - - 
DHA - - 
Stearidonic acid 1.1 0.03 
LA 48.3 1.4 
γ-linolenic acid 3.1 0.1 
Cholesterol, g - - 
Vitamin A, UI 9.5 0.3 
Vitamin E, UI 14.9 0.4 
Niacin (B3), mg < 0.001 < 0.0001 
Calcium, mg 9.8 0.3 
Phosphorus, mg 0.013 < 0.001 
Iron, mg 0.004 < 0.001 
Magnesium, mg 0.004 < 0.001 
Notes: ALA, α-linolenic acid; DHA, docosahexaenoic acid; 
EPA, eicosapentaenoic acid; HSO, group treated with 
hempseed oil; LA, linoleic acid; MUFAs, monounsaturated 
fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, 
saturated fatty acids. 
 
 
Statistical analysis 
Sample size was calculated from previous studies in order to detect significant differences in the 
serum lipid concentration and FA composition of RBC phospholipids (Del Bo’ et al. 2013; Orem 
et al. 2013). In particular, 18 subjects per group were estimated sufficient to demonstrate a 5% 
variation of LDL-C concentration after the supplementation with a p value of 0.05 and a power of 
80%. Analysis of difference was applied to compared the effect of treatments (HSO vs control 
group) on lipid profile. Since baseline levels of FAs in RBCs in control subjects differed from HSO 
group, the analysis was carried out on percentage changes (obtained as differences between post- 
to pre-treatment) calculated for each variable considered. Data are reported as mean ± standard 
deviation (SD) or by mean changes (described as mean of single variation), with 95% confidence 
interval (CI). STATISTICA software (Statsoft Inc., Tulsa, OK, USA) was used for statistical 
analysis of data. Significance of difference was set as p≤0.05.  
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3.3.2 RESULTS 
Subject characteristics 
All families of eligible children agreed to participate in the study. A total of 36 hyperlipidemic 
subjects (23/13, M/F) aged between 6-15 years old (mean age 11.8 ± 2.4) successfully completed 
the 8-week intervention and were included in the data analysis: 2 patients were affected by FH, 9 
by FCHL and 25 by PHC. The supplementation was well tolerated by almost all participants in the 
HSO group. 
Characteristic of patients at baseline and after the study period are reported in Table 3.11. Blood 
pressure levels and BMI were in the normal range (except for eight subjects slightly overweight) 
and remained unchanged throughout the treatment period.  
Energy and nutrient intake at baseline and during the study period did not changed, as reported 
in Table 3.12. 
 
Table 3.11 Baseline characteristics of subjects in the two study groups. 
 
 
Variables 
Control (n=18)  HSO (n=18) 
Baseline Week 8  Baseline Week 8 
Age (years) 12.2 ± 2.3 12.4 ± 2.3  11.3 ± 2.4 11.5 ± 2.4 
Sex (male/female) 13/5  10/8 
Weight (kg) 49.5 ± 16.5 50.0 ± 16.6  48.8 ± 16.7 49.4 ± 16.3 
Height (cm) 151.8 ± 15.6 152.9 ± 16.0  149.5 ± 14.6 150.8 ± 14.4 
BMI (kg/m2) 20.9 ± 3.9 20.8 ± 4.0  21.2 ± 4.2 21.2 ± 4.1 
SBP (mmHg) 106.8 ± 9.8 109.0 ± 7.5  108.3 ± 12.4 105.0 ± 9.2 
DBP (mmHg) 68.0 ± 5.1 67.1 ± 6.9  66.1 ± 11.4 62.8 ± 10.0 
Notes: BMI, body mass index. DBP, diastolic blood pressure; HSO, hempseed oil group; SBP, sistolic 
blood pressure. Values are reported as mean ± SD. 
 
 
Table 3.12 Daily energy and nutrient intake during the intervention period in the control and HSO 
group. 
 
Variables 
Control (n=18)  HSO (n=18) 
Baseline Week 8 p  Baseline Week 8 p 
Energy (kcal) 1126.5 ± 281 1163.5 ± 14 0.675  1062.6 ± 221.9 1058 ± 181.7 0.828 
Protein (% of E) 17.0 ± 2.6 16.4 ± 2.9 0.633  15.7 ± 2.1 15.1 ± 2.4 0.500 
Carbohydrate (% of E) 50.7 ± 4.3 50.3 ± 3.9 0.781  53.8 ± 4.5 53.1 ± 3.4 0.608 
Total fat (% of E) 32.5 ± 3.0 33.3 ± 3.1 0.512  30.5 ± 4.79 31.9 ± 4.38 0.395 
SFA (% of E) 10.1 ± 2.6 10.0 ± 2.2 0.870  8.9 ± 1.7 9.6 ± 2.3 0.352 
MUFA (% of E) 14.7 ± 1.9 15.5 ± 3.0 0.473  13.8 ± 3.31 15 ± 3.3 0.306 
PUFA (% of E) 3.5 ± 0.9 3.3 ± 0.5 0.594  3.4 ± 0.82 3.3 ± 0.5 0.515 
ω-3 (% of E) 0.6 ± 0.1 0.6 ± 0.1 0.958  0.6 ± 0.13 0.6 ± 0.12 0.703 
ω-6 (% of E) 2.2 ± 0.8 2.1 ± 0.4 0.612  2.4 ± 0.76 2.2 ± 0.4 0.44 
Fibers (g) 9.0± 2.6 9.9 ± 2.5 0.380  10.7 ± 2.8 9.8 ± 2.8 0.497 
Cholesterol (mg) 137.5 ± 35.9 138.8 ± 59.1 0.949  137.6 ± 75.6 128.9 ± 44.8 0.759 
Notes: CHO, carbohydrate; HSO, group treated with hempseed oil; MUFAs, monounsaturated fatty 
acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids. 
Values are expressed as mean ± SD. * Significantly different as compared to baseline (p≤ 0.05). 
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Effect of hempseed oil supplementation on serum lipid profile and RBC phospholipid 
composition 
The serum lipid concentrations and FA composition of phospholipids in RBCs at baseline and 
mean changes after treatments are reported in Table 3.13 and Table 3.14, respectively. For each 
parameter, post-treatment variations, with respect to baseline, were considered for the statistical 
analysis. 
At baseline, TC, LDL-C and non-HDL-C levels exceeded the 90th percentile for age and sex, 
while HDL-C values were in the normal range. Compared with control group, the analysis of 
differences revealed a significant effect of HSO treatment in the reduction of HDL/LDL ratio 
(p<0.0001), while other serum lipid levels did not change over the study period (Table 3.14). 
In RBC phospholipids, 8-week of HSO supplementation led to a significant (p<0.001) decrease 
of total SFA and MUFA levels and an increase (p<0.0005) of total PUFA, n-3 and n-6 PUFA, and 
n-3 and n-6 LC-PUFA levels, when compared to control group. Moreover, in the HSO group a 
significant improvement (p<0.001) of omega-3 index was observed after HSO treatment compared 
to control, even if the value remained lower than the cut-off level (<4%). The completed list of 
variation of the single FA concentration in RBCs are reported in Table 3.14. Notably, despite the 
level of ALA in RBCs did not differ between the two study groups, a significant increase of RBC 
EPA and DHA, possibly derived from the enzymatic convertion of ALA, was observed after HSO 
supplementation. 
 
 
Table 3.13 Serum lipid profile evaluated at baseline and post-treatment variation observed after 
8-weeks of treatments in both control and HSO groups. 
 
Serum lipids Control (n=18)  HSO (n=18) 
     (mg/dl) Baseline Δ (95% CI)  Baseline Δ (95% CI) 
TC 210.3 ± 50.0 -6.2 (-19.7; 7.2)  207 ± 14.9 -4.5 (-13.6; 4.6) 
TG 76.5 (35-185) -6.3 (-24.1; 11.6)  86.4 ± 44.0 16.0 (-3.6; 35.6) 
HDL-C 55.4 ± 14.9 0.1 (-3.3; 3.5)  58.2 ± 11.9 -1.8 (-5.2; 1.7) 
LDL-C 136.7 ± 45.2 -4.8 (-13.6; 4.0)  136.2 ± 18.7 -10.3 (-21.4; 0.7) 
HDL/LDL 0.5 ± 0.2 0.04 (-0.01; 0.08)a  3.7 ± 0.8 -3.25 (-3.73; -2.78)b 
Non-HDL-C 154.9 ± 47.5 -6.3 (-17.6; 4.9)  153.4 ± 23.1 3.4 (-31.2; 37.9) 
Notes: HDL-C, high-density lipoprotein cholesterol; HSO, group treated with hempseed oil; LDL-C, low-
density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. 
Values are expressed as mean ± SD at baseline and as changes (Δ) calculated considering post-treatment 
variations (calculated as differences between post- to pre-treatment), with 95% confidence interval (CI min; 
max). Data with different letters within the same row differ significantly (p<0.05). 
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Table 3.14 FA composition of RBC phospholipids evaluated at baseline and post-treatment 
variation observed after 8-weeks of treatments in control and HSO groups. 
 
FA composition of  Control (n=18)   HSO (n=18) 
RBC phospolipids (%) Baseline Δ (95% CI)   Baseline Δ (95% CI) 
Total SFAs 48.52 ± 2.79 +3.10 (0.50; 5.70)a  59.59 ± 7.33 -5.02 (-8.97; -1.07)b 
Total MUFAs 18.57 ± 1.07 +0.40 (-0.30; 1.09)a  21.91 ± 2.09 -2.12 (-3.23; -1.01)b 
Total PUFAs 32.91 ± 2.75 -3.50 (-6.62; -0.37)a  18.50 ± 8.25 +7.14 (2.48; 11.81)b 
Total PUFAs n-3 5.16 ± 1.28 -0.83 (-1.51; -0.16)a  1.68 ± 1.73 +1.57 (0.60; 2.55)b 
Total PUFAs n-6 25.90 ± 1.26 -2.40 (-4.69; -0.10)a  15.26 ± 5.92 +5.39 (1.82; 8.96)b 
PUFAs n-3/n-6 0.20 ± 0.05 -0.02 (-0.04; 0.00)a  0.09 ± 0.06 +0.05 (0.02; 0.09)b 
Total LC-PUFAs n-3 5.08 ± 1.28 -0.83 (-1.50; -0.16)a  1.57 ± 1.73 +1.57 (0.60; 2.53)b 
Total LC-PUFAs n-6 14.89 ± 1.47 -2.08 (-3.93; -0.24)a  6.77 ± 4.60 +4.08 (1.39; 6.76)b 
LC-PUFAs n-3/n-6 0.34 ± 0.08 -0.02 (-0.04; 0.01)a  0.19 ± 0.08 +0.08 (0.04; 0.13)b 
Omega-3 index 3.94 ± 1.09 -0.65 (-1.19; -0.10)a  1.12 ± 1.24 +1.18 (0.47; 1.88)b 
SFAs       
14:0 (myristic acid) 0.38 ± 0.07 +0.10 (-0.02; 0.23)a  0.53 ± 0.16 -0.07 (-0.16; 0.03)b 
15:0 (pentadecanoic acid) 0.16 ± 0.03 +0.02 (0.00; 0.04)a  0.20 ± 0.05 -0.03 (-0.06; 0.00)b 
16:0 (palmitic acid) 23.83 ± 1.07 +1.58 (0.10; 3.07)a  29.54 ± 3.96 -3.27 (-5.73; -0.80)b 
17:0 (margaric acid) 0.46 ± 0.13 +0.16 (0.02; 0.31)a  0.61 ± 0.18 -0.10 (-0.22; 0.02)b 
18:0 (stearic acid) 15.02 ± 1.53 +0.34 (-0.19; 0.87)  17.17 ± 2.72 -0.40 (-1.92; 1.12) 
20:0 (arachidic acid) 0.63 ± 0.25 +0.02 (-0.11; 0.16)  0.77 ± 0.14 -0.11 (-0.19; -0.02) 
22:0 (behenic acid) 2.07 ± 0.36 +0.22 (0.02; 0.41)a  2.77 ± 0.51 -0.45 (-0.67; -0.22)b 
23:0 (tricosanoic acid) 0.30 ± 0.05 +0.04 (0.00; 0.08)a  0.40 ± 0.06 -0.06 (-0.09; -0.03)b 
24:0 (lignoceric acid) 5.68 ± 0.81 +0.61 (0.13; 1.10)a  7.58 ± 2.33 -0.54 (-1.49; 0.41)b 
MUFAs       
16:1n-9 (hypogeic acid) 0.11 ± 0.02 +0.003 (-0.012; 0.018)  0.12 ± 0.04 -0.01 (-0.03; 0.01) 
16:1n-7 (palmitoleic acid) 0.22 ± 0.06 +0.05 (-0.05; 0.15)a  0.25 ± 0.08 -0.02 (-0.04; 0.00)b 
18:1n-9 (oleic acid) 10.86 ± 1.09 +0.20 (-0.23; 0.63)a  12.67 ± 1.47 -1.14 (-1.90; -0.38)b 
18:1n-7 (vaccenic acid) 1.08 ± 0.07 -0.02 (-0.07; 0.03)  1.16 ± 0.17 -0.10 (-0.15; -0.04) 
20:1n-9 (eicosenoic acid) 0.23 ± 0.13 -0.03 (-0.10; 0.05)  0.26 ± 0.07 -0.03 (-0.06; 0.00) 
24:1n-9 (nervonic acid) 6.06 ± 1.21 0.19 (-0.39; 0.77)  7.45 ± 1.10 -0.83 (-1.30; -0.35) 
n-6 PUFAs       
18:2n-6 (LA) 10.68 ± 1.12 -0.26 (-0.96; 0.44)a  8.22 ± 1.72 +1.28 (0.26; 2.29)b 
18:3n-6 (γ-linolenic acid) 0.06 ± 0.02 +0.002 (-0.013; 0.017)  0.07 ± 0.03 +0.01 (-0.02; 0.05) 
20:2n-6 (EDA) 0.27 ± 0.10 -0.04 (-0.10; 0.05)  0.20 ± 0.08 +0.03 (-0.01; 0.07) 
20:3n-6 (DGLA) 1.91 ± 0.43 -0.19 (-0.37; 0.02)a  0.94 ± 0.52 +0.43 (0.13; 0.72)b 
20:4n-6 (ARA) 11.11 ± 1.01 -1.60 (-3.03; -0.17)a  4.80 ± 3.38 +3.06 (1.05; 5.07)b 
22:4n-6 (adrenic acid) 1.88 ± 0.57 -0.31 (-0.63; 0.01)a  1.03 ± 0.90 +0.59 (0.13; 1.05)b 
n-3 PUFAs      
18:3n-3 (ALA) 0.08 ± 0.03 -0.003 (-0.022; 0.015)  0.10 ± 0.04 +0.01 (-0.02; 0.04) 
20:5n-3 (EPA) 0.35 ± 0.13 -0.18 (-0.32; 0.04)a  0.18 ± 0.12 +0.11 (0.03; 0.18)b 
22:5n-3 (DPA) 1.14 ± 0.27 -0.02 (-0.08; 0.04)a  0.45 ± 0.50 +0.39 (0.12; 0.66)b 
22:6n-3 (DHA) 3.58 ± 0.99 -0.63 (-1.15; -0.10)a  0.94 ± 1.13 +1.07 (0.43; 1.71)b 
Notes: ALA, α-linolenic acid; ARA, arachidonic acid; DGLA, dihomo-γ-linolenic acid; DHA, 
docosahexaenoic acid; DPA, docosapentaenoic acid; EDA, eicosadienoic acid; EPA, eicosapentaenoic acid; 
HSO, group treated with hempseed oil; LA, linoleic acid; LC-PUFAs, long chain polyunsaturated fatty acids 
(C ≥20, double bonds ≥3); MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; n-6 
PUFAs, omega-6 PUFAs; n-3 PUFAs, omega-3 PUFAs; RBC, red blood cell; SFAs, saturated fatty acids. 
Omega-3 index: sum of EPA + DHA.  
Values are expressed as mean ± SD at baseline and as changes (Δ) calculated considering post-treatment 
variations (calculated as differences between post- to pre-treatment), with 95% confidence interval (CI min; 
max). Data with different letters within the same row differ significantly (p<0.05). 
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3.4 DISCUSSION  
A proper nutritional intervention is considered the primary strategy to prevent the onset of chronic 
degenerative diseases. This concept is relevant when applied to the general population, and, even 
more, to children affected by primary hyperlipidemias whose future CV risk is relatively high. In 
fact, hyperlipidemia is a well established risk factor for atherosclerosis, conceivably associated 
with an increased oxidative stress (Nourooz-Zadeh et al. 2001; Botto et al. 2002; Harangi et al. 
2002; Real et al. 2010; Da Silva Pereira et al. 2013; Tangvarasittichai 2015) already from the 
pediatric age (Martino et al. 2008; Kliemann et al. 2012; Loffredo et al. 2013). Thus intervention 
treatments must start since childhood to improve cardiovascular prognosis.  
To the best of our knowledge, for the first time it was documented that specific dietary 
interventions with HZNs (with or without skin) or hempseed oil, sources of unsaturated fats and 
other bioactives, are effective in the management of pediatric hyperlipidemia, improving serum 
lipid profile and RBCs phospholipid composition, but also oxidative stress markers as 
demonstrated through the HZN intervention. In addition, our study is the first providing reference 
value on the FA composition of RBC phospholipids in a group of Italian children and adolescents 
with primary hyperlipidemia.  
 
In our study, hyperlipidemic children and adolescents were characterized for serum lipid profile 
and RBC phospholipid composition, showing an overall low omega 3 index and differences 
according to sex and patient diagnosis of primary hyperlipidemia. The FA composition of RBCs 
phospholipid has been suggested as an additional marker to monitor serum lipoprotein profile 
changes (Harris et al. 2004; Novgorodtseva et al. 2001) and as an outcome parameter in the 
management of hyperlipidemia, although no reference values exist neither for healthy nor 
hyperlipidemic children. In our characterisation, children affected by FH showed significantly 
lower levels of MUFA, vaccenic acid and n-6 PUFA γ-linolenic acid in RBCs, with respect to 
patients affected by other genetic forms of primary hyperlipidemia (FCH or PCH). These data are 
consistent with earlier findings in adults demonstrating that subjects with hypercholesterolemia 
and advanced coronary heart disease exhibited a decreased PUFA level and increased cholesterol 
and SFA concentrations in erythrocytes, that were related to the atherosclerotic condition (Taylor 
1994; Lausada et al. 2007; Vayá et al. 2009; Novgorodtseva et al. 2011). Moreover, in the present 
study we observed sex-related differences in RBC phospholipids among hyperlipidemic children, 
showing a significantly greater proportion of the SFA stearic acid, and lower proportion of n-6 
PUFA (in particular DGLA) in females. Lower DGLA values were also observed in serum 
glycerophospholipids of healthy young girls when compared with boys (Glaser et al. 2010). In 
addition, in females we found a trend towards lower levels of MUFA and MUFA/SFA ratio in 
RBCs with respect to males. Venäläinen et al. (2016) reported that a higher plasma level of SFA 
myristic acid, MUFA palmitoleic acid and reduced concentrations of n-6 PUFA (linoleic acid) was 
correlated with increased cardiometabolic risk in children. However, since no similar studies were 
conducted in hyperlipidemic children, the comparison of our data with other from literature is 
extremely difficult. 
Correlation analysis showed a positive association between n-6 PUFA levels in RBCs and serum 
HDL-C concentrations, which was similar to other observations in young or adults, showing a 
direct relationship between serum n-6 PUFAs and HDL-C (Ferrucci et al. 2006; Motoyama et al. 
2009; Jelenkovic et al. 2014). Furthermore, we observed an inverse correlation between MUFA in 
RBCs and serum TC concentration and HDL/TG ratio. These results are in agreement with those 
from previous clinical studies showing that diet rich in MUFA have potential hypocholesterolemic 
effect (Yu et al. 1995; Gill et al. 2003; Fernandez et al. 2005; Mukuddem-Peterson et al. 2005).  
Finally, as previously anticipated, in the whole sample of hyperlipidemic children and adolescent 
we registered a low mean omega-3 index (EPA+ DHA <4%), a factor that contribute to classify 
them as at future high risk for CVD, according to Harris & Von Schacky (2004). In the pediatric 
population, only one other study examined the omega-3 index and concluded that a greater 
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proportion of obese children had a lower index compared with non-obese children (Burrows et al. 
2011). However, in an observational study conducted on 16000 patients it was documented a 
tendency to rise omega-3 index through the lifespan, with an increase by about 1.5 percentage 
points across the decades (Harris et al. 2013). Since EPA and DHA derive from essential fatty 
acids, our results suggest a likely reduced synthesis due to the lipid metabolism disorder. However, 
is noteworthy that our patients did not regularly consume LC-PUFA rich food sources, confirming 
the importance of the quality of dietary FAs intake. In this regard, the use of whole dietary 
strategies and/or specific supplements (e.g. with PUFA, MUFA or other food bioactives) could be 
fundamental to improve this index above all in at risk subjects such as hyperlipidemic children.  
 
 
Dietary treatment design to replace the intake of SFA and cholesterol with unsaturated fatty acids 
are considered the primary approach in the management of hyperlipidemia and CVD prevention 
(Gidding et al. 2005), especially at pediatric age. Clinical and epidemiological studies in 
hyperlipidemic and healthy adults have consistently demonstrated the favorable effects of nuts in 
the reduction of coronary artery disease (Zhou et al. 2014) and in the overall health improvement 
(Alexiadou & Katsilambros 2011; Ros 2015; Grosso & Estruch 2016). 
HZNs are among the most popular tree nuts consumed worldwide, and the second richest source 
of MUFAs - mainly oleic acid- vitamin E and other phytochemicals with remarkable cholesterol 
lowering effect (i.e. phytosterols) and antioxidant properties (i.e. polyphenols, vitamin E) (López-
Uriarte et al. 2009; Bolling et al. 2011). In our study, Italian hazelnuts Corylus avellana L. ‘Tonda 
Gentile delle Langhe’ were administer peeled (HZN-S) or unpeeled (HZN+S) to evaluate potential 
differences in the antioxidant properties associated with hazelnut skin. Indeed, a portion of HZN+S 
or HZN-S provides similar amounts of MUFAs, phytosterols, α-tocopherol and minerals, but 
different amount of polyphenols (mostly gallic acid), which are mainly present in the skin. 
Although generally considered a byproduct of peeled HZNs, skins are an interesting edible source 
of polyphenol compounds with antioxidant properties (Del Rio et al. 2011). Moreover, aavailable 
evidence suggests a lowering effect of polyphenol-rich foods on cholesterol and postprandial 
triglycerides (Sanchez-Gonzalez et al. 2015) even if, studies ascertaining the impact of nut 
polyphenols in the modulation of lipid profile are scarce.  
The primary aim of our intervention study was to assess the effect of regular intake of HZN+S 
or HZN-S in the modulation of DNA damage and ox-LDL levels, both markers of oxidative stress, 
in children and adolescents with primary hyperlipidemia. In particular, after HZN consumption 
we observed a reduced level of endogenous (FPG-sensitive site) and H2O2-induced DNA strand 
breaks, while we could not demonstrate any effect of HZN+S on ox-LDLs, whose levels remained 
stable in treated and untreated patients. 
To our knowledge, no previous study investigated the impact of HZN intake on DNA damage in 
patients at risk of oxidative stress, like children with primary hyperlipidemia, nor the potential 
different impact associated with the consumption of peeled vs. unpeeled hazelnuts. Based on our 
data, both types of HZNs significantly reduced the levels of endogenous DNA damage, but only 
HZN+S significantly decreased the oxidatively-induced DNA damage in PBMCs, a suggested 
marker of antioxidant protection or cell resistance from an ex vivo induced oxidative insult. Indeed, 
it is noteworthy that high amounts of vitamin E, with well-recognized antioxidant properties, are 
regularly introduced through HZN intake. Moreover, it may be hypothesized that the higher 
phenolic content and overall antioxidant capacity demonstrated in HZN+S increased treatment 
efficacy. In fact, the ability of polyphenol-rich foods to increase antioxidant cell protection by 
reducing DNA oxidized bases and strand breaks have been documented in several in vivo studies 
(Del Bo’ et al. 2015; Martini et al. 2016). 
Correlation between regular nuts consumption and reduced markers of oxidative DNA damage 
was also observed in other intervention studies conducted in adults supplemented with almonds 
(Li et al. 2007; Jia et al. 2009), brazil nuts (Cominetti et al. 2011), or mixed nuts (López-Uriarte 
et al. 2010). In particular, two studies carried out in smokers demonstrated that daily almond 
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supplementations for 4 weeks could decrease the oxidative DNA damage mediated by tobacco (Li 
et al. 2007; Jia et al. 2009). Furhtermore, 8-week intake of selenium-rich Brazil nuts significantly 
decreased the levels of DNA strand breaks in a group of obese women with wild-type genotype of 
glutathione peroxidase1 Pro198Leu polymorphism (Cominetti et al. 2011). A significant reduction 
of DNA damage, evaluated as 8-OH-dG, was also observed after 8-week treatment with mixed 
nuts, including hazelnuts, in adult patients with metabolic syndrome (López-Uriarte et al. 2010). 
However, to our knowledge, no other available studies investigated the relationship between HZN 
consumption and oxidative stress in humans.  
Despite HZNs are rich in MUFAs, which have been associated with reduced susceptibility of 
LDL to oxidation (Berry et al. 1992), we did not observe significant changes in ox-LDL levels 
after HZN treatments. A possible explanation is that our study was carried in children with primary 
hyperlipidemia, showing mild LDL-C elevation and instructed to healthy lifestyle 
recommendations. The unchanged ox-LDL levels were also observed in other studies following 
the intake of different nuts (Ros et al. 2004; López-Uriarte et al. 2010). As expected, cholesterol 
values were directly correlated to ox-LDL. Moreover, the LDL-C concentrations were positively 
associated with the levels of oxidatively-induced DNA damage, suggesting that both markers may 
be considered of special interest from the clinical point of view, providing an overall indication of 
the oxidative status secondary to hyperlipidemia. 
A secondary aim of this study was to investigate the lipid lowering effects of HZNs as well as 
potential additional benefit of their skin, in the management of pediatric hyperlipidemia. Our 
findings showed that 8-week consumption of both HZN+S and HZN-S significantly reduced serum 
levels of LDL-C by about 6%, when compared to basal values. LDL-C is considered at present the 
best biomarker of CV risk when applicable, and different cut-off levels are recognized as target 
levels. This caution applies also to children, in order to avoid the damaging effects related to the 
hyperlipidemia later in life (Catapano et al. 2011). In particular, serum LDL-C levels decreased 
towards 130 mg/dL which represents the LDL-C target to be reached in childhood when primary 
hyperlipidemia occurs, while LDL-C levels of 110 mg/dL or less is suggested for patients with FH 
(Reiner et al. 2011). Moreover, following HZN interventions, hyperlipidemic children showed an 
overall improvement of non-HDL-C levels and HDL-C/LDL-C ratio, biomarkers that greatly 
correlates with the CV risk. Although HDL-C levels did not change, it should be mentioned that 
HDL-C/LDL-C ratio is more related to the risk of CVD events than HDL-C “per se”. 
Overall, these results are in line with other observations reported in dietary intervention studies 
in healthy (Durak et al. 1999; Yücesan et al. 2010) and hyperlipidemic adults or young adults 
(Mercanligil et al. 2007; Tey et al. 2011; Orem et al. 2013), showing an improved plasma lipid 
and lipoproteins profile following the regular HZNs intake. For example, similarly to our findings, 
Orem et al. (2013) reported that 4-week intervention with HZN-enriched diet (30 g/day), 
significantly reduced TC (-7.8%), triacylglycerol (-7.3%) and LDL-C (-6.2%), while increased 
serum HDL-cholesterol levels (6.1%), in hypercholesterolemic adult volunteers. Furthermore, in 
a randomized crossover study, the consumption of 30 g/day of ground, sliced or whole HZNs for 
4 weeks improved lipoprotein profile in mildly hypercholesterolemic subjects (Tey et al. 2011). 
Although it should be recognized the good nutritional quality of HZN+S, providing a higher 
amount of polyphenols, the positive changes observed on lipid levels in our study were comparable 
following both interventions with HZN+S or HZN-S. The lipid lowering effect of polyphenols is 
widely debated. A study performed in atherosclerosis-susceptible mice showed that the 
consumption of whole walnuts (providing PUFAs and polyphenols), but not only walnut oil 
(containing only PUFAs), reduced atherosclerotic plaques and decreased the levels of circulating 
and hepatic lipids (Nergiz-Ünal et al. 2013). Caimari et al. (2015) reported, for the first time, that 
an extract derived from HZN skin and rich in dietary fiber, phytosterols and polyphenols had lipid-
lowering blood effects, decreasing the circulating levels of total and LDL-C, triglycerides and non-
esterified free fatty acids in hamsters fed with a high fat diet for 8 weeks. In our experimental 
conditions, the intake of both HZN+S and HZN-S was able to reduce LDL-C and to improve 
HDL/LDL-C ratio, independently from the presence of polyphenols. Since the results are difficult 
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to compare due to the different models used, further investigations are needed in order to ascertain 
the contribution of polyphenols introduced through nuts in the modulation of lipid profile in human 
volunteers. 
Finally, since adult dyslipidemia was correlated with an alterated RBC FA composition - that 
was partly confirmed in our previous preliminary observation in pediatric hyperlipidemia - another 
aim of this study was to evaluete the potential role of HZN-enrich diet in the improvement of RBC 
phospholipid composition, which is determined by a combination of metabolism and diet. We 
failed to demonstrate an effect of HZN consumption on the low omega-3 index previously 
observed in hyperlipidemic pediatric patients, probably due to the low content of PUFAs. 
However, 8-week HZN intervention increased the levels of MUFAs, oleic acid and MUFAs/SFAs 
ratio in RBC phospholipids in both the HZN groups. Since HZN fat composition was mainly 
represented by MUFA and in particular by oleic acid, whose concentration exceeded 80% of total 
fats, these results support the effectiveness of HZN interventions in the modulation of RBC 
phospholipid composition. Similar findings were observed in a crossover study by Rajaram et al. 
(2009), who reported an increased amount of PUFA, linoleic acid, and ALA in the RBC 
membranes following 4-week supplementation with walnuts (40 g/day) in a group of normal and 
mildly hyperlipidemic volunteers. Similarly, English walnuts intake (30 g/day, 30 days) increased 
RBC PUFA levels in healthy participants (Fitschen et al. 2011). Moreover, in our trial, we also 
observed a significant decrease of palmitoleic and linoleic acid levels in RBCs following the 
consumption of HZN-S, but not HZN+S, that is apparently without a plausible explanation. A 
reduction of linoleic acid could be postulated as the consequence of ex-novo synthesis of 
arachidonic acid, the major n-6 fatty acid in the RBC membranes. However, the synthesis rates of 
arachidonic acid from linoleic acid have been reported to be less than 1% (Harris et al. 2013) and 
no significant change in its content was observed following HZN interventions. Regarding the 
control group, at the end of the study period we documented a significant increase in the levels of 
total SFAs, in particular margaric acid, and a significant decrease of eicosenoic acid and total 
PUFAs n-6 (in particular DGLA). Even if DGLA is the immediate precursor of arachidonic acid 
and dairy intake of this fatty acid can increase plasma pentadecanoic and margaric acids 
(Aslibekyan et al. 2012), based on the analysis of food diaries, we did not document modifications 
of nutrient intake and of eating behavior (e.g. increase of dairy products) in our controls. On the 
contrary, the inclusion of HZNs to the dietary protocol increased the total fat intake (with specific 
regard to MUFA and PUFA) and decreased the carbohydrate intake without significantly affecting 
total energy intake. Furthermore, it should be underlined that we found an overall underestimation 
of energy intake and a moderate deviation from general dietary recommendations (CHILD 1), 
showing higher protein and fat intake than suggested. Moreover, BMI did not change during the 
intervention, while height and weight increased probably due to the related growth, in agreement 
with results reported in a recent meta-analysis of controlled trials (Del Gobbo et al. 2015). 
Overall, it could be stated that by considering published data, the effect of nuts intake on 
oxidative stress markers and lipid profile is dependent on several variables – including the daily 
dose of nuts administered (ranging from 28-30 to 60-70 g/day for HZNs), different preparation 
(e.g. rosted vs raw, peeled vs. unpeeled, etc.) and changed nutritional composition among different 
nut cultivars (Alasalvar et al. 2003; Maguire et al. 2004). Another variable is represented by the 
impact of factors associated with nut consumption, i.e. combination with other foods, intake of 
one portion vs. multiple portions or time of consumption. The characteristics of the subjects 
enrolled is also relevant. Indeed, the cardiometabolic health benefits associated with nut 
consumption were mainly described in studies conducted in adults reporting a favorable effect on 
plasma lipid profile, making the comparison of data difficult in case of pediatric population. In 
addition to the present study, only two intervention trials were performed in children and 
adolescents to evaluate the efficacy of nuts in reducing CV risk (Maranhão et al. 2011; O’Neil et 
al. 2012), but none of them included hyperlipidemic patients.  
Even if a possible limitation of the present study is the absence of a control group of healthy 
children and adolescents, which makes data applicable only to children with primary 
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hyperlipidemia, this is the first trial documenting the beneficial effect of the supplementation with 
different form of HZNs (HZN+S or HZN-S), associated with a balanced diet able to improve cell 
protection fromDNA damage, to reduce serum LDL-C and to increase MUFA  RBC 
phospholipids, in children and adolescents affected by primary hyperlipidemia. 
 
 
The importance of the development of dietary intervention for the modulation of the above-
mentioned biomarkers related to hyperlipidemia is well recognized and there is specific interest 
also in food supplements which can have a favorable effect. In our pilot trial we ascertained 
whether dietary supplementation with HSO, composed by over 80% in PUFAs and other 
nutritional components, was more effective in enhancing the low RBCs omega-3 index and the 
overall lipid profile in the same population of hyperlipidemic children and adolescents. 
The cardioprotective effect of diets rich in PUFA on hyperlipidemia and coronary artery disease 
(Chiesa et al. 2016; Pan et al. 2009) have been mainly attributed to the marine n-3 LC-PUFAs EPA 
and DHA from fish oil (Chiesa et al. 2016; Eslick et al. 2009). In fact, strong evidence associated 
a reduced levels of EPA and DHA in both diet and RBC membranes with higher risk for CVD and 
early mortality (Harris et al. 2013). Despite ALA, a plant-derive essential n-3 PUFA, is the direct 
precursor of EPA and DHA and demonstrated a beneficial role for heart diseases prevention, there 
is a lack of sufficient evidence from large randomized clinical trials on the CVD benefits of ALA 
vs. EPA and DHA (Fleming and Kris-Etherton 2014; Pan et al. 2012). Moreover, the major 
experimental data derived from randomized trials were conducted using the flaxseed oil as a source 
of ALA. Even if HSO has been used in our diet for hundreds of years, surprisingly little research 
have been published on its physiological effects (Schwab et al. 2006). HSO has an excellent 
nutritional composition providing large amounts of PUFAs, (over 80%) mostly represented by the 
two essential PUFAs ,i.e. the n-3 ALA and the n-6 LA (Callaway 2004). Despite its high content 
of LA, HSO is among the richest food sources of ALA (23 g ALA/100 g HSO, see Table 3.10) 
(Rodriguez-Leyva and Pierce 2010).and the omega-6 to omega-3 ratio (n-6/n-3) in HSO is 2:1.In 
the present trial, the daily dose of HSO supplementation was specifically calculated for our 
pediatric patients to meet the Italian nutritional recommendation, which suggest to introduce n-3 
PUFA in the amount of 0.5–2% of total energy intake (Società Italiana di Nutrizione Umana 2014). 
Specifically, a daily intake of ALA corresponding to 0.5% of total calories is sufficient to meet 
current recommendations for adequate intake (EFSA Scientific Opinion on Dietary Reference 
Values for Fats (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA) 2010). 
Our findings showed that 8-week dietary supplementation with HSO, providing 700 mg 
ALA/die, did not affect the lipoprotein profile, except for the significant decrease of HDL/LDL 
ratio due to a slight (not significant) reduction of HDL-C concentration. Similar results, but in 
healthy subjects, were also obtained in another trial following HSO consumption (Schwab et al. 
2006). The lipid lowering effect of increasing dietary ALA intake is controversial and the limited 
studies available on hyperlipidemics make the comparison difficult. For example, in a recent 
randomized controlled trail conducted in hypertrigliceridemic subjects, Dittrich et al. (2015) 
documented a significant reduction of TC and LDL-C after 10-weeks consumption of linseed oil 
(7.4 g/die of ALA). Accordingly, similar findings were observed after the consumption of 11.4 g 
ALA/die from camelina oil for 6 weeks in hypercholesterolemic subject (Karvonen et al. 2002). 
On the contrary, a significant reduction of HDL-C and TC concentration was found after 12 weeks 
of ALA-enriched diet (15 g ALA/die) from flaxseed oil in subjects with an atherogenic lipoprotein 
phenotype (Wilkinson et al. 2005). Moreover, authors subtitled that the beneficial ALA effect was 
not equivalent to CVD benefits demonstrated for dietary EPA and DHA, including fish oil-induced 
changes in HDL cholesterol and LDL subclasses (Wilkinson et al. 2005). In addition, a review of 
short term trials (6–12 weeks) in healthy individuals showed no or inconsistent effects of 1.2–3.6 
g/die ALA intake on blood lipids and lipoprotein (Geleijnse, De Goede, and Brouwer 2010).  
The secondary aim of this study was to evaluate the effect of HSO supplementation on the 
modulation of RBC phospholipid composition. Differently to what was observed after HZN intake, 
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the supplementation was able to improve the overall FA composition of RBC phospholipids by 
increasing the levels of total PUFA, n-3 and n-6 PUFA subclasses and n-3/n-6 PUFA ratio, while 
significantly reducing RBC levels of SFA and MUFA. The opposite trend was observed in the 
control group. Moreover, the intervention with HSO significantly raised the omega-3 index, as 
well as the relative RBC contents of EPA and DHA, even if the index remained below the cut-off 
level associated with higher risk for CV events (<4%). By considering the modulation of single 
RBC fatty acids, in respect to control diet, 8-week intake of HSO significantly increased the levels 
of LA in RBC, mainly due to the high concentration of this fatty acid in the supplement. This result 
confirms the efficacy of HSO supplementation in the modulation of RBC phospholipids 
composition. Similar finding was obtained in a study conducted by Schwab et al. (2006), in which 
the HSO intake increased the proportion of LA in serum cholesteryl esters and TG. Unexpectedly 
and in contrast with other studies, the increased dietary intake of ALA was not associated with 
higher content of ALA in RBC phospholipids with respect to baseline and control. One possible 
explanation is that increased consumption of ALA could modestly stimulate the ALA pathway for 
its endogenous conversion into the LC-PUFA derivatives EPA, DPA and DHA. In fact, EPA and 
DHA levels in RBCs were found to be significantly higher after 8-week ALA supplementation 
(Burdge 2006). However, as noted by Burdge & Calder (2006), the ALA conversion is limited. In 
addition, it should be noted that the other studies were conducted in adults, testing an effect of 
higher doses of ALA. In the whole, our results are in line with few others human trials investigating 
the impact of increased ALA intake on RBC FA composition. In particular, Barceló-Coblijn et al. 
(2008), in a study conducted on subjects at high CVD risk, showed that 12-week supplementation 
with two different doses of flaxseed oil, rich in ALA (2.4 or 3.6 g ALA/die) led to a significant 
increased EPA, DHA and ALA in RBC phospholipids. The authors, by comparing multiple doses 
and different time-points, concluded that 2 weeks of treatment with 2.4 g ALA/die was sufficient 
to obtain alterations of n-3 PUFA in RBC phospholipids (Barceló-Coblijn et al. 2008). Comparable 
findings on the modulation of RBC FAs with flaxseed oil were also observed in patients with 
atherogenic lipoprotein phenotype treated with 15 g ALA/die for 6 and 12 weeks (Wilkinson et al. 
2005), or in a more recent study conducted in hypertriglyceridemic subjects supplemented with 7.4 
g ALA/die (Dittrich et al. 2015). On the contrary, the consumption of margarine fortificated with 
ALA (4.4 g ALA/die) was not associated with an increased RBC EPA level and omega-3 index 
but with an increased DHA level (Egert et al. 2012). However, the subjects included in this trial 
were healthy and the RBC contents of EPA and DHA, as well as the omega-3 index, were relatively 
high, indicating a good n-3 PUFA status (Egert et al. 2012). In the pediatric population, the effect 
of ALA supplementation was mainly studied in children with neuro-developmental disorder (Raz, 
Carasso, and Yehuda 2009; Dubnov-Raz et al. 2014). Only one study carried out in obese children 
concluded that daily ALA supplementation (1000 mg/die, 6-weeks) increased significantly n-3 FA 
composition of plasma lipids (Lohner et al. 2007). 
Despite the differences in RBC FA composition observed between controls and treated group are 
plausibly attributed to the HSO supplementation, we could not exclude that such differences may 
result from the different baseline RCB FA concentrations registered in the two groups. For this 
reason, to normalize data obtained the statistical analysis was carried out on percentage changes 
between post- to pre-treatment. Besides this possible limitation and the lack of a placebo-controlled 
group, this pilot intervention is the first documenting the potential beneficial effect (i.e. 
improvement of RBC lipid profile) of increase intake of ALA through HSO supplementationin 
children and adolescents affected by primary hyperlipidemia. 
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4.1 MATERIAL AND METHODS 
 
Chemicals 
Eicosapentaenoic acid (EPA) and arachidonic acid (ARA) in free fatty acid form and vitamin D3 
(1α,25-(OH2)D3) (all from Larodan, Malmö, Sweden) were dissolved in sterile dimethylsulfoxide 
(DMSO, Sigma-Aldrich, USA) to produce stock solutions of 100 mM (for EPA and ARA) or 10 
µM (for vitamin D), stored at -80°C or -20°C respectively.  
 
Collection and preparation of blood samples  
Buffy coats and whole blood samples (lithium-heparin) were collected from peripheral blood of 
healthy donors who gave their written consent. In order to isolate the PBMCs, buffy-coated blood 
was diluted with phosphate buffered saline (PBS; PAA, Cölbe, Germany) at a ratio of 1:1, layered 
onto lymphocyte separation medium (LSM) 1077 (1.077 g/ml; PAA; ratio 1:1) and centrifuged at 
700 g for 20 min at 20°C. The PBMC interphase was collected, washed three times with PBS, and 
resuspended in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% 
endotoxin-free heat-inactivated fetal bovine serum (FBS) and 1% L-arginine (all reagents from 
Invitrogen, Karlsruhe, Germany). 
 
PBMCs viability 
To assess the impact of high-dose EPA and ARA on cell viability, PBMC (1 × 106 /ml) were 
incubated without or with 25, 50, 100, 150, or 200 μM of EPA or ARA for 24 h in a 5% CO2 
humidified atmosphere at 37°C. Control cultures contained 0.2% DMSO vehicle, according to the 
maximal volume in the treatments. Cell viability was analyzed by flow-cytometrically, as 
described previously (Jaudszus et al. 2013). 
 
Evaluation of lytic activity of NK cells 
The lytic activity of NK cells against target human K562 cancer cell line, at two different ratios of 
PBMC:K562 (25:1 and 12.5:1), was determined by flow cytometry (FACSCalibur, Becton 
Dickinson, Heidelberg, Germany), according to the method described by Chang et al. (1993) and 
calculated as the percentage of dead target cells in the test samples minus the percentage of dead 
target cells in the control samples without effector cells. 
Briefly, isolated PBMCs from buffy coats were suspended in a 6-well plate with complete RPMI 
medium (2 x 106 cells/ml) and incubated with increasing concentrations of EPA or ARA (25, 50, 
100 µM), with or without 40 nM of vitamin D, for 24 h at 37°C and 5% of CO2. As two controls, 
PBMCs were also incubated with DMSO or DMSO with vitamin D 40 nM. Meanwhile, K562 
target cells were held under standard culture conditions and passaged the day before the assay. To 
discriminate effector from target cells, K562 cells were fluorescence labeled with 
dioctadecyloxacarbocyanine (DiO; Molecular Probes, Leiden, Netherlands). After 24 h, PBMCs 
were pelleted, resuspended in new RPMI medium and transferred into polystyrene tubes together 
with labeled K562 cells at the effector:target ratios of 25:1 and 12.5:1, respectively. For controls, 
K562 were also incubated alone. For an accurate viability cell analysis, the propidium iodide (PI) 
dye solution (0.252 mg/ml; Molecular Probes) was added to all samples. After 75 min of incubation 
in the dark, the analysis was performed by means of flow cytometry: affected cells will finally 
appear double stained. NK cell activity was calculated as the difference in the percentages of PI-
positive target cells in the presence and in the absence of effector cells. 
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Phagocytic activity and intensity 
Assessment of phagocytic intensity (number of phagocytized E. coli expressed as mean 
fluorescence) in granulocytes and monocytes was based on a flow cytometric method according to 
O’Gorman (2002). Briefly, aliquots of 100 µl of whole blood (lithium-heparin) were transferred in 
polystyrene tubes and preincubated with increasing concentrations of EPA or ARA (25, 50, 100 
µM), with or without 40 nM of vitamin D, in duplicate, for 24h at 37°C and 5% of CO2. As controls, 
two blood samples were incubated with DMSO and DMSO with vitamin D 40 nM, in duplicate. 
To measure phagocytosis, 5 mL opsonized BODYPY FL-labeled E. coli (Molecular Probes) and 
100 mL chilled whole blood were mixed (i.e. 2 x 1012 E. coli/L whole blood) and incubated at 37°C 
or kept on ice (control) for 10 min. The reaction was stopped by adding 100 µL ice-cold quenching 
solution (10% trypan blue in PBS). After washing with PBS (without Ca and Mg), whole blood 
cells were fixed with 100 µL FACS lysing solution (BectonDickinson). DNA was stained with 300 
µL of PI solution (0.05 mmol/L PBS) and fluorescence was directly measured by flow cytometry 
(FACSCalibur; BectonDickinson).  
 
Statistical analysis 
A linear mixed model was used to estimate the effect of treatment (EPA or ARA without vit D 
versus EPA and ARA with vit D) and concentrations of EPA or ARA (0, 25, 50 or 100 µM). Beside 
main effects, two-way interactions (concentration x treatment) were included. A posthoc test was 
performed for signiﬁcant two-way interactions and adjustment for multiple testing (Tukey-
Kramer) was applied. Normality of the conditional studentized residuals was checked by visual 
inspection of the QQ-plot. If the residuals did not show normal distribution, the dependent variable 
was log-transformed. Further, homogeneity of the residuals was checked by visual inspection of 
the conditional studentized residual versus predicted values plot. All calculations were carried out 
using SAS 9.4. PROC MIXED and PROC GLIMMIX. Significance of difference was set at p < 
0.05 and data are expressed as means ± SD. 
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Effect of EPA and ARA on PBMCs viability 
First we tested whether incubation with EPA or ARA at high concentration has an impact on the 
viability of primary lymphocytes and monocytes over a period of 24 h. Compared with the DMSO 
control, neither EPA nor ARA showed any cytotoxic effect at 100 μM. A drop in viability was 
observed only at concentrations higher than 150 μM (data not shown). Based on these data, a 
maximum fatty acid concentration of 100 μM was used in all subsequent experiments. 
 
Effect of LC-PUFAs with vitamin D on NK cell activity against K562 target cells 
The lytic activity of NK cells measured at the two effector:target ratios (25:1; 12.5:1) was not 
significantly affected by treatment with EPA or ARA incubated alone or in conjunction with 
vitamin D (p>0.05). Moreover, no significant concentration x treatment interaction was found 
demonstrating a similar trend in the different experimental conditions. On the contrary, a 
concentration-dependent effect was found (p<0.0001) with a significant reduction in NK activity 
with increasing concentration of both EPA and ARA, independently from the compresence of 
vitamin D (Figure 4.1; 4.2). In particular, in all experimental conditions tested, the highest 
concentration of EPA and ARA (100 µM) showed a significant reduced (p<0.001) NK activity 
compared to the other concentrations (control, 25 µM, 50 µM). In addition, at effector:target ratio 
of 12.5:1, the reduced NK activity after the incubation with 50 µM of EPA was significantly 
different (p= 0.01) with respect to control. Furthermore, a dose-dependent response was observed 
after ARA stimulation: the NK lytic activity significantly decreased with increasing concentration 
of ARA at both effector:target ratio. 
 
 
 
A) Effector:target ratio of 25:1 
 
 
 
 
 
 
 
Figure 4.2 Effect of EPA treatments (EPA or EPA+ vit D) at different concentrations (EPA: 0, 25, 50 
or 100 µM) on NK activity at effector:target ratio of 25:1 (A) and 12.5:1 (B), with relative treatment 
(i) and concentration (ii) effects 
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Figure 4.1 Effect of EPA treatments (EPA or EPA+ vit D) at different concentrations (EPA: 0, 25, 
50 or 100 µM) on NK activity (i) and relative concentration-dependent effect (ii), at effector:target 
ratio of 25:1 (A) and 12.5:1 (B). Data with different letters differ significantly (p≤0.001). 
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Figure 4.2 Effect of of ARA treatments (ARA or ARA+ vit D) at different concentrations (ARA: 0, 
25, 50 or 100 µM) on NK activity (i) and relative concentration-dependent effect response (ii), at 
effector:target ratio of 25:1 (A) and 12.5:1 (B). Data with different letters differ significantly 
(p≤0.001). 
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Effect of LC-PUFAs with vitamin D on phagocytic activity of monocytes and granulocytes 
Compared to the treatment with only fatty acids (EPA or ARA alone), the 24 h co-incubation of 
EPA or ARA with vitamin D significantly increased the percent of phagocytic activity of 
monocytes independently from the concentration tested (Figure 4.3(b) and 4.4(b)), showing a 
significant treatment effect (p= 0.001). 
As far as the granulocytes responsiveness to EPA or ARA treatments (with and without vitamin 
D) is concerned, there was no treatment and concentration effect; a significant interaction between 
treatment and concentrations was found for ARA (p= 0.05).  
 
 
Figure 4.3 Effect of different EPA concentrations (0, 25, 50 or 100 µM) incubated with vitamin D 
(40 nM) or without (0 nM) (a), and relative treatment effect (b), on phagocytic activity in 
monocytes. *, p= 0.001. 
 
 
 
 
 
 
Figure 4.4 Effect of different ARA concentrations (0, 25, 50 or 100 µM) incubated with vitamin D 
(40 nM) or without (0 nM) (a), and relative treatment effect (b), on phagocytic activity in 
monocytes. *, p= 0.001. 
 
 
  
 
 
 
 
0 25 50 100
Conc tion
0.0
2.5
5.0
7.5
10.0
12.5
P
h
a
g
o
c
y
to
s
is
 M
o
n
o
c
y
te
s
 [
%
]
40 nM0 nMTreatment
EPA, Phagozytose, Monozyten
0 25 50 100
Concentr
0.0
2.5
5.0
7.5
10.0
12.5
P
h
a
g
o
c
y
to
s
is
 M
o
n
o
c
y
te
s
 [
%
]
40 nM0 nMTreatment
ARA, Phagozytose, Monozyten
* 
* 
EPA 
EPA + vit D 
ARA 
ARA + vit D 
0 nM = EPA without vit D 
40 nM= EPA + vit D 
a) b) 
0 nM = ARA without vit D 
40 nM= ARA + vit D 
a) b) 
4.3 Discussion 
83 
 
4.3 DISCUSSION  
The optimal functioning of the immune system depends on balanced and adequate nutrition able 
to affect the immune status and susceptibility to pathogens (Calder 2001; Kelley 2001). Dietary 
LC-PUFAs, such as ARA, EPA and DHA, are involved in a great number of immune responses, 
such as lymphocyte proliferation, cytokine synthesis, NK cell activity, phagocytosis and 
inflammation. While LC-PUFA-rich sources, in particular EPA and DHA, are widely 
recommended in prevention and attenuation of chronic diseases characterized by inflammation and 
an overactivation of immune system (Watson et al. 2010; Husson et al. 2016), in some 
circumstances, high doses of LC-PUFA seem responsible for an increased susceptibility to 
infectious microorganisms by generating an immunedepressed state (McMurray et al. 2011; 
Husson et al. 2016). Even if the mechanisms of action are not fully understood, previous 
investigations underline the importance for clinical trials to define the optimum LC-PUFA doses 
considered safe for supplemented patients.  
In our study, we tested different concentrations of the n-3 fatty acid EPA and the n-6 ARA to 
evaluate their dose-specific effects in the modulation of the phagocytosis and NK activity, the two 
main innate immune responses that specifically act against infectious agents as well as cancer cells. 
In addition, since previous data have demonstrated a beneficial effect of vitamin D3 in enhancing 
these mechanisms (Lee et al. 2011; Harvey & Cantorna 2013; Min et al. 2013; Djukic et al. 2014), 
we also investigated the effects of stimulating ex vivo innate immune cells only with EPA/ARA at 
different dose in comparison with their effect in association with vitamin D3. We found that NK 
activity is negatively affected by increasing concentration of both EPA and ARA, with a significant 
strong reduction with the highest dose tested of both fatty acid (100 µM). Even if studies reported 
that 10 to 25 µM are the LC-PUFAs concentrations that approximate the in vivo situations, i.e. 
after ingestion of fish oil (Lamaziere et al. 2015) and 100 µM of in vitro LC-PUFA concentration 
could be considered non-physiological, in our study neither EPA nor ARA showed any cytotoxic 
effect at 100 μM, when the viability test was performed. A decreased in cell viability was observed 
only at concentrations higher than 150 μM. Our observations are in line with other LC-PUFAs 
supplementation studies in humans as well as in animal models. For example, 6-month intake of 
foods enriched with n-3 LC-PUFA (1 g/day) in healthy humans led to a significantly lower number 
of circulating NK cells than in controls, that was associated with higher amount of EPA and DHA 
in erythrocytes (Mukaro et al. 2008). Similarly, in healthy subjects aged <55 years, 12-week 
supplementation with fish oil (720 mg EPA + 280 mg DHA) resulted in a significant lower NK 
activity, even if no effect was observed after ARA supplementation (Thies et al. 2001). A reduced 
NK activity following n-3 PUFA-enrich diet intake, but not after n-6 PUFA diet, was also observed 
after feeding female rats for 6-week with different fat diets containing a pool of n-3 or n-6 fatty 
acids (Sasaki et al. 2000). In our study, even if we found a strong significant concentration-effect 
(p< 0.0001) for both fatty acids used, the ex-vivo lymphocytes stimulation with ARA generated a 
more intense dose-dependent response than EPA, with a significantly decreased NK lytic activity 
with increasing concentration of ARA at both effector:target ratio tested. In accordance with our 
observations, a recent study conducted in young rats demonstrated that, compared to controls, long-
term ARA administration (240 mg/kg body weight) had an inhibitory effect on the tumor 
cytotoxicity of NK cells evaluated on ex vivo rat spleen lymphocytes (Juman et al. 2013). As regard 
vitamin D, even if recent findings demonstrated the beneficial role of vitamin D3 in increasing the 
NK activity or in enhancing the immuno-attack of NK cells against malignant cells (Lee et al. 
2011; Harvey & Cantorna 2013; Min et al. 2013), we failed to demonstrate that vitamin D3, 
associated with increasing dose of EPA or ARA could counteract the detrimental effect exerted by 
these two fatty acid on NK lytic activity.  
As far as the phagocytic activity is concerned, here we showed that increasing concentration of 
LC-PUFAs did not significantly affect the phagocytosis, even at higher dose tested. Similar 
findings were observed in a placebo-controlled study conducted in 150 healthy subjects, in which 
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the supplementations with two doses of the n-6 fatty acid ALA (4.5 or 9.5 g /day) or the n-3 
EPA+DHA (0.77 or 1.7 g/day) were not sufficient to increase the percentages of blood monocytes 
or neutrophils engaged in phagocytosis of Escherichia coli or the phagocytic activity (Kew et al. 
2003). Similarly, 12-week intake of EPA-enriched oil, providing different and higher doses of EPA 
(1.35, 2.7, or 4.05 g EPA/day), did not influence the neutrophil or monocyte phagocytosis in both 
young or older men (Rees et al. 2006). On the contrary, in a murine investigation, the ex vivo 
macrophages from mice supplemented for 9 weeks with sea cod oil or flaxseed oil (providing 900 
and 2000 mg n-3 PUFA/body weight, respectively), showed a significantly more efficient 
phagocytosis and intracellular killing of Streptococcus pneumonia than controls (Saini et al. 2013). 
Overall, the impact of an increased intake of LC-PUFAs on human blood monocyte phagocytosis 
are contradictory, mainly due to the scarce number of placebo-controlled studies in humans and 
the type of controls and supplements used (e.g. purified fatty acids vs. oils containing a mix of 
different PUFAs). 
Recently, there has been a considerable interest in the role that vitamin D might play in host 
resistance to infection. Despite we did not observe any differences after EPA or ARA ex vivo 
stimulation, the same treatments with EPA or ARA but associated with 40 nM of vitamin D were 
able to significantly increased the percent of phagocytic activity of monocytes independently from 
the concentration tested, showing a strong significant treatment effect. Previous data also reported 
that vitamin D3 (1×10–7 M) was able to enhanced the phagocytic potential also in subjects with a 
low phagocytic index (less than 20%) (Selvaraj et al. 2004). Moreover, a recent study observed 
that a vitamin D deficiency condition was associated with decreased rates of phagocytosis and 
intracellular killing of E. Coli K1 in microglial cells in respect to relative control cells. These data 
suggested a role of vitamin D in the resistance against bacterial infections even in the local immune 
system of the central nervous system (Djukic et al. 2014). However, at present, there is not adequate 
information available to understand the mechanism underlying the effect of vitamin D and/or 
vitamin D deficiency on the innate immune system, and specifically on the ability of a host to 
counteract infection or the shaping of cancer cells (Bruce et al. 2010; Harvey & Cantorna 2013). 
Overall, our results seem to confirm previous observations demonstrating a significant reduction 
of NK cell lytic activity after the ex vivo lymphocytes stimulation with increasing concentration of 
EPA or ARA, highlighting that caution should be exercised when prescribing high-dose and 
prolonged supplementation with LC-PUFAs in humans. Differently, the monocyte phagocytosis 
activity was enhanced by supplementation with vitamin D combined with EPA or ARA, suggesting 
a specific role of vitamin D, or a synergistic effect with LC-PUFA, in the phagocytosis process. 
Even if these data could give more information about immunomodulatory effects of LC-PUFAs 
and vitamin D, additional in vitro experimentations are required to define the mechanisms of action 
of these nutrients, as well as their effect after the interaction with other dietary compounds. 
Moreover, since current evidence is insufficient to make a definite nutritional recommendation in 
both physiological and pathological conditions, the use of supplementations in the future will 
depend on a better understanding of the appropriate dosage by which micronutrient modulate 
immune responses and inflammatory processes defined through in vivo investigations. 
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5 CONCLUSIONS 
In conclusion, through this PhD thesis it was possible to provide novel results concerning the 
potential benefits of bioactives rich-diet on the modulation of risk factors for chronic-degenerative 
diseases. This aspect is particular important in at risk target groups of population for whom 
appropriate and personalized nutritional interventions are considered the primary prevention 
approach.  
In the first part of the research, we provided the first data on the phospholipid composition of 
RBCs in a target population of children and adolescents affected by primary hyperlipidemia, one 
of the major risk factor for CVD. In particular, we documented an overall low omega-3 index, a 
factor that contribute to classify them as at future high risk of CVD. Specific dietary treatments are 
fundamental to improve this index and, above all, biomarkers related to hyperlipidemia. 
Subsequently, in the same target population we demonstrated the effectiveness of dietary 
treatments designed to replace the intake of SFA with unsaturated fatty acids as a primary 
intervention for the management of hyperlipidemia since pediatric age. In particular, we firstly 
showed that HZN-enrich diet could improve serum lipid profile, FA composition of RBC and 
oxidative stress markers. These positive effects were mainly attributed to the bioactive components 
contained in the HZN kernel and skin, in particular MUFA, phytosterols and polyphenols. In the 
subsequent pilot study, the impact of a food supplements consisting of HSO, rich in PUFAs was 
investigated. In this case, the supplementation was able to enhance the omega-3 index and the RBC 
phospholipid composition. Overall, these data give strengths to the development of dietary 
recommendation tailored to meet the specific needs of hyperlipidemic subjects since childhood, 
when the treatment should effectively start. Future and larger studies are necessary to confirm the 
beneficial effect of the supplementation with HZN or HSO on hyperlipidemia-related markers, 
focusing also on the mechanisms of action involved. 
In the second part of the research, an ex vivo experimentation was performed to improve 
understanding on the mechanisms of action of specific bioactives suggested as modulators of the 
innate immune functions, often compromised in several chronic and autoimmune diseases. In 
particular, our findings showed that elevated dose of LC-PUFA can negatively affect the NK cell 
lytic activity, underling that the immunomodulatory properties of bioactives could be dose-
dependent. Moreover, it is envisaged that caution should be exercised in case of prolonged 
supplementation. In addition, the results on the phagocytic activity showed that in some cases, it is 
important to considered the synergistic effect of different bioactives in the modulation of immune 
function. In fact, the phagocytic activity was significantly enhanced when LC-PUFA were 
combined with vitamin D. Future studies are needed to confirm our results and increase knowledge 
on the specific mechanisms of action involved in the immunomodulatory properties of food 
bioactives, including their interaction and active doses, before they may be considered for 
preventive and/or therapeutic supplementations. 
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Background: Cigarette smoke adversely affects vascular function by promoting endothelium 
injury via reactive oxygen species and nitric oxide dysregulation. Emerging evidence suggests an 
important role of dietary factors in modulating endothelial function. In particular, blueberries 
(Vaccinium corymbosum) appear to have beneficial effects on peripheral arterial dysfunction 
induced by acute cigarette smoking in young healthy volunteers.  
Objective: The aim of this study is to investigate the possible effect of one portion of blueberries 
on peripheral arterial function in young smokers with endothelial dysfunction. 
Methods: The study involves 16 male smokers with endothelial dysfunction. Subjects are 
randomized in a 3-armed controlled study with the following 3 experimental conditions: - smoking 
(S) treatment (one cigarette); - blueberry treatment (300 g of blueberry) + smoking (BS); - control 
treatment (300 mL of water with glucose and fructose) + smoking (CS). One week of wash-out 
period is scheduled between each treatment. Blood pressure (BP), heart rate (HR), and peripheral 
arterial function (reactive hyperemia index, RHI) are measured before and 20 min after smoking 
by using finger plethysmography method (Endo-PAT2000). Results obtained are elaborated by 
analysis of variance (ANOVA). Post-hoc analysis of differences between treatments is assessed by 
the least significant difference (LSD) test with p ≤ 0.05 as level of statistical significance. 
Results and Conclusion: Elaboration of preliminary data on 5 subjects showed that smoking does 
not affect RHI, BP and HR in subjects with endothelial dysfunction differently from what observed 
in smokers with normal endothelial function. However, ANOVA revealed a significant difference 
in the effect of the 3 treatments on RHI (p= 0.01). In particular, BS and CS treatments improved 
RHI index with respect to S treatment (+30.9  24.2% BS vs S, p= 0.0055; +25.3  27.2% CS vs 
S, p= 0.014). On the contrary, no effect was observed for systolic and diastolic BP, and HR (p= 
0.80, p= 0.75 and p= 0.94, respectively). Further analysis of data on the whole group of subjects 
will help clarifying the protective effect of blueberry consumption in subjects with endothelial 
dysfunction. 
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Introduction: Several studies suggest that dyslipidemic patients could be more prone to oxidative 
stress and cardiovascular disease (CVD) risk. Possible strategies to manage dyslipidemia and 
oxidative stress include dietary interventions.  
Aim: The aim is to investigate, in children with primary dyslipidemia, the effect of a hazelnut 
snacks rich in unsaturated fatty acids and bioactives on markers of oxidative stress and lipid profile.  
Methods: An 8-week randomized, controlled, parallel, dietary intervention study has been 
scheduled. The study involves 60 children (11.8 ± 2.6 years) affected by primary dyslipidemia. 
Main inclusion criteria were: total cholesterol (TC) and/or triglycerides (TR) value >95° percentile 
and BMI <95° percentile. Subjects received dietary guidelines and were assigned to the following 
snack treatment (0.43 g/Kg): 1- hazelnuts with skin, 2- hazelnuts without skin and 3- only the 
dietary guidelines (control). Before and after the interventions the serum lipid profile and the 
endogenous and H2O2-induced DNA damage (by comet assay) were evaluated.   
Results and Conclusion: Results presented are relative to 8 subjects who completed the 
intervention. Baseline lipid profile were TC: 218.8 ± 53.8 mg/dl, HDL-C: 55.4 ± 15.5 mg/dl, TR: 
92.8 (32-194) mg/dl and LDL-C: 149.8 ± 41.3 mg/dl. After the hazelnut treatment, the level of 
LDL-C was significantly reduced (-11.2%, p=0,020), as compared with control group. At baseline, 
H2O2-induced DNA damage was 39.4  5.6 %. After 8-week hazelnut intake, a DNA damage 
decrease by 15.3% (not significant) was found in subjects assigned to hazelnut treatment (from 
43.7 ± 3.2% to 37.9 ± 6.8%; n=4). No effect was observed in the control treatment (from 35.1 ± 
3.8% to 35.1 ±  8.7%; n=4;). 
Since the samples analysed are limited (8 out of 60 subjects involved), further elaborations on data 
of the whole group of children will help understanding the effect of hazelnut consumption on 
oxidative stress in children with dyslipidemia. 
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Dyslipidemia is a traditional risk factor for atherosclerosis and cardiovascular disease 
development; it is associated closely th an increase of oxidative stress and a decrease of 
antioxidative defense mechanisms. Nuts are a rich source of bioactives such as polyunsaturated 
fatty acids, vitamins, phytosterols and polyphenols. These compounds could play an important role 
not only in the management of dyslipidemia, but also in the modulation of oxidative stress.  
The objective of the present study is to evaluate the effect of hazelnut consumption on markers of 
oxidative stress, fatty acid composition of erythrocytes and serum lipids, in children with primary 
dyslipidemia. 
Sixty children (11.5 ± 2.5 years) have participated in an 8-week controlled, parallel, dietary 
intervention study with hazelnuts (0.43 g/kg body weight per day). Subjects received dietary 
guidelines and were randomized in 3 groups: 1- hazelnuts with skin; 2- hazelnut without skin; 3- 
control (without hazelnuts).  
Before and after intervention, blood samples were collected and used to evaluate the levels of 
formamidopyrimidine-DNA glycosylase (FPG)-sensitive sites and H2O2-induced DNA damage in 
peripheral blood mononuclear cells (by comet assay), serum lipid profile (by automatic analyzer) 
and erythrocyte membrane phospholipids composition (by gas chromatography analysis).  
Preliminary results on a subgroup (5 subjects receiving hazelnut with skin and 5 controls) show a 
reduction in the FPG-sensitive sites (from 13.8 ± 3.16% to 7.88 ± 2.98%) and H2O2-induced DNA 
damage (from 44.4 ± 3.1% to 35.7 ± 7.6%) following 8-week hazelnut consumption, while no 
effect seems occur in the control group.  
Hazelnut decreases serum LDL-C level (-11.2%; p= 0.01) and seems to affect erythrocyte 
membrane phospholipids composition compared to baseline, while at this time no difference in 
triglycerides, total and HDL-cholesterol levels has been documented.  
These preliminary results show a tendency towards a decrease in the levels of FPG-sensitive sites, 
H2O2-induced DNA damage and serum LDL-C after an 8-week hazelnut intervention. Data 
elaboration on the whole group of subjects will help understanding the effect of hazelnut 
consumption on lipid profile and markers of oxidative stress in children affected by primary 
dyslipidemia. 
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The consumption of berries (e.g. strawberries, cranberries and blueberries) has been shown to 
improve vascular function, inflammation and oxidative stress.   
The aim of the present study was to investigate the effect of a single blueberry portion on markers 
of arterial function and oxidative stress in a group of smoker volunteers.  
Sixteen healthy male smokers were recruited for a randomized controlled crossover study. Three 
types of conditions were assessed: 1-smoking treatment (S); 2-control treatment (300 mL of water 
with sugar + smoking (CS); 3-blueberry treatment (300 g of blueberry + smoking (BS). Each 
treatment was separated by one week of wash-out period. Peripheral arterial function (reactive 
hyperemia index, RHI) was measured before and 20 min after smoking. Plasma aminothiol 
concentrations, endogenous (formamidopyrimidine-DNA glycosylase (FPG)-sensitive sites) and 
oxidatively induced DNA damage (resistance to H2O2-induced DNA damage) in peripheral blood 
mononuclear cells (PBMCs) were measured at baseline and 20, 60, 90, 120 min and 24 h after 
smoking. Blueberry consumption, but not the control drink, counteracted the impairment of RHI 
(-4.4±0.8% BS treatment vs -22.0±1.1% S treatment, p<0.01) after acute cigarette smoking. 
Analysis of variance did not show a significant effect of treatment on the modulation of plasma 
aminothiol concentrations and the levels of FPG-sensitive sites (P > 0.05) and H2O2-induced DNA 
damage (P > 0.05) in PBMCs, but revealed an effect of time for plasma concentrations of total 
cysteine (P = 0.007) and cysteine-glycine (P = 0.010) that increased following the three treatments.  
In conclusion, the consumption of a single blueberry portion counteracted the impairment of 
endothelial function but failed to modulate markers of oxidative stress. Further studies are 
necessary to confirm this finding and help clarifying the mechanisms of protection of blueberry 
against endothelial dysfunction. 
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Dyslipidemic subjects are more exposed to oxidative stress and inflammation by increasing their 
risk to develop atherosclerosis. A dietary approach with nuts could improve dyslipidemia and 
counteract oxidative stress due to the content of mono- and polyunsaturated fatty acids and 
bioactive compounds.  
The objective of the present study was to evaluate the effect of regular consumption of hazelnuts 
as a snack on lipid profile, fatty acid composition of red blood cells and DNA oxidative damage in 
children with primary dyslipidemia.  
Sixty child (11.8 ± 2.6 years old) affected by primary dyslipidemia (total cholesterol and/or 
triglycerides value >95° percentile and BMI <95° percentile) were enrolled in an 8-week 
randomized, controlled, parallel, dietary intervention study. Subjects were divided into 3 groups of 
twenty subjects each, with the following conditions: one group consuming 0.43 g/Kg of hazelnuts 
with skin, one group consuming 0.43 g/Kg of hazelnuts without skin and a control group receiving 
only the dietary guidelines, without nuts, for 8 weeks. Serum lipid profile, the fatty acid 
composition of erythrocytes, and the levels of endogenous (formamidopyrimidine-DNA 
glycosylase (FPG)-sensitive sites) and oxidatively induced DNA damage (resistance to H2O2-
induced DNA damage) in peripheral blood mononuclear cells (PBMCs) were evaluated at the 
beginning and at the end of the intervention. 
Preliminary results on 20 subjects shown that hazelnut consumption significantly reduces the levels 
of total LDL-cholesterol (- 6.37%, p=0.04) and H2O2-induced DNA damage (-26.5%, p=0.01), 
while increases the ratio HDL/LDL-cholesterol (+7.62%, p=0.01) and monounsaturated fatty acid 
composition of erythrocytes (+4.65%, p=0.006) as compared with control group.  
Further elaborations on data of the whole group of subjects will help understanding the effect of 
hazelnut consumption on markers of oxidative stress, lipid profile and fatty acid composition of 
erythrocytes membrane in children with dyslipidemia. 
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Introduction: Regular intake of nuts is suggested to reduce risk factors for cardiovascular disease 
(CVD) and to improve lipid profile. Dyslipidemic patients seem to be more susceptible to oxidative 
stress and CVD risk thus, they may benefit from nuts and their bioactives. 
Objectives: The aim of this study was to investigate the effect of hazelnuts consumed as snack on 
oxidative stress markers, erythrocytes fatty acid composition and serum lipids, in children with 
primary dyslipidemia. 
Methods: Sixty children (11.5 ± 2.5 years) with primary dyslipidemia were enrolled into an 8-
week controlled, parallel, dietary intervention study with hazelnuts (0.43 g/kg body weight per 
day). Subjects received dietary guidelines and were randomized in 3 groups: 1- hazelnuts with 
skin; 2- hazelnut without skin; 3- control (without hazelnuts). Before and after the interventions, 
lipid profile, endogenous and H2O2-induced DNA damage and erythrocyte membrane 
phospholipids were evaluated. 
Results: Preliminary results (n=15 subjects) show that, compared with baseline concentrations, a 
significant reduction in serum LDL-C level was observed only after hazelnut with skin treatment 
for 8 weeks (-11.2%; p= 0.01). No difference in triglycerides, total and HDL-cholesterol levels 
were demonstrated. At baseline, H2O2-induced DNA damage was 41.7  10.0%. DNA damage 
decreased after hazelnut with skin (from 44.4 ± 3.1% to 35.7 ± 7.6%; n=5) as well as following 
hazelnut without-skin treatments (from 42.4 ± 16.0% to 33.3 ± 4.0%; n=5). No difference was 
observed in the control group. Moreover, data seem to suggest only a slight modulation of hazelnut 
treatment on erythrocyte membrane phospholipids composition. 
Conclusion: Results on the subsample analysed show a tendency towards a decrease in the levels 
of H2O2-induced DNA damage and serum LDL-C after 8-week of hazelnuts. Further data on the 
whole group of subjects will help understanding the effect of hazelnut consumption in dyslipidemic 
children. 
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Introduction: EndoPAT2000 is a non invasive pletysmographic method used for the evaluation 
of arterial function in several epidemiological studies, while its use in human intervention studies 
is still poor exploited. In this regards, it has been suggested that multiple evaluations performed 
within the day could improve endothelium-dependent vasodilatation. This could 
mask/overestimate the effect of intervention with vasoactive dietary compounds in the modulation 
of arterial function. 
Objective: The objective of the present study was to investigate the inter- and intraday 
repeatability of RHI measured by EndoPAT2000 in healthy volunteers.  
Methods: Twenty-two male subjects were recruited for the interday study in which RHI 
repeatability was tested in two consecutive days at the same time points. Sixteen volunteers were 
enrolled for the RHI intraday repeatability study measured at baseline, after 2 and 4 h. Data were 
evaluated by analysis of variance. Agreement between paired RHI was evaluated by Bland–Altman 
method, coefficient of variation (CV), coefficient of repeatability (CR) and intraclass correlation 
coefficient (ICC).   
Results: The RHI mean did not vary significantly between day 1 and 2 (2.00 ± 0.41 vs 1.96 ± 0.33; 
p= 0.429) and showed a good repeatability as documented by CV (6%), CR (0.505), and ICC 
(0.773).  
Multiple evaluations within the day significantly affected RHI (p=0.0001) and the repeatability of 
the measurement. A significant increase occurred at 4 h compared to baseline (+37.5%; p=0.0001) 
and 2 h (+21.5%; p=0.004), respectively. In addition, RHI at 4 h showed a low repeatability (CV: 
18.8%; CR: 1.26; ICC: 0.48).   
Conclusions: In conclusion, RHI showed a good interday repeatability in healthy subjects, while 
intraday repeatability can be acceptable till 2 h. Further investigations and standardization of the 
protocols are needed to assess the postprandial effect of vasoactive dietary compounds. 
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Dyslipidemic patients are more prone to oxidative stress and inflammation, increasing their risk to 
develop atherosclerosis. A dietary approach is crucial in the management of dyslipidemia, 
especially during childhood. Regular intake of nuts, source of mono- and polyunsaturated fatty 
acids, vitamins and bioactive compounds, could improve lipid profile and counteract oxidative 
stress.  
The aim of the study was to investigate the effect of regular intake of hazelnuts consumed as a 
snack, on serum lipid levels, fatty acid composition of erythrocyte membranes and levels of DNA 
damage, as marker of oxidative stress, in children with primary dyslipidemia.  
A randomized, controlled, parallel dietary intervention study was scheduled. The study involved 
60 children (11.5 ± 2.5 years) affected by primary dyslipidemia, with total cholesterol and/or 
triglycerides value >95° percentile and BMI <95° percentile). Subjects received dietary guidelines 
and were divided into 3 groups of twenty subjects each, with the following conditions: one group 
consuming 0.43 g/Kg of hazelnuts with skin, one group consuming 0.43 g/Kg of hazelnuts without 
skin and a control group receiving only the dietary guidelines, without nuts, for 8 weeks. Before 
and after the intervention, blood samples were collected for the evaluation of serum lipid profile, 
fatty acid composition of erythrocyte membranes (by gas-chromatography), and levels of 
endogenous and oxidatively induced DNA damage in peripheral blood mononuclear cells (by 
comet assay).  
Preliminary results on 20 subjects shown that hazelnut consumption significantly reduced the 
levels of total LDL-cholesterol (-6.37%, p=0.04) and H2O2-induced DNA damage (-26.5%, 
p=0.01), while increases the ratio HDL/LDL-cholesterol (+7.62%, p=0.01) and monounsaturated 
fatty acid composition of erythrocytes (+4.65%, p=0.006), as compared with control group. Further 
analysis of data on the whole group of subjects will help understanding the potential beneficial 
effect of hazelnut consumption on oxidative stress markers and lipid profile in children with 
dyslipidemia. 
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Background: Dyslipidemia, a key independent modifiable risk factor for cardiovascular disease, 
is associated to an increase of inflammation and oxidative stress. A dietary approach is crucial in 
the management of dyslipidemia, especially during childhood. Regular intake of nuts, source of 
monounsaturated fatty acids, phytosterols, vitamins (i.e. vitamin E) and polyphenols, could 
improve lipid profile and counteract oxidative stress.  
Objective: The aim of the study was to investigate the effect of the regular intake of hazelnuts 
(Corylus avellana L.) consumed as a daily snack, on serum lipid profile and cell protection against 
DNA damage (endogenous and oxidatively-induced), as marker of oxidative stress, in children 
with primary dyslipidemia.  
Methods: An 8-weeks randomized, controlled, parallel dietary intervention study with hazelnuts 
(20-30 g based on weight) was scheduled. The study involved 60 children (11.5 ± 2.5 years) 
affected by primary dyslipidemia, with total cholesterol and/or triglycerides value >95° percentile 
and BMI <95° percentile. Subjects received dietary guidelines and were randomized into 3 groups: 
1- group consuming hazelnuts with skin; 2- group consuming hazelnuts without skin; 3- control 
group (no hazelnuts) receiving only the dietary guidelines. Before and after intervention, blood 
samples were collected for the evaluation of serum lipid profile and levels of endogenous and 
oxidatively-induced DNA damage in peripheral blood mononuclear cells.  
Results: The regular intake of hazelnuts, with and without skin, significantly (p<0.05) reduced the 
levels of serum LDL-cholesterol (-6.6% and -5.5%, respectively) and endogenous DNA damage 
(-28.6% and -26.9%, respectively) compared to baseline, while no significant effect was observed 
in the control group. Furthermore, the consumption of hazelnut with skin significantly decreased 
(-20.3%, p=0.042) the levels of oxidatively-induced DNA damage 
Conclusion: Our findings suggest that hazelnut consumption can improve lipid profile and reduce 
oxidative stress markers in children affected by familiar dyslipidemia.  
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Background: Blueberries are a rich source of polyphenol-bioactive compounds such as 
anthocyanins and phenolic acids that have shown to improve vascular function, reduce 
inflammation and oxidative stress. We previously documented that a portion of blueberries 
reversed endothelial dysfunction induced by acute cigarette smoking. 
Aim: The aim of the present study was to evaluate whether the beneficial effects observed on 
endothelial function were mediated by modulation of markers of oxidative stress and 
inflammation in the same group of smoker volunteers. 
Methods: Fourteen out of 16 healthy male smokers previously enrolled participated in a 3-arm 
randomized controlled study. Three types of conditions were assessed: 1-smoking treatment (S); 
2-control treatment (300 mL of water with sugar + smoking (CS); 3-blueberry treatment (300 g 
of blueberry + smoking (BS). Each treatment was separated by one week of wash-out period. 
Plasma aminothiol concentrations, serum C-reactive protein, endogenous (formamidopyrimidine-
DNA glycosylase (FPG)-sensitive sites) and oxidatively induced DNA damage (resistance to 
H2O2-induced DNA damage) in peripheral blood mononuclear cells (PBMCs) were measured at 
baseline, 20, 60, 90, 120 min and 24 h after smoking. Results were analysed by analysis of 
variance. 
Results: ANOVA did not show an effect of treatment on the modulation of plasma aminothiol 
concentrations, but revealed a significant effect of time. In particular, we observed a significant 
increase in total cysteine (P=0.007), cysteine-glycine (P=0.010), but not glutathione (P>0.05) and 
homocysteine (P>0.05), following acute cigarette smoking in all the three treatments. No 
significant effect of treatment was also reported for the levels of FPG-sensitive sites and H2O2-
induced DNA damage in PBMCs, and serum circulating levels of C-reactive protein. 
Conclusion: In our experimental conditions, the consumption of a single blueberry portion did 
not affect markers of oxidative stress and inflammation in young smokers. Further studies are 
necessary to clarify the mechanisms of protection of blueberry against endothelial dysfunction. 
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Aim: Dyslipidemia is the major cause for atherosclerosis and is associated to an increase of 
oxidative stress. Children affected by primary dyslipidemia may run an additional risk to develop 
CVD during adulthood. Diet rich in unsaturated fatty acids and bioactives can positively influence 
the blood lipid profile and the antioxidant status. The aim of the study was to investigate the effect 
of daily intake of hazelnuts consumed as a snack, on lipid profile, erythrocytes fatty acid 
composition and markers of oxidative stress in dyslipidemic children. 
Methods: An 8-week randomized, controlled, parallel dietary intervention study with hazelnuts 
(20-30 g based on weight) was scheduled. The study involved 60 children affected by primary 
dyslipidemia. Subjects received dietary guidelines and were randomized to the following 
treatment: 1- hazelnuts with skin; 2- hazelnuts without skin; 3- control group (no hazelnuts). Before 
and after intervention, blood samples were collected for the evaluation of serum lipid levels, fatty 
acid composition of erythrocytes membrane and levels of endogenous and oxidatively-induced 
DNA damage in peripheral blood mononuclear cells.  
Results: The regular intake of hazelnuts, with and without skin, significantly (p<0.05) reduced the 
levels of serum LDL-cholesterol and endogenous DNA damage, while increased the ratio of 
MUFA/SFA and MUFA in erythrocytes membrane. Furthermore, the consumption of hazelnut 
with skin significantly decreased the levels of oxidatively-induced DNA damage. No effect was 
observed in the control group. 
Conclusion: Our findings suggest a beneficial effect of hazelnut-enriched diet in the management 
of dyslipidemia and oxidative stress in children. 
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Effect of bioactive-rich diet on risk factors for chronic-degerative diseases in “at risk” groups of 
population.  
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The aim of the present PhD project was to evaluate the effect of specific foods and food bioactives 
in the modulation of risk factors for chronic-degenerative diseases in at risk groups of population, 
thorough the exploitation of in-vivo and ex-vivo approaches. In particular, the first part of the 
project was focused on a dietary intervention study on children affected by primary hyperlipidemia 
to evaluate the impact of hazelnut intake on markers of oxidative stress and lipid profile. While in 
the second part of the project, different food bioactives were investigated for their potential 
immunomodulatory effect through ex-vivo measurements. 
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Background: Hyperlipidemia is a modifiable risk factor for atherosclerosis and children affected 
by primary hyperlipidemia may have an additional risk to develop cardiovascular diseases during 
adulthood. Diet rich in polyunsaturated fatty acids (PUFA) can positively influence the lipid 
profile. 
Objective: The study aimed to investigate the effect of α-linolenic acid (ALA) supplementation 
on fatty acid composition of red blood cell (RBC) phospholipids and serum lipid profile in children 
and adolescents with primary hyperlipidemia. 
Methods: An 8-week parallel dietary intervention study was scheduled. Thirty-six hyperlipidemic 
probands (6-16 years) on diet therapy were subdived into 2 groups: 1- ALA group, receiving 0,7 
g/die of ALA supplement; 2- control group, receiving only the dietary guidelines. Before and after 
the 8-week of treatment, blood samples were collected for the analysis. 
Results: Preliminary results (n=20) showed that patients supplemented with ALA significantly 
reduced the levels of RBC saturated and monounsaturated fatty acids (mean of change from 
baseline: -7.8% and -2.6%, respectively), while increased the levels of PUFA (+10.4%) and the 
omega-3 index (+ 1.6%) compared to control group. In particular, ALA supplementation enhanced 
the RBC levels of n-3 PUFA (+2.2%) and n-6 PUFA (+8.1%). No effect was observed on serum 
lipid profile. 
Conclusion: In conclusion, these preliminary results seem to support the contribution of ALA 
supplementation in the modulation of RBC phospholipid composition and omega-3 index. Further 
analysis on the whole group of subjects will help understanding the effect of ALA on RBC 
phospholipid composition and lipid profile in hyperlipidemic children. 
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